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2014 Statistics at a Glance 
THE TOTAL NUMBER  
OF NEW HUMAN  
MEDICINES AUTHORISED
NEW MEDICINES 
FOR VETERINARY 
USE AUTHORISED
THE NUMBER OF INDIVIDUAL 
AUTHORISATIONS ISSUED UNDER 
DIRECTIVE 2010/63/EU ON THE 
PROTECTION OF ANIMALS USED  
FOR SCIENTIFIC PURPOSES
  
APPLICATIONS FOR 
CLINICAL INVESTIGATIONS 
OF MEDICAL DEVICES 
TO BE CONDUCTED IN 
IRELAND
  
HPRA RANK IN TERMS OF REPORTING RATES FOR ADVERSE 
REACTIONS AMONG 121 FULL COUNTRY MEMBERS PARTICIPATING  
IN THE WHO INTERNATIONAL DRUG MONITORING PROGRAMME 
NEW PRODUCTS CONSIDERED 
BY THE INTERNAL HUMAN 
MEDICINES CLASSIFICATION 
COMMITTEE
NOTIFICATIONS TO THE HPRA 
MEDICAL DEVICE REGISTER FOR 
CLASS I, IN-VITRO DIAGNOSTIC AND 
CUSTOM MADE MEDICAL DEVICES
VARIATIONS TO MARKETING AUTHORISATIONS ISSUED 
FOR HUMAN MEDICINES AUTHORISED THROUGH THE 
NATIONAL OR MUTUAL RECOGNITION PROCEDURES
HPRA RANK IN EU FOR 
RAPPORTEURSHIPS FOR 
CENTRALLY AUTHORISED  
HUMAN PRODUCTS
CLINICAL TRIALS WERE APPROVED 
TO COMMENCE IN IRELAND ON 
MEDICINES FOR HUMAN USE
INFORMATION  
DAYS AND  
SEMINARS 
ORGANISED 
FOR EXTERNAL 
STAKEHOLDERS
ACTIVE SUBSTANCES INCLUDED 
ON THE INTERCHANGEABLE 
MEDICINES LIST ON THE HPRA 
WEBSITE AT YEAR END
INDIVIDUAL REBRAND TASKS 
IMPLEMENTED ACROSS  
THE ORGANISATION FOR  
THE INTRODUCTION OF  
THE NEW HPRA NAME  
AND BRAND IDENTITY
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10th 
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MANUFACTURING 
LICENCES IN  
PLACE AT YEAR  
END FOR HUMAN  
AND VETERINARY 
MEDICINES
PSURS EVALUATED ON 
INDIVIDUAL VETERINARY 
MEDICINES
PACKS OF EXEMPT MEDICINES 
NOTIFIED TO THE HPRA
THE NUMBER OF UNIQUE VISITORS WHO 
ACCESSED THE NEW HPRA WEBSITE 
BETWEEN JULY AND DECEMBER
ENFORCEMENT CASES INITIATED  
IN RESPECT OF POTENTIAL BREACHES  
OF HEALTH PRODUCTS LEGISLATION
NATIONAL 
AND FOREIGN 
INSPECTIONS  
AND AUDITS 
PERFORMED
RECALLS OF HUMAN MEDICINES 
AND VETERINARY MEDICINES
PSURS FOR HUMAN MEDICINES 
SUBMITTED AS NATIONAL, MUTUAL 
RECOGNITION, CENTRALISED, EU 
SINGLE-ASSESSMENT AND PSUR 
WORK-SHARING PROCEDURES
REPORTS OF SUSPECTED ADVERSE 
REACTIONS ASSOCIATED WITH USE  
OF VETERINARY MEDICINES RECEIVED
MEDICAL DEVICE VIGILANCE REPORTS 
RECEIVED AND ASSESSED
SUSPECTED ADVERSE REACTIONS REPORTS FOR 
HUMAN MEDICINES RECEIVED
INCREASE IN THE NUMBER OF 
EXPORT CERTIFICATES ISSUED117
1,759
852 
3,235,232 
126,000  3,703
260
102 
3002,113  
2,884 
29% 
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Health products can improve the quality of our lives 
and indeed can be life-saving. However, there are 
inherent side effects associated with the use of many 
of the products we regulate. The role of the HPRA is 
to apply its expert knowledge using the best available 
data so as to ensure that members of the public 
continue to have access to products that work as 
intended and that are as safe as possible.  
The HPRA’s five year strategic plan for 2011 to 
2015, which the Authority is tasked with overseeing, 
sets out five high level strategic objectives and a 
clear roadmap to achieve these goals within that 
timeframe. Our annual report outlines the extensive 
work programmes and areas of activity across all our 
departments under year four of the strategic plan 
whilst also demonstrating the HPRA’s unique and 
important role in the wider national healthcare arena. 
This organisations remit is comprehensive, acting as 
the competent authority for the regulation of human 
and veterinary medicines, clinical trials, medical 
devices, blood and blood components, and tissues 
and cells. It also has a role in regulating the use of 
human organs intended for transplantation, cosmetic 
products and the protection of animals used for 
scientific purposes. 
Our primary objective is to safeguard public and 
animal health by regulating specific health product 
sectors in line with applicable legislation. For some 
health products like medicines, we regulate across 
the entire product lifecycle from clinical trials, through 
manufacturing, to marketing authorisation, distribution 
and use by healthcare professionals, patients and 
animal owners. For others we have no our role in 
authorising products, our role starts when they first 
come to market and we then monitor those products 
and act upon any safety issues that are identified. 
However, underpinning all our activity regardless of 
the legislative framework is our core focus on effective 
regulation. This requires harnessing the best scientific 
and clinical knowledge available to us through both 
our specialist staff and experts nationally and through 
our participation at European committees which 
inform our decisions and policies. 
Our work programme is delivered through our 
effective divisional structure. Many thousands of 
applications were assessed and processed for both 
human and veterinary medicines in 2014. These 
included new applications, renewals and variations to 
existing medicines. The licensing of new products in 
particular is an important regulatory function once a 
positive assessment of safety, quality and effectiveness 
can be confirmed.
Chairman’s Statement
It is with great pleasure that I present 
the annual report for the first time 
under our new name – the Health 
Products Regulatory Authority (HPRA).  
During 2014, we transitioned from 
being the Irish Medicines Board to 
the HPRA, our new organisational title 
which more accurately reflects our 
broader remit and regulatory functions 
that have grown significantly since we 
were first established.   
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As in previous year, a key focus of our work in 2014 
involved continuously monitoring the safety of health 
products on the Irish market and, where appropriate, 
taking action quickly so as to protect patient and / or 
user safety. A significant part of this action involves 
the HPRA alerting healthcare professionals and 
patients to new information as required across an 
extensive range of health products and cosmetics. 
In 2014, we received and investigated over 2,800 
adverse reaction reports to human medicines, some 
300 for veterinary medicines and over 2,100 vigilance 
reports in relation to medical devices. Each of these 
reports is individually assessed by the HPRA and 
shared at EU level to form part of a European wide 
surveillance programme that utilises cumulatively 
assessed data to enhance patient safety. The HPRA is 
extremely grateful to all those healthcare professionals 
as well as members of the public who contact us 
with observations or concerns in relation to health 
products. 
During June 2014, the HPRA again participated in 
Operation Pangea, the INTERPOL coordinated week 
of action targeting the online sale of counterfeit and 
illegal medicines. Ireland was one of 110 participating 
countries and during this week-long initiative we 
detained, in collaboration with the Revenue’s Customs 
Service and An Garda Síochána, over 100,000 
illegal prescription medicines. It was an honour later 
in 2014 for the HPRA to co-host an international 
Interpol conference entitled Ten Years of Combating 
Pharmaceutical Crime: Review and Prospects. Some 
200 delegates from 50 countries were in attendance. 
These initiatives were in addition to the HPRA’s 
ongoing efforts to counter illegal practices linked to 
the manufacture and supply of medicines and medical 
devices. We continue to highlight to the general 
public the serious risks associated with sourcing 
prescription medicines from unauthorised suppliers 
such as those found online as there can be no 
guarantee of the safety or quality of these products.
In addition to protecting public health, a robust 
regulatory system is also important for Ireland as a 
major international location for the life sciences sector. 
The pharmaceutical industry alone accounts for over 
50% of all exports with nine out of 10 of the largest 
pharmaceutical companies having operations here. 
The HPRA’s robust regulatory role supports the sectors 
continued success by ensuring compliance with good 
manufacturing practices and adherence to legal 
requirements. 
The life sciences sector is also an increasingly 
globalised, evolving and growing arena. As such, it 
requires the HPRA to adapt its practices to effectively 
regulate more innovative and complex products. 
A key element to our approach to meeting this 
challenge is to enhance our international co-operation 
thereby giving us access to the most up-to-date 
information and best practices that can be use to 
maximum effect here in the Irish market. This year in 
review saw the HPRA again participate actively in EU 
and international activities designed to enhance the 
safety of health products while also contributing to 
policies in respect of manufacturing and distribution. 
The changing regulatory landscape will require us to 
develop our global links further while simultaneously 
working to develop the skills base of our staff. 
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* Reappointed May 2014         ** Appointed May 2014
Authority Members
The Authority of the HPRA 
is appointed by the Minister 
for Health in accordance 
with the powers conferred 
by subsection 2 of section  
7 of the Irish Medicines Board 
Act, 1995. There were nine 
Authority members as of  
31 December 2014.
Mr. Wilfred J. Higgins*
Mr. Noel O’Donoghue
Ms. Anne Horan  
Mr. Michael D. Hayes 
(Chairman)
Mr. Pat Brangan*
Professor Caitriona 
O’Driscoll
Professor Mary Horgan
Dr. Diarmuid Quinlan**
Dr. Elizabeth Keane*
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Management Committee
Dr. J.G. Beechinor 
Director of  
Veterinary Sciences
Mr. Pat O’Mahony 
Chief Executive
 
Dr. J.M. Morris  
Director of Scientific 
Affairs
Dr. Joan Gilvarry  
Director of Human  
Products Monitoring
Dr. Lorraine Nolan  
Director of Human  
Products Authorisation  
and Registration
Mr. Kevin Horan 
Director of ICT and 
Business Services 
Ms. Lynsey Perdisatt 
Director of Human  
Resources and Change 
Mr. John Lynch  
Director of Compliance
Ms. Rita Purcell  
Director of Finance, 
Corporate Affairs and 
International
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Strategic Plan 2011 – 2015 
The layout of the annual report for 2014 is structured to 
ensure that the main chapters are closely aligned with 
the HPRA’s five high-level strategic goals.
These goals are to:
1.  Enhance healthcare product safety and patient 
outcomes by effective risk management and market 
surveillance.
2.  Deliver clear, relevant and timely communications  
to patients, consumers and healthcare professionals.
3.  Improve service delivery within a high quality,  
risk-based regulatory framework.
4.  Influence legislation and policy development at 
European and international levels for the benefit  
of public and animal health.
5. Build future capabilities to meet evolving regulatory 
requirements, and scientific and technological 
advances.
Chief Executive’s Report
Our new name is a reflection of a far broader 
regulatory remit which has expanded and developed 
over a number of years since the establishment of 
the IMB in 1996 and indeed its predecessor, the 
National Drugs Advisory Board, (NDAB) back in 1966. 
This is the beginning of an exciting new chapter in 
the history of our organisation and I am pleased to 
present our first annual report under the HPRA  
name and brand. 
2014 was a very significant year 
for our organisation as on 1 July 
the Irish Medicines Board (IMB) 
became the Health Products 
Regulatory Authority (HPRA). 
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Authorisation, Registration  
and Licensing Activities  
The pre-market authorisation and registration of 
healthcare products, as well as the licensing of 
manufacturing, wholesaling and related activities, is 
one of the HPRA’s primary public health functions. 
We are committed to providing an effective and 
efficient regulatory framework that is focused on 
timely availability of appropriate health products. The 
activities of note during 2014 included the following:
• There were 80 clinical trials for human medicines 
approved to commence in Ireland compared with 
102 the previous year. There were 10 applications 
for clinical investigations of a medical device, a 
level of activity broadly similar to the previous 
12-month period.
• In the area of human medicines, the HPRA 
assessed 179 new national applications (including 
parallel product authorisations), 40 applications 
via mutual recognition procedures (MRP) and 265 
via decentralised procedures (DCP). The total 
number of new products authorised continues 
to decrease relative to previous years and this is 
reflective of a trend throughout Europe which has 
been attributed to product patent lifecycles.
• Continuing our active contribution to the 
European human medicines licensing system, we 
acted as reference (lead) Member State for the 
assessment of seven MRP and DCP procedures. 
The HPRA was also allocated as rapporteur or co-
rapporteur for eight new marketing authorisation 
applications by the European Medicines Agency 
(EMA). Based on 2014 allocations, the HPRA is 
ranked as fifth in the EU for rapporteurships for 
centrally authorised human products. We acted 
as lead in 42 scientific advice procedures for 
medicines proposed for the treatment of a broad 
range of conditions.
• We assessed and approved a total 75 applications 
for new veterinary medicines, a slight reduction 
when compared to the previous year. 
• Over the course of 2014, the HPRA issued 13,205 
variations to marketing authorisations for human 
products authorised through the national or MR 
procedures. This reduction of 25% in the volume 
of variations issued is due to the implementation 
of a new work-sharing procedure for national 
variations which came into effect in 2013. Of note, 
at a European level, we acted as rapporteur for 
eight paediatric Article 45 procedures and 13 
procedures relating to Paediatric Investigational 
Plans (PIPs). The HPRA approved 1,502 variations 
to veterinary authorisations granted through the 
national, MR or centralised procedures which 
continued the upward trend in numbers during 
recent years.
• There were a total of 361 notifications of medical 
devices to the medical device register while 26 
organisations registered with the HPRA as Irish 
based manufacturers of medical devices.
• A total of 117 manufacturers’ licences were 
in place at year end for human and veterinary 
medicines. There were four authorisations 
for blood establishments and 24 for tissue 
establishments.
1 July
THE IRISH MEDICINES 
BOARD BECOMES THE 
HEALTH PRODUCTS  
REGULATORY  
AUTHORITY
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Safety and Compliance 
Monitoring 
A core public health function of the HPRA is to 
monitor the safety and quality of medicines, medical 
devices and other health products that have been 
licensed or registered for use in Ireland. This is known 
as post-market surveillance. Our regulatory decisions 
are always based on the best available information 
regarding benefit and risk.
• The operation of a national pharmacovigilance 
scheme for adverse reactions, or side effects, 
associated with the use of human medicines is a 
key element of the HPRA’s post-market activities. 
In the past year, the HPRA received a total of 
2,884 valid new adverse reaction reports. This 
figure is consistent with the reporting rates seen 
in the previous three years. It is worth noting that 
nearly 20% of the reports received in 2014 were 
associated with the use of medicines subject 
to additional monitoring requirements. These 
requirements were introduced in the context of 
the pharmacovigilance legislative revisions in 
2012.
• The HPRA continued to contribute to work-sharing 
for signal detection within the EU during 2014. In 
the area of human medicines, we acted as lead 
member state for the detection and management 
of signals for 58 active substances authorised 
nationally. We also retained responsibility for 
assessing any signals arising as a result of signal 
detection for 21 centrally authorised active 
substances (or combination of active substances).  
In addition, the HPRA acted as concerned 
Member State in 15 EU safety-related referrals.
• Periodic safety update reports (PSURs) are 
vigilance reports submitted by marketing 
authorisation holders which are intended to 
provide an evaluation of the benefit-risk balance 
of a medicine. For human medicines, the total 
HPRA output in 2014 was 1,759 PSURs submitted 
as national, mutual recognition, centralised, 
EU single-assessment and PSUR work-sharing 
procedures.
• The HPRA received 300 national reports of 
suspected adverse events to veterinary medicines 
in 2014 continuing the upward trend in the 
number of reports received in recent years. We 
also completed the evaluation of 852 PSURs for 
veterinary medicines. While this was a decrease 
from the 1,072 figure in 2013, our PSUR activity 
accounts for approximately 30% of the HPRA’s 
overall veterinary medicines workload.
• Post-market surveillance and vigilance are tools 
used to monitor the safety and quality of medical 
devices. A total of 2,113 medical device vigilance 
reports were received and assessed representing 
a slight decrease on 2013. We commenced 
319 market surveillance cases with a significant 
number of these cases relating to notified body 
certificate withdrawals.
Another key function of the HPRA is to monitor and 
inspect industry compliance with legislation, policies 
and procedures. We are committed to ensuring 
that all health products manufactured, processed or 
distributed in Ireland meet essential quality standards.
• During 2014, 260 inspections and audits were 
performed compared to 313 in 2013 and 315 
in 2012. The 2014 figure included 106 Good 
Manufacturing Practice (GMP) inspections, 76 
Good Distribution Practice (GDP) inspections, 
12 Good Clinical Practice (GCP) inspections, 20 
medical device audits and 23 covering blood, 
tissues and organs.
• We sent a total of 506 product samples for 
analytical testing / examination during 2014.  
This represented a 16% annual increase. 
• It may be necessary in certain cases to withdraw, 
or recall, products from the Irish market in order 
to protect public health. In 2014, 102 medicine 
recalls occurred. Of these, 96 related to human 
medicines while six were veterinary medicines.
• The HPRA initiated ten prosecutions in the 
District Courts during the course of 2014 as a 
result of illegal activity involving the manufacture, 
supply and/or sale of medicines. In total, 3,703 
enforcement cases were initiated with 730,056 
dosage units being detained.
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Legislative and Regulatory 
Developments
The remit and role of our organisation continues to 
change and expand due to changes in our operating 
environment, such as new national and European 
legislation, and in response to the addition of further 
competencies.
New Clinical Trials Regulation 
New clinical trials legislation (Regulation (EU) No 
536/2014) was adopted and published in May 2014. 
It will come into effect in Europe in mid 2016. The 
new Regulation is intended to increase the number 
of clinical trials conducted in Europe and provide 
for improved transparency. The HPRA contributed 
significantly to the consultation proposals on the 
development of the new Regulation. Since its 
publication, the HPRA has been working to progress 
the development of systems and procedures to meet 
the new requirements.
Interchangeable Medicines
Under the Health (Pricing and Supply of Medical 
Goods) Act in June 2013, the HPRA was tasked with 
publishing a list of interchangeable medicines to 
facilitate generic substitution by pharmacists and to 
allow for the introduction of a reference pricing system 
by the HSE. There was further significant progress in 
the development of the list during 2014. By the end 
of 2014, the list included a total 44 active substances 
and includes more than 2,500 individual medicines. 
It is estimated that generic penetration of the first 15 
substances published is now at 90% and savings to 
the state are estimated at €50 million for 2014.
 
Legal Classification of Medicines
In July, the HPRA published a group of 12 substances 
which are considered suitable for reclassification. 
Medicines containing these substances can, in certain 
circumstances, be reclassified to be made available 
over the counter in pharmacies and supplied without 
prescription. The industry was invited to make 
reclassification applications for these medicines. 
On foot of this proactive approach, a number of 
applications are pending and further progress is 
anticipated during 2015. 
 
Reclassification of NRT to General Sale 
from Pharmacy Only Status 
There was a significant development in 2014 
regarding smoking cessation therapies. In July, the 
HPRA confirmed the authorisation of a nicotine 
replacement therapy (NRT) product to be sold in 
general retail and grocery outlets. NRT products 
were previously only available in pharmacies and 
the HPRA’s decision to switch Nicorette™ NRT 
from ‘pharmacy only status’ to ‘general sale status’, 
followed an application from the authorisation holder 
and a detailed assessment of applicable safety and 
efficacy data. 
Responding to Medicine Shortages
We continue to work closely with the Department  
of Health and the HSE in relation to the management 
of shortages of medicines within the Irish market 
place. One mechanism used by the HPRA to help 
alleviate shortages is the granting of a temporary 
authorisation for a batch of a product known as a 
‘batch specific request’. In the past year, the HPRA 
issued 129 such approvals. 
Veterinary Clinical Field Trials
The role of the HPRA expanded yet further when  
our organisation became the competent authority for 
the authorisation of clinical field trials on veterinary 
medicines on 17 July 2014. 
Under legislation, tests and trials on a veterinary 
medicine for the purpose of generating data to 
support a marketing authorisation, or for other 
purposes shall not be conducted without prior licence 
from the HPRA. A clinical field trial licence application 
must be submitted and approved in order for work 
to commence on any clinical field trial. Relevant 
application forms, guides and fee details are available 
from our website.
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Revision of European Medical  
Devices Legislation
During 2014, the negotiation of the European 
Commission’s proposed Regulations on medical 
devices and in-vitro diagnostics continued at the 
European Council’s Working Party on Pharmaceuticals 
and Medical Devices. The two proposed Regulations 
represent a significant development and improvement 
of the existing system. The associated legal text are 
large and complex and have necessitated detailed 
review, discussion and negotiation. 
The HPRA continues to provide support to the 
Department of Health for the purposes of the Working 
Party negotiations and we are also active contributors 
to a number of relevant expert working groups. It is 
anticipated that these proposals, which are subject to 
the ordinary legislative process including examination 
by both the European Council and the European 
Parliament, will be finalised by the end of 2015. 
European Commission’s Joint Plan for 
Immediate Actions on Medical Devices
In February 2012, the European Commission ‘joint 
plan of immediate actions’ was published with the 
objective of reinforcing the existing regulatory system 
for medical devices in advance of the proposed 
revision to the medical devices legislation. The HPRA’s 
approach to medical devices regulation has been 
closely aligned with the recommendations of the 
plan in recent years and we remain fully committed 
to supporting and using the provisions of the joint 
plan as a basis for development. During 2014, further 
progress was achieved in respect of the oversight and 
performance of notified bodies for medical devices 
and in the area of market surveillance and vigilance.
Participation in the European and 
International Regulatory Systems
The health products regulated by the HPRA are part 
of an international industry that is constantly changing 
and developing. Those products manufactured 
here are used around the world, while products 
manufactured elsewhere are used by Irish patients 
and consumers. The HPRA is therefore committed to 
playing its part in the global regulatory network and 
ensuring that we represent and protect the interests  
of Irish patients and consumers.
Our participation and contribution at a European 
level continues to be significant with HPRA scientific 
and technical staff contributing to a broad range of 
committees and working parties at the EMA, the 
European Commission, the Heads of Medicines 
Agencies (HMA) and via other platforms. We also 
recognise the importance of contributing where 
possible and appropriate to relevant international 
organisations. 
The following highlights some of main developments 
and HPRA contributions from 2014. 
• The HPRA attended the 8th International Summit 
of Heads of Medicines Regulatory Agencies. The 
HPRA continued in the role of Vice-Chair of the 
International Coalition of Medicines Regulatory 
Authorities (ICMRA) where discussion continued 
on the development of terms of reference, rules of 
procedure and future membership criteria. ICMRA 
continues to dialogue with existing international 
regulatory groups and to pursue initiatives with a 
view to streamlining and enhancing international 
cooperation.   
• The HPRA continued as a member of the 
European delegation on the Management 
Committee of the International Medical Device 
Regulators Forum (IMDRF). This forum seeks to 
promote the harmonisation of medical device 
regulation across the globe.
• The Irish PRAC delegate continued to fulfil the 
role of Vice-Chair of this important EMA public 
health committee. 
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• The HPRA continued its work with relevant 
stakeholders on the phased implementation 
of EU pharmacovigilance legislation. We also 
contributed to the Strengthening Collaborations 
for Operating Pharmacovigilance in Europe 
(SCOPE) Joint Action project which aims to 
support the operation of pharmacovigilance in 
Europe. 
• The Pharmacovigilance and Risk Management 
Lead was the Regulatory Chair for the ICH 
Implementation Working Group for the E2C R2 
guideline on Periodic Benefit Risk Evaluation 
Reports which successfully completed its intended 
deliverables in 2014.
• Our Pharmacovigilance Manager for human 
medicines continues to represent the World 
Health Organization (WHO) as a member of the 
Board of the Uppsala Monitoring Centre (UMC) 
and WHO Collaborating Centre for International 
Drug Monitoring. 
• Our contribution to the veterinary medicines 
regulatory network is primarily through our 
involvement at the EMA, where our Veterinary 
Assessment Manager is the Vice-Chair of the 
Committee for Medicinal Products for Veterinary 
Use, and at the HMA. 
• The revision of the legal framework for veterinary 
medicines was a key focus in 2014 and the HPRA 
was an active participant in the review of the 
proposed new framework by both the EMA & 
HMA. 
• A HPRA enforcement officer was elected vice 
chair of the HMA Working Group of Enforcement 
Officers (WGEO).
• The HPRA was an active participant in the Medical 
Devices Expert Group (MDEG) and is the chair 
of three taskforces including the vigilance co-
ordinating competent authority role.
• The HPRA was elected to the newly formed 
Executive Group of the Competent Authority for 
Medical Devices (CAMD).
• The Inspection Manager continued as a member 
of the Executive Bureau of the Pharmaceutical 
Inspection Co-operation Scheme (PIC/S) and as 
chair of its Sub-Committee on Compliance.
Scientific Animal Protection
The HPRA continued to interact with the Department 
of Health and all relevant stakeholders in relation 
to the overall implementation of Directive 2010/63/
EU on the protection of animals used for scientific 
purposes. Of particular note in 2014 was the 
publication by the HPRA of its first annual statistical 
report on the use of animals for scientific purposes in 
Ireland. We also provided support during the year to 
the National Committee for the Protection of Animals 
used for Scientific Purposes. 
Stakeholder Engagement  
and Communications
The HPRA is committed to expanding and improving 
our communications activities and to ensuring that 
all our stakeholders have timely access to relevant 
safety and regulatory information. As well as our 
regular meetings and ongoing publication of safety 
and regulatory updates, newsletters and guidance 
documents, a number of significant communications 
programmes and initiatives took place during 2014. 
A primary focus was the introduction of the Health 
Products Regulatory Authority name and brand.
 
The Irish Medicines Board becomes the 
Health Products Regulatory Authority
Following the decision to adopt the new HPRA name, 
a new brand identity was developed to help us 
communicate in a consistent and clear manner with 
all our stakeholders. The identity consists of a number 
of core elements, including our logo, fonts and 
colour palette, that come together to create a strong, 
credible and unique brand for the HPRA. Our new 
brand identity reflects what we stand for – protecting 
and enhancing public and animal health. 
Throughout the first six months of 2014, a significant 
programme of work was undertaken which 
incorporated a wide-ranging external communications 
plan to inform stakeholders in addition to a 
comprehensive staff engagement strategy. 
The external plan consisted of a range of activities 
and projects that were planned to coincide primarily 
with the 1 July introduction date and included 
the launch of a new corporate website, a series 
of ‘all-stakeholder’ e-mails and the publication of 
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a new corporate brochure and video. In addition, 
an information notice was placed in a number of 
health and related industry publications and series of 
press releases were issued to national, regional and 
specialist media. A range of publications including 
information leaflets, guides, forms and newsletters 
were also redesigned and there were updates to our 
corporate stationery and office signage. 
On the morning of the launch a stakeholder event 
was held in the HPRA offices in Dublin 2 with over 
60 external attendees representing patient and 
healthcare professionals, the Department of Health 
and other government departments and agencies. 
We were very pleased to welcome RTÉ journalist Mr 
Tommie Gorman and the then Chief Executive of the 
IDA, Mr Barry O’Leary, as our guest speakers.
To prepare internally for the change of name and 
new corporate identity, a brand implementation 
group was convened with representatives from a 
range of different organisational functions. This 
group identified close to 200 individual rebrand tasks 
that were required to ensure a smooth and efficient 
introduction of the new name and identity. The vast 
majority of the tasks were completed in advance of or 
on the key 1 July date with the remainder planned for 
completion on a phased basis thereafter. 
Finally, an internal communications plan was also 
implemented to support the introduction of the 
HPRA name and brand. This was a key element of 
the communications activity due the associated 
impact on all departments and sections across the 
organisation and there is no doubt that the support 
of all our colleagues was central to what was a hugely 
successful renaming and rebranding project.
Our New HPRA Website
The development of the new HPRA website which 
began in 2013 was completed to coincide with the 
introduction of the HPRA name and brand on 1 July. 
This was a complementary project as the existing IMB 
website was due for essential upgrade. In particular, 
there was a requirement for the introduction of a new 
content management system to ensure a professional 
and modern online presence for the HPRA. A primary 
focus was on ensuring an improved navigation so that 
all content could be easily found and accessible.  
Other enhancements, in addition to the incorporation 
of the HPRA’s new brand identity, are an improved 
search facility, the ability to access medicines product 
information directly from the homepage and a more 
targeted alerting system for subscribers. Based on 
feedback received from the users of the website, we 
also introduced redesigned sub homepages for each 
product area and new sub homepages for our key 
stakeholder groups: members of the public, industry 
and healthcare professionals. 
Events
In November 2014, the HPRA and An Garda 
Síochána co-hosted Ten Years of Combating 
Pharmaceutical Crime: Review and Future Prospects, 
an INTERPOL conference held in Dublin. This 
was a major international conference which was 
attended by senior law enforcement officials from 
across the world as well as representatives from 
government, intergovernmental organisations and the 
pharmaceutical industry. Almost 200 delegates from 
some 50 countries and 17 international organisations 
were in attendance. There was significant national 
and international media interest in the event and the 
opening address was delivered by Minister of State at 
the Department of Justice and Equality, Aodhán  
Ó Ríordáin, TD. 
HPRA information days and seminars provide 
regulatory guidance and updates to a range of 
stakeholders and include presentations from HPRA 
staff and, where appropriate, external contributors. 
These events, which are all organised and managed 
by an in-house events team, enable all attendees 
to submit questions, seek clarifications and network 
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with colleagues. The past 12 months saw a number 
of information days and seminars being organised 
focused on topics such as clinical trials, the regulation 
of medical devices, the regulation of veterinary 
medicines, and pharmacovigilance. Information days 
were also held for both manufacturers and distributors 
of medicines. 
In January 2014, we participated at the BT Young 
Scientist and Technology Exhibition for the fifth time. 
Thousands of students as well as teachers, parents 
and members of the general public from all over 
Ireland visited the HPRA’s exhibition stand which 
focused on the important issue of medicines and 
medical devices safety.
 
Publications
The HPRA produces an extensive range of publication 
each year and 2014 was no different in that respect. 
In addition to new and updated regulatory guides, we 
continued to publish our drug safety, medical devices 
and medicinal products newsletters which are focused 
on updating stakeholders in respect of key safety and 
regulatory issues. All these documents are available 
from our website and interested parties can subscribe 
to our e-mail alerting system to receive notifications 
when new editions are published. 
In November, the HPRA also published a new 
information leaflet providing guidance to members 
of the public on the use of self-test products. This 
leaflet was developed in response to the increasing 
availability of self-test products for a variety of health 
conditions and the concerning trends and issues 
observed by the HPRA when following up on adverse 
incidents relating to their use. The leaflet can be 
downloaded from our website while printed versions 
are also available.
Oireachtas Joint Committee on  
Health and Children
In June, the Oireachtas Joint Committee on Health 
and Children met to consider the use and availability 
of adrenaline auto-injectors. The HPRA was invited 
to present an update on the authorisation and safety 
monitoring of these products.
 
 
Organisational Management  
and Development
It is vitally important that we continue to build our 
organisational capabilities in line with regulatory and 
scientific developments and we must also display 
the flexibility required to adapt to changes in the 
environment in which we operate.
Human Resources and Change
Having the necessary human resources in place and 
operating to the highest standards of performance, is 
central to us delivering on our public health mission. 
There was a particular focus in 2014 on the areas of 
staff retention and engagement and further advancing 
the public sector reform agenda. The organisational 
‘motivation and development’ competency, part of 
the HPRA’s Performance Development Programme 
(PDP), provided the overarching framework for the 
development of many of our HR initiatives during the 
past year. 
PDP continues to be one of our core platforms to 
support high performance, superior service delivery 
and the development of our staff. The programme 
was enhanced during 2014 with new features piloted 
across the organisation prior to a planned full 
implementation in 2015.
Our learning and development strategy continued 
to focus on staff development as one of our key 
motivation and retention tools. In support of this, a 
development planning process was launched while 
a group of managers commenced our externally 
accredited Leadership Development Programme 
(LDP).
The HPRA continues to recognise the importance of 
supporting employee engagement and commitment. 
In 2014, we focused on delivering a series of initiatives 
designed to support employees in meeting the 
challenges facing them both inside and outside of the 
workplace. This included financial planning support 
and the development of a range of staff health and 
wellness initiatives.
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We continue to develop and manage our resources 
in line with public sector policy. This requires a 
particular focus on internal skills development and the 
reallocation of tasks and responsibilities in response 
to specific challenges. Where appropriate, recruitment 
of staff in specialist areas was completed in line with 
Department of Health approvals.
Finally, the remit of the HR department expanded in 
late 2014 to incorporate the Change Management 
function. This was preceded by the implementation, 
testing and piloting of a new human resource IT 
system during the first six months of the year. The 
benefits of the system in terms of effectiveness and 
efficiency have already been realised with users 
reporting a reduction in time spent administrating 
routine tasks.  
Information Technology and  
Business Services 
Technology is recognised as a key component in 
supporting regulatory activities at both national and 
international levels. The HPRA continues to contribute 
to, and actively lead, a number of key technology 
projects at a national and European level. This 
includes the ongoing development and management 
on behalf of the wider EU regulatory community of 
the Common Electronic Submission Portal (CESP). 
The CESP activity levels grew substantially in 2014, 
handling over 250,000 submissions on behalf of 
32 European regulatory organisations and the 
pharmaceutical industry.
The HPRA is also actively engaged at national level 
through its involvement with the National Health 
Data Standards Committee and we work closely 
with other relevant agencies including the HSE, 
NSAI and HIQA on mutually beneficial projects. This 
includes the provision of technological support to the 
interchangeable medicines initiative in co-operation 
with Department of Health and the HSE.    
The HPRA is committed to continuous improvement 
across all areas of our organisation. A key current 
focus is the development of a new workflow 
technology solution which will enable the 
consolidation and replacement of a number of legacy 
solutions and will provide a new workflow and data 
management platform for the organisation. The 
tendering process for the provision of this new system 
was completed at the end of 2014 and the design and 
development is scheduled to be carried out in 2015. 
Financial Performance
In common with many of its peers internationally, the 
HPRA is largely self-funded through a regulatory fee 
system. Fees are approved annually by the Minister 
for Health following a public consultation. The HPRA is 
committed to the highest standards of independence 
and governance so as to ensure quality of service 
combined with value for money. Throughout 2014, 
we continued to successfully manage the affairs of the 
HPRA in line with our statutory obligation that income 
at least meets costs.
100+
PEOPLE GIVE OF THEIR TIME  
VOLUNTARILY TO THE WORK  
OF THE HPRA THROUGH  
PARTICIPATION ON THE  
AUTHORITY AND ITS  
COMMITTEES.
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The Future
To ensure the best possible outcomes for Irish citizens, 
the HPRA must be ready to respond to both the new 
challenges and the new opportunities that will no 
doubt arise during 2015 and beyond. 
The overall workload for the organisation will continue 
to increase and diversify as we respond to the 
development of new and innovative products and to 
changes in respect of new European legislation and 
the addition of further national competencies. The 
former includes the ongoing development of new 
legislation in respect of both veterinary medicines and 
medical devices which are likely to result in significant 
changes to the regulatory regimes of these products. 
As in previous years, we will continue to take a risk-
based approach to our regulatory activities. We will 
adopt changes across the organisation where these 
are deemed necessary and beneficial, and we will 
continue to enhance our performance and quality 
management systems, our IT capabilities and our 
communications efforts. There will be an ongoing 
review of our funding provision and we will manage 
our cost base to ensure optimal use of resources. We 
expect to see fees introduced for our regulatory role 
in respect of medical devices. 
As regards human resources, we will continue our 
commitment to applying best practices and to 
ongoing staff learning and development. This is 
critical for the HPRA as we must maintain and enhance 
the skills that are required for our increasingly complex 
and expanding remit.
Whilst our name has changed, our mission remains 
the protection and enhancement of public and animal 
health and this will be at the core of all our work, 
deliberations and decisions.
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AUTHORISATION,  
REGISTRATION AND  
LICENSING ACTIVITIES  
A core public health function of the HPRA is 
the authorisation and registration of health 
products. These are the regulatory actions 
which are carried out before a health product 
can be marketed and supplied in Ireland.  
The HPRA is committed to the timely 
approval of new product applications once 
we can confirm a positive assessment of their 
safety, quality and effectiveness.
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Borderline Product Classification
The HPRA regularly receives queries in regard to the 
correct classification of human medicines, veterinary 
medicines and medical devices.
For products for human use, a classification service 
is operated for products which are on the borderline 
between human medicines and other products 
such as food supplements, cosmetics and medical 
devices. Requests for classification, whether external 
or internal, are presented to an internal, multi-
disciplinary, classification committee.
The Committee, which met 11 times in 2014, consists 
of appropriately experienced HPRA staff from across 
the organisation and is chaired by the Director of 
Scientific Affairs. During the past 12 months, a total 
of 60 new products were considered consisting of 57 
internal applications and three external applications. 
In addition, there were 20 products revisited from 
pre-2014.
The Committee has a close working relationship 
with the Food Safety Authority of Ireland (FSAI) and 
during the past year there were a number of referrals 
between both organisations. In total during 2014, 
the FSAI notified the HPRA of 105 products that it 
considered relevant to the HPRA’s remit and these 
were reviewed and followed up as appropriate. The 
committee also engaged in regular dialogue with 
the Department of Health and with other European 
regulatory authorities.
Human Medicines
The HPRA is responsible for the authorisation  
of medicines and clinical trials and for the registration 
of certain medical devices. We also licence 
manufacturers and wholesalers of human medicines, 
manufacturers of veterinary medicines as well as 
blood and tissue establishments and organ transplant 
centres. In addition, we are responsible for issuing 
export certificates.
The HPRA also provides a classification service to 
assist stakeholders in clarifying which products should 
be categorised as human medicines, veterinary 
medicines, medical devices or cosmetics. Products in 
these categories fall under the remit of the HPRA from 
a regulatory perspective and are distinct from other 
products which are outside the HPRA’s remit.
Number of Applications  Received 2010 2011 2012 2013 2014
Source Internal 72 132 127 161 57
 External 33 21 17 7 3
Classification Outcome Medicinal Product 63 88 91 108 28
 Medical Device 4 9 6 7 
 Food Product 24 36 26 28 8
 Cosmetic Product 6 4 10 19 
 Biocide   2 1 1 
 Pending 7 12 6 1 22
 Other 1 2 4 4 2
 Total 105 153 144 168 60
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Clinical Trials
The role of the HPRA is to assess applications from 
sponsors to conduct clinical trials in Ireland. Sponsors 
include pharmaceutical companies and / or research 
institutions. The HPRA approves the clinical trial 
protocols which describe in detail how each trial is to 
be conducted and outlines the steps that will be taken 
to protect the health of volunteers or patients.
In 2014, 80 clinical trials were approved to commence 
in Ireland down from a total of 102 in the previous 
year. The key areas of interest continue to include 
oncology and haematology. There were four clinical 
trials authorised which involved the use of advanced 
therapy medicinal products (ATMPs). 
Voluntary Harmonisation Procedures
The HPRA participated in seven voluntary 
harmonisation procedures (VHP) during 2014. A VHP 
is a co-ordinated work sharing assessment procedure 
for multinational clinical trials. This procedure was 
established by the national competent authorities 
for clinical trials from across the EU. In two of these 
VHPs, the HPRA acted as lead Member State for the 
assessment. 
New Marketing Authorisation 
Applications  
Before a new medicine can be placed on the Irish 
market, it must be firstly assessed and authorised 
(licensed) by the HPRA or by the European 
Commission on the recommendation of the European 
Medicines Agency (EMA). The assessment involves 
establishing that a medicine’s public health benefits 
outweigh its known risks. Where this is the case, it may 
be granted a marketing authorisation.
There are a number of routes through which a product 
can be authorised by the HPRA. These include the 
national procedure, the mutual recognition procedure 
(MRP) and the decentralised procedure (DCP). Both 
MRP and DCP involve the simultaneous submission of 
applications in a number of EU Member States. The 
assessment involves the input from all of the relevant 
competent authorities in evaluating the benefit / risk 
of the product(s). The DCP route differs from the MRP 
in that the product has not previously been authorised 
within the EU. 
During 2014, the following applications were assessed 
by HPRA: 
• 179 new national applications (including parallel 
product authorisations); 
• 40 applications made under the MRP; 
• 265 applications made under DCP. 
The HPRA acted as reference (lead) Member State 
for the assessment of seven of the MRP and DCP 
procedures. 
The centralised route is another mechanism whereby 
products can be authorised in Ireland. In this 
procedure, the assessment is co-ordinated out by the 
EMA and the authorisation is granted by the European 
Commission. The centralised route involves the 
submission of a single application to the EMA, and 
the authorisation once granted is valid in all Member 
States. The HPRA was allocated as lead assessor 
(rapporteur) or joint lead assessor (co-rapporteur) for 
eight new marketing authorisation applications by 
the Committee for Medicinal Products for Human 
Use (CHMP) at the EMA in 2014. These included 
treatments for a range of orphan diseases such as 
Huntington’s Disease and Wilson’s Disease as well  
as treatments for respiratory diseases and will be 
included in our assessment work during 2015. 
 
80
CLINICAL TRIALS  
WERE APPROVED TO 
COMMENCE IN IRELAND 
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Based on 2014 allocations, the HPRA was ranked  
fifth in the EU for rapporteurships for centrally 
authorised human products.
The total number of new products authorised in 
2014 was 615. This figure also includes 116 products 
authorised through the centralised route where the 
HPRA was not rapporteur or co-rapporteur. In overall 
terms, the number of products authorised continues 
to decrease relative to previous years and this is 
reflective of a trend throughout Europe which has 
been attributed to product patent lifecycles. The  
total number of new products authorised during  
2013 was 752.
 
Products Naming Group
During 2014, a team of human medicine assessors 
reviewed the existing policy on product names. To 
facilitate this process, an internal product naming 
group was established under the chairmanship of the 
Director of Scientific Affairs. The group advises on 
product name queries arising from the assessment 
process. Also in the past year, it revised the HPRA 
guidance document on names of medicinal products 
for human use.
Traditional Herbal and 
Homeopathic Medicinal Products
During 2014, 16 traditional herbal medicinal 
products (THMPs) were authorised by the HPRA. 
This is a simplified registration scheme which takes 
into account the tradition of use of these products. 
Legislation requiring registration for THMPs came 
into effect in full in 2011. The number of applications 
received by the HPRA since that time has remained 
low. A total of 35 THMPs were authorised by the end 
of 2014, relative to 19 at the end of the previous year.
There were 11 homeopathic medicinal products 
registered during 2014 under the simplified rules 
scheme, bringing the total number of products 
registered to 98.
Transfer Applications 
The HPRA processed a total 185 human medicine 
transfer applications in 2014. Of these, 158 related to 
the transfer of an existing marketing authorisation to a 
new marketing authorisation holder while, the balance 
related to a transfer of marketing authorisation holder 
prior to authorisation.
Variations 
After a medicine has been authorised, the terms 
of the marketing authorisation may need to be 
changed and the process whereby these changes are 
implemented is known as a “variation”. Examples of 
variations include the addition of a new indication, a 
new potential side effect, or updates to the company’s 
manufacturing or contact details. In the past year, 
the HPRA issued 13,205 variations to marketing 
authorisations for products authorised through the 
national or MR procedures. The number of variations 
was reduced relative to 2013. This was due to the 
implementation of a new work-sharing procedure for 
national variations which came into effect in 2013  
and has reduced submission numbers.
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Articles 45 and 46 - Variations to  
Update Product Information
The HPRA acted as rapporteur for eight paediatric 
Article 45 procedures and 14 procedures relating 
to Paediatric Investigational Plans (PIPs) during the 
past 12 months. These are important procedures 
from a public health viewpoint as they increase the 
availability of medicinal products specifically indicated 
for use in children.
Renewals 
In 2014, 349 renewals to marketing authorisations 
for products authorised through the national or MR 
procedures were processed. In general, the numbers 
of renewals are decreasing reflecting the lifecycle of 
the products in question.
Scientific Advice 
Scientific advice is a pre-authorisation activity which 
assists product and technology innovation and 
development. The EMA operates a scientific advice 
system for innovative products which will ultimately 
be the subject of applications under the centralised 
authorisation system. During 2014, the HPRA acted 
as lead in 42 EMA scientific advice procedures 
for medicines proposed for the treatment of a 
broad range of conditions. Areas of focus included 
medicines used in a variety of treatment areas 
including respiratory disorders, inflammatory diseases, 
diabetes mellitus and cardiovascular disease.
615
THE TOTAL NUMBER OF 
NEW PRODUCTS  
AUTHORISED  
IN 2014
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Veterinary Medicines
The HPRA, through its veterinary medicines licensing 
activities, is committed to protecting the welfare of 
treated animals, including fish, poultry, bees and 
domestic animals, as well as ensuring the safety 
of foodstuffs obtained from animals treated with 
veterinary medicines. The assessment of veterinary 
products also includes an evaluation of any possible 
risks to the user as well as the elaboration of risk-
management measures to control any risks. Finally, we 
also evaluate the potential impact of new veterinary 
medicines on the environment.
Product Classification Requests 
As the competent authority, the HPRA has an 
important role in deciding which types of products 
fall within the scope of the veterinary medicines 
legislation. Products that are regarded as medicinal 
but which do not have a marketing authorisation are 
deemed illegal in Ireland and may be seized by the 
Department of Agriculture, Food and the Marine. The 
HPRA work in this area is often secondary to that of 
the Department which polices the market. 
During 2014, 49 product classification queries were 
received in respect of veterinary medicines. A total of 
32 queries had been received the previous year.
 
New Applications
Before a new veterinary medicine can be authorised, 
it must be evaluated to confirm that its animal and 
public health benefits outweigh its known risks. The 
HPRA is responsible for authorising the majority of 
new products coming to the Irish market and is very 
active at a European level in leading the evaluation 
of medicines under the so-called decentralised and 
mutual recognition authorisation procedures. This 
work continues to be a key focus for the HPRA as, in 
addition to providing a service to industry, it leads to 
an increase in the number of available medicines in 
this country. Additional products coming to the Irish 
market, relating to innovative or high-tech veterinary 
medicines, are authorised centrally under the 
responsibility of the EMA.
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The accompanying graph shows new applications 
output for veterinary medicines during the past  
five years.
Variations
After a medicine has been authorised, the terms of 
the marketing authorisation may subsequently be 
varied. Examples of variations include the addition of 
a new indication or potential side effect, an alteration 
to the method of manufacture or a change in active 
substance suppliers.
Under European legislation, such variations must 
be notified to the competent authority which must 
evaluate and approve any significant changes. The 
goal is to ensure that medicines are produced in a 
robust and standardised manner, thus safeguarding 
against sub-standard products. This requirement, 
together with a more global manufacturing 
environment, has led to in an increasing number of 
variations in recent years. As a result, variations now 
represent approximately half of the total number 
of applications for veterinary medicines processed 
annually. 
The upward trend in variations output is shown in  
the accompanying graph. 
Renewals
New marketing authorisations are valid for five years 
from the date of first issue, after which time they are 
usually renewed for an indefinite period. The number 
of renewals is therefore a reflection of the number of 
new products brought to the market five years earlier 
which continue to be marketed nationally. In 2014, 
83 renewals of marketing authorisations for veterinary 
medicines were issued. HPRA activity levels in this 
area have fallen to around 3% of all case types, which 
is quite a significant decline since the earlier part of 
this decade. This reduction reflects a change in the 
legislative requirements in 2004 which eliminated the 
need for periodic renewals for all products.
Work-in-Progress Applications
The HPRA actively monitors work-in-progress data 
as an important indicator of our customer service 
levels. The overall figure for work-in-progress at the 
end of the year relevant to veterinary medicines was 
656 units (comprising various application types). The 
overall work-in-progress overdue figure was 65. These 
2014 figures are broadly similar to those recorded in 
the previously 12 month period. 
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The HPRA became the national competent authority 
responsible for the implementation of Directive 
2010/63/EU on the protection of animals used 
for scientific purposes on 1 January 2013. The 
accompanying national Regulations are set out in S.I. 
No. 543 of 2012. This authority was transferred from 
the Department of Health which regulated this area 
until 31 December 2012.
The work of the HPRA in this area represents a very 
important opportunity to improve the welfare of 
animals used for scientific purposes and to ensure 
that animals are used only where justified or required. 
The HPRA’s role involves inspection of animals 
and animal facilities as well as the evaluation of 
projects and individuals who carry out procedures 
or conduct euthanasia at the establishments 
concerned. Inspections, which may be announced or 
unannounced, follow a risk-based approach. 
Significantly during 2014, the HPRA as required under 
legislation, completed the inspections of all relevant 
national establishments previously licensed by the 
Department of Health. There was also an obligation 
to ensure that all those working in the sector had the 
required authorisations in place before the end of the 
year. This resulted in a significant increase in the level 
of activity as indicated in the following graph: 
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Medical Devices
Classification Requests
The HPRA received 25 applications for classification 
of medical devices or products queried as medical 
devices in 2014. This was a reduction relative to 2013 
when 45 applications were received. The queries 
emanated from other medical device competent 
authorities in Europe / the European Commission, 
from medical device manufacturers and from 
distributors.
The HPRA circulated six enquiries on medical device 
classification issues to other European medical device 
competent authorities with a view to seeking a 
consensus opinion in Europe on the classification or 
qualification of a specific product. 
Clinical Investigation 
Applications
The HPRA received 10 applications for clinical 
investigations of medical devices to be conducted in 
Ireland in 2014. The investigations related to areas 
such as respiratory, cardiac and software. This level of 
activity was broadly similar to the previous 12-month 
period. 
 
Product Registrations
The HPRA received 361 notifications of medical 
devices to the medical device register. These 
related to class I, in-vitro diagnostic and custom 
made medical devices and to system and procedure 
packs. Registration of these devices in the Member 
State in which the manufacturer or their authorised 
representative is based is required by legislation as 
there is a self-declaration of conformity made by the 
manufacturer. 
During 2014, 26 organisations registered with the 
HPRA as Irish based manufacturers or authorised 
representatives of class I, custom-made, in-vitro 
diagnostic medical devices, as manufacturers of 
system or procedure packs, or as sterilisers of medical 
devices. This was the same number of registrations  
as recorded in 2013.
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Controlled Substances 
Controlled Drugs
Import, export and holding of controlled drugs (for 
legitimate purposes) are subject to licensing. The 
Department of Health is the licensing authority while 
the HPRA handles the administrative and technical 
aspects of the application and licensing process.
Licensing activity, which consists primarily of export 
and import licences and letters of no objection, has 
increased marginally during recent years. 
 
Precursor Chemicals 
Precursor chemicals are legally used in a wide variety 
of industrial processes and consumer products, such 
as medicines, flavourings and fragrances.
The HPRA has been the licensing authority for 
precursor chemicals since 2010. Precursor chemicals 
are subject to different licensing requirements, 
dependant on the category.  
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Authorisation / Licensing  
of Sites and Facilities
The authorisation / licensing of manufacturers  
and wholesalers of medicines, of blood and  
tissue establishments and the approval of contract 
laboratories permits those facilities to carry out 
specified activities. The authorisation is based on 
satisfactory outcomes to HPRA inspections (see also 
under Safety Monitoring and Surveillance) during 
which adherence to relevant European guidelines  
is evaluated.
The total number of licences / authorisations in place 
at year end for the past five years is presented by 
category in the accompanying table. 
Variations to authorisations / 
licences for sites and facilities
Applications from authorisation and licence holders 
to vary the information on which the authorisation / 
licence is based are processed regularly by the HPRA. 
These variations, including updates and amendments, 
are classified as either administrative or technical.
  
Total Number of Licences/Authorisations (Sites) 2010 2011 2012 2013 2014
Manufacturers of Medicines for Human Use 86 88 87 89 92
Manufacturers of Veterinary Medicines 27 24 23 24 25
Investigational Medicinal Products for Human Use 51 50 47 49 53
Wholesalers of Medicines for Human use 220 243 258 269 272
Blood Establishments 4 4 3 4 4
Tissue Establishments 16 22 21 23 24
Laboratory Approvals 16 16 17 16 16
Total 420 447 456 474 486
Total number of Variations 2010 2011 2012 2013 2014
Total  645 684 1068 947 815
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Registrations for Active 
Pharmaceutical Ingredients 
and Brokers of Medicinal 
Products 
Under amendments (via the so-called ‘Falsified 
Medicines Directive’) to the Medicines Directive, 
2001/83/EC, that came into force at the beginning 
of 2013, manufacturers, importers and distributors 
of active pharmaceutical ingredients are required 
to register with the HPRA. Brokers of medicines for 
human use are also required to register. 
In 2014, there were 18 registrations relating to 
active pharmaceutical ingredients consisting of 
three for manufacturers, five for importers and 10 for 
distributors. In addition, there were 67 annual updates 
to existing registrations for active pharmaceuticals 
ingredients. No applications were received for 
registration of brokers of medicines for human use.
During 2013, the first year of registration, the  
HPRA had accepted 95 registrations consisting of 
22 manufacturer, 35 importer and 38 distributor 
registrations. There was also one registration accepted 
for a broker of medicines in 2013.
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Export Certificates 
Export certificates are required by health authorities 
in many non-European Economic Area markets as 
an indication that a product registered, authorised 
and / or manufactured in the country of origin is 
of appropriate quality. The inspection, audit and 
authorisation / registration programmes operated 
by the HPRA form the basis on which certificates 
are issued. Where possible, certificate formats, as 
published by the World Health Organization, are used.
There was an output of 5,219 export certificates as  
set out below. This represents an overall annual 
increase of 29% compared with 2013.
Export certificates can also be required to facilitate 
the registration of cosmetics in third countries. The 
certificates issued by the HPRA are based on the 
product concerned having a valid registration in  
the EU.
 
*The HPRA became the competent authority for cosmetics in October 2010 
Product Certification Activity  2010 2011 2012 2013 2014
Certification of Documents 234 239 272 223 231
Certificates of Good Manufacturing Practice  255 272 276 252 255 
for Active Substance and Finished Product  
Manufacturers 
Certificates for Medicinal Products  1200 1416 1350 1510 2112
Medical Device Free Sale Certificates 2142 1780 1522 1987 2535
Other  28 51 16 50 86
Total  4033 4146 3436 4022 5219
Product Certification Activity  2010 2011 2012 2013 2014
Cosmetics Free Sale Certificates 174* 388 210 242 246
29%
OVERALL ANNUAL  
INCREASE IN 2013,
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SAFETY AND  
COMPLIANCE  
MONITORING   
The ongoing monitoring of the safety of 
medicines, medical devices and other health 
products that have been authorised, licensed 
or registered for use in Ireland is a primary 
function of the HPRA. These activities are 
often referred to as post-market surveillance.
Pharmacovigilance 
Pharmacovigilance is defined as the science and 
activities relating to the detection, assessment, 
understanding and prevention of adverse reactions, or 
side effects, associated with the use of medicines. 
The HPRA, in co-operation with pharmacovigilance 
professionals in Europe and further afield, monitors 
adverse reaction reports to look for new types of 
reactions or changing trends in reporting. In particular, 
there is a focus on serious and potentially life-
threatening risks. If there appears to be a new and 
serious risk, the issue must be assessed to determine 
the impact on the overall benefit-risk profile of the 
medicine concerned and consideration is given as 
to how any new risks should best be managed and 
communicated to healthcare professionals  
and patients.
During 2014, the HPRA received a total of 2,884 valid 
new adverse reaction reports associated with the use 
of human medicines in Ireland. While this represents 
a slight increase when compared with the 2,835 
reports received in 2013, overall reporting rates have 
remained quite consistent in recent years. In addition, 
3,285 follow-up reports were received during the past 
12 months. 
The majority of adverse reaction reports are notified 
to the HPRA by pharmaceutical companies marketing 
the medicines, also known as marketing authorisation 
holders. It is important to note that reports submitted 
by pharmaceutical companies to the HPRA, in the 
  
 
context of their regulatory reporting obligations,  
will have initially been notified to them by healthcare 
professionals, patients or consumers.
Nearly 20% of the reports received in 2014 were 
associated with the use of medicines subject to 
additional monitoring requirements. The requirements 
for additional monitoring, introduced in the context 
of the pharmacovigilance legislative revisions in 2012, 
highlight the importance of reporting all suspected 
adverse reactions associated with the use of these 
products which are identifiable by a black inverted 
triangle included on the accompanying package 
leaflet (PL) and the summary of product characteristics 
(SmPC). The contribution of reporters in highlighting 
experience with these new medicines, for which 
limited data may be available, is especially helpful. 
Source of Suspected New Adverse  
Reaction Reports % 
Pharmaceutical company 67 
Community Care doctor 7
General Practitioner 4
Hospital Doctor/Specialists 4
Hospital Pharmacist 4
Community Pharmacist 4
Nurse 4
Patient/Consumer 3
Clinical Trial reports 2
Other 1
Human Medicines
A range of tools is employed to monitor the safety of 
health products including the assessment of reports 
of suspected adverse events / incidents and reactions 
(also known as side effects), conducting scheduled 
safety reviews, monitoring field safety corrective 
actions to medical devices and evaluating new 
and emerging data from trials and studies. Quality 
issues concerning how a product is manufactured, 
packaged, labelled or distributed and stored may also 
arise at the post-market stage.
In certain cases, where it is established that the risks 
associated with a particular product outweigh the 
benefits for those using it, the manufacturer and/or 
the HPRA may decide that it is necessary to remove or 
recall that product from the market. We work with all 
stakeholders impacted to ensure that such recalls are 
managed in a timely and effective manner.
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Reporting rates are also influenced by their ease 
of recognition and may be stimulated by publicity 
about a particular medicine or reaction. In addition, 
reporting rates are also influenced by proactive 
and repeated requests to healthcare professionals 
to submit reports on certain medicines as part of 
ongoing post marketing surveillance, as well as other 
promotional and data collection activities. All reports 
received are carefully evaluated and monitored, with 
reports of experience with use regularly highlighted 
and reinforced through HPRA communications.
In many instances, reports submitted to the HPRA 
stem from suspicions raised by observation of an 
unexpected and/or unwanted event, in the context of 
use of a medicine. They also include adverse reactions 
known to occur in association with medicines such as 
those described in the product information.
The medicines most frequently included in reports 
to the HPRA accounted for over 60% of the adverse 
reaction reports received during 2014 (see below 
table). It is incorrect to interpret the presence or place 
of a medicine on this list as an indicator of safety or 
risk. The number of reports received cannot be used 
as a basis for determining the incidence of a reaction 
as neither the total number of reactions occurring, nor 
the number of patients using a medicine, is known.   
Suspect Medicine(s)/  
Class of Medicines  
included in Reports
Number of 
Reports in 2014
Monoclonal Antibodies 624
Vaccines used in the primary  
immunisation
286
Clozapine 198
Tyrosine Kinase Inhibitors 162
Anticoagulants 156
Fingolimod 128
Human Papilloma Virus (HPV) 
Vaccine
56
Bortezomib 50
Levodopa/carbidopa 50
Interferons 49
 
Of the reports received by the HPRA, 168 patients 
were reported to have died while on treatment. 
The following table outlines the medicines / class 
of medicines associated with the highest number of 
reports.
Suspect Medicine(s)/  
Class of Medicines
Number of 
Reports in 2014
Monoclonal Antibodies 48
Anticoagulants 19
Tyrosine kinase inhibitors 13
Clozapine 13
Antidepressants 11
Ceprotin 7
Mefloquine 4
Colony-stimulating factors  4
Methotrexate 3
Bortezomib 3
 
In many of these cases, the patients concerned had 
significant underlying illness and were treated with 
multiple medicines and/or surgery, which may also 
have contributed to the outcome. In addition, many 
of these cases were influenced by disease progression 
or other complications unrelated to the medicine. 
The majority were associated with medicines used in 
the context of products subject to close monitoring, 
those used in the management of severe underlying 
medical conditions, in patient support programmes 
and special patient monitoring programmes such as 
those in place for clozapine. 
Online Reporting 
The online reporting system, available to healthcare 
professionals and patients / consumers, continued to 
be used during 2014 with some 391 reports submitted 
via our website by year end. While this indicated a 
decrease compared with usage of the online system 
in 2013, the volume of reports received directly from 
patients and consumers increased, with the majority  
of these reports received by telephone.  
 
Monitoring Compliance with  
Pharmacovigilance Obligations
Company / sponsor compliance with 
pharmacovigilance obligations is continuously 
monitored and the associated inspection programme 
continued in 2014 (see also Inspections and Audits on 
page 51).
In May 2014, the HPRA hosted an information session 
for the Association of Pharmaceutical Manufacturers 
of Ireland (APMI) which included an overview of the 
HPRA’s pharmacovigilance inspection programme.
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Vigilance Assessment  
and Risk Management
The HPRA proactively participates and leads in risk 
management planning for medicines in the pre-
authorisation phase, throughout product lifecycles, in 
signal management, as well as benefit-risk evaluations 
delivered through evaluation of periodic safety 
update reports and pharmacovigilance referrals. 
The HPRA is represented at a European level on 
the Pharmacovigilance Risk Assessment Committee 
(PRAC) and works continuously with the EMA and 
other Member States within the EU to ensure robust 
and timely decision-making on safety-related issues.
Signal Management Activities
Signal detection and management activities allow 
for enhanced detection of new or changing safety 
issues relating to medicines available on the Irish 
and EU market thus allowing more rapid action when 
necessary to protect public health. During 2014, the 
HPRA continued its participation in the work-sharing 
initiative for signal detection within the EU acting as 
lead member state in the detection and management 
of signals for 58 active substances authorised 
nationally. The HPRA was also responsible for the 
management of any signals detected in relation to 21 
centrally authorised active substances / combination 
of active substances for which the HPRA was 
rapporteur. Labelling changes were also implemented 
for nationally authorised products during the past 
year following PRAC recommendations thus ensuring 
improved medicines information is provided to 
healthcare professionals and patients. 
The HPRA also participated in the Signal Management 
Review Team at EMA on a regular basis which focuses 
on improving tools, methods and processes for signal 
detection as well as developing methodological 
guidance.
Periodic Safety Update Reports
Periodic safety update reports (PSURs) are 
pharmacovigilance documents submitted by 
marketing authorisation holders at defined time 
points following authorisation of products. PSURs are 
intended to provide a continuous cumulative update 
and analysis on the benefit-risk profile of a medicine 
throughout its lifecycle. 
The new EU PSUR single assessment (PSUSA) 
procedure, which allows medicines which are the 
subject of different marketing authorisations, but 
containing the same active substance or combination 
of active substances, to undergo a single periodic 
assessment at EU level, was fully implemented 
during 2014. The outcome of these procedures may 
lead to automatic harmonised regulatory action if 
considered necessary (such as variation, suspension or 
revocation). The HPRA also actively participated in the 
HMA PSUR work-sharing project. National and HMA 
PSUR work-sharing procedures will now be phased 
out as a result of full implementation of the PSUSA 
procedure.
During 2014, the total HPRA output was 1759 PSURs 
submitted as national, mutual recognition, centralised, 
EU single-assessment and PSUR work-sharing 
procedures.
Safety Referrals
For a safety-related referral, the EMA conducts a 
scientific assessment of a particular medicine or class 
of medicines, through the PRAC, on behalf of the 
EU. Following this assessment, the PRAC makes a 
recommendation for a harmonised position across  
the EU which is ultimately implemented nationally  
by the HPRA.
The past 12 months was a very active period in 
terms of EU safety-related referrals with the HPRA 
participating as concerned member state in 15 of 
these procedures. The implementation of more 
rigorous timescales for referrals has resulted in more 
prompt assessments that contribute to safer and 
more effective use of medicines though labelling 
changes and, when necessary, restrictions. There 
has been increased involvement of stakeholders in 
decision-making during the referrals process at EU 
level and the HPRA has also engaged directly with 
healthcare professionals and patient organisations 
in order to enhance stakeholder involvement in risk 
communication at national level.
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Risk Management Plans and Risk  
Communications 
All new applications for marketing authorisations for 
human medicines now include a risk management 
plan (RMP) documenting the proposed risk 
management system to be implemented once a 
marketing authorisation is granted. This facilitates 
the balancing of access to medicines with proactive 
planning of post authorisation studies and risk 
minimisation measures. During 2014, the total 
output was 523 RMPs (new or updated) submitted 
via national, mutual recognition, decentralised and 
centralised procedures. The HPRA has consistently 
demonstrated its commitment to the European 
pharmacovigilance processes by acting as PRAC 
rapporteur for 10 new marketing authorisation 
applications since the establishment of the new 
processes in July 2012.
As part of its role to promote and support the safe 
and effective use of medicines, the HPRA reviewed 
and approved 36 Direct Healthcare Professional 
Communications (DHPCs) which provided new safety 
information or risk minimisation advice to prescribers. 
These were published on the HPRA website. The 
HPRA also continued to actively review and approve 
educational materials, required to support the safe 
and effective use of medicinal products on the Irish 
market, for distribution to healthcare professionals 
and/or patients.
Post Authorisation Safety Studies
Post Authorisation Safety Studies (PASS) are non-
interventional studies carried out in order to obtain 
further information on the safety of medicinal 
products which are already authorised, or to measure 
the effectiveness of risk minimisation activities that 
have been introduced. The results of a PASS help to 
further evaluate the safety and benefit-risk profile of 
a medicine already in use and may have an impact on 
the marketing authorisation of the product. During 
2014, the HPRA provided assessment input to 131 
PASS protocols and reports.
36 
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Haemovigilance
The HPRA is the competent authority for legislation 
concerning blood and blood components. 
Haemovigilance refers to a set of organised 
surveillance procedures relating to serious adverse or 
unexpected events or reactions in donors or recipients 
and the epidemiological follow-up of donors.
The HPRA continued its interaction with the National 
Haemovigilance Office (NHO) during 2014, including 
discussion of issues of mutual interest and concern at 
bilateral quarterly meetings. 
Following collaboration with the NHO, the HPRA 
submitted an annual report of serious adverse 
reactions and events to the European Commission 
during 2014. The report reflected information 
received from January to December 2013 and 
included information on 72 serious adverse reactions 
and 167 serious adverse events which met the 
mandatory legislative reporting requirements. While 
the overall figures for reporting remain consistent, 
they reflect a decrease in the order of approximately 
44% for serious adverse reactions and an increase 
of 42% for serious adverse events when compared 
with the previous year’s reporting rates. These trends 
are not unexpected and are consistent with the 
impact of changes to agreed, EU reporting criteria. 
The remaining 14 donor reaction reports, while not 
fulfilling the mandatory reporting requirements, were 
included on a voluntary basis as requested by the 
Commission.   
The HPRA continued to work closely with the Irish 
Blood Transfusion Service (IBTS) and the Department 
of Health to progress with formalising arrangements 
for haemovigilance activities. This included a 
contribution to the review of options proposed by 
the IBTS / NHO for the online reporting system, to 
facilitate simultaneous submission of mandatory 
reports to both the NHO and HPRA. Pending 
finalisation of these formalised arrangements, and 
access to an online reporting system, the interim 
arrangements first agreed for reporting to the HPRA in 
2008 continued to operate throughout the past year. 
These arrangements have facilitated consistency and 
timeliness in reporting allowing appropriate regulatory 
oversight. The HPRA also completed an audit of the 
NHO’s monitoring system and activities during 2014. 
Blood, Tissues  
and Cells, Organs
THE HPRA COMPLETED  
AN AUDIT OF THE NHO’S  
MONITORING SYSTEM AND  
ACTIVITIES DURING 2014
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Tissue and Cell Vigilance
The HPRA is the competent authority in Ireland for 
the purposes of the EU tissues and cells legislation. 
The legislation focuses on standards of quality and 
safety for donation, procurement, testing, processing, 
preservation, storage and distribution of human 
tissues and cells.
There were a number of tissue and cell vigilance 
activities progressed during 2014. 
The HPRA submitted an annual report on serious 
adverse reactions and events associated with tissues 
and cells to the EU Commission during 2014. The 
report reflected information received in 2013 and 
consisted of some 47 reports, 42 of which met the 
legislative reporting requirements, including nine 
serious adverse reactions and 33 serious adverse 
events. The overall figures reflect a slight increase 
over the previous year’s reporting rates with increased 
numbers of adverse reactions and a slight decrease 
for serious adverse events. The remaining five donor 
reaction reports, while not fulfilling the mandatory 
reporting requirements, were included on a voluntary 
basis as requested by the Commission.   
Human Organs for  
Transplantation
The HPRA and the Health Service Executive 
(HSE) were appointed as the responsible national 
competent authorities for the legislation on standards 
of quality and safety of human organs intended for 
transplantation in 2012. During 2014, the HPRA 
continued to liaise closely with the HSE lead and 
colleagues responsible for this area in relation to 
the development of report forms and guidance to 
facilitate serious adverse reaction and event reporting. 
During the past year, the HPRA received nine reports 
of serious adverse reactions and events associated 
with organ donation / transplantation. The majority 
of these reports involved issues related to retrieval, 
assessment and equipment which have been followed 
up with the HSE. In the context of its regulatory role, 
the HSE acts as the competent authority for clinical 
and transplant related matters under the framework 
for quality and safety.
THE HPRA COMPLETED  
AN AUDIT OF THE NHO’S  
MONITORING SYSTEM AND  
ACTIVITIES DURING 2014
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Pharmacovigilance
The operation of a national pharmacovigilance 
system, which is based on the receipt and review of 
reports of suspected adverse events, is a primary 
role of the HPRA. An effective system enables us to 
monitor the continued safety and efficacy of veterinary 
medicines under actual use conditions. Where 
necessary, the HPRA will intervene and introduce new 
risk management measures for a product. In so doing, 
we strive to prevent adverse effects in other animals 
as well as in humans exposed to the medicine.
The effectiveness of the system is dependent on the 
submission of reports by veterinarians, pharmacists, 
licensed merchants and others involved in dispensing 
or using the products concerned. These reports may 
be submitted either directly to the HPRA or to the 
companies’ marketing the products. The companies, 
in turn, must relay the data to the HPRA.
During the 12 months under review, the HPRA 
received 300 national reports of suspected adverse 
events with veterinary medicines. This continued the 
upward trend in the number of reports received in 
recent years. 
Periodic Safety Update Reports
Evaluating PSURs on individual products accounts for 
approximately 30% of the HPRA’s overall veterinary 
medicines workload currently and is evidence of 
our commitment to the ongoing assessment of 
benefits and risks. Our work includes the assessment 
of individual medicines on the market in Ireland as 
well as a work-sharing initiative where we lead, or 
contribute to, the assessment of a class of veterinary 
medicines for the European Union.
The HPRA completed the evaluation of 852 PSURs in 
2014 down from a figure of 1,072 in the previous year. 
 
Use of Veterinary Antimicrobials 
in Ireland
Under a European programme known as the European 
Surveillance of Veterinary Antimicrobial Consumption 
(ESVAC), the HPRA collects annual information on 
the consumption of antibiotics from each marketing 
authorisation holder. This information is important 
as it allows us to benchmark our usage rate against 
those of our European neighbours. It also establishes 
a baseline against which future policy decisions 
regulating the use of antibiotics can be mapped.  
The consumption level for 2013 was 100 tonnes.  
Even if there has been an increase in the overall 
tonnage used since we started collating the 
information in 2009, it should be noted that 
fluctuations of +/- 5% can occur annually due to a 
variety of factors, such as seasonal disease patterns, 
end of year sales promotions, animal slaughterings 
and exports. Moreover, the size of the national 
livestock herd is expected to have increased during 
this period. 
The HPRA continues to work with other EU veterinary 
medicines agencies and the EU Commission to help 
ensure that veterinary antibiotics are used responsibly 
in accordance with their approved conditions of use.
Veterinary Medicines
Consumption of Antibiotics 2009 2010 2011 2012 2013
Tonnes sold 88.3 93.9 85.2 97.4 100
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2011 2012 2013 2014
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The HPRA is responsible for a number of risk-based 
market surveillance programmes. These include 
proactive activities such as the sampling and 
analysis programme and the advertising compliance 
programme, and reactive activities such as the quality 
defect and recall programme. 
We also operates an exempt medicines notification 
scheme designed to monitor the importation and 
supply of unauthorised medicines. In addition, we 
carry out a programme of regulatory compliance 
inspections at the premises of marketing authorisation 
holders. The latter is designed to assess the level of 
compliance against national legislation relating to the 
placing on the market and advertising of medicines.
Sampling and Analysis  
Programme
The risk based sampling and analysis programme 
is part of our monitoring of the quality and safety 
of medicines and our identification of borderline 
medicinal / non-medicinal products that may be on 
the Irish market. This is achieved through analytical 
testing and / or examination of packaging and 
labelling of medicines, active substances, borderline 
medicinal / non-medicinal products and enforcement-
related samples. 
A total of 506 product samples were sent for 
analytical testing / examination work during 2014. 
This was a 16% increase compared with the number 
tested the previous year. Details are provided in the 
accompanying tables.
Examination of Packaging and Labelling 
The packaging and labelling of 169 medicines and 
other products available on the Irish market were 
examined. Over 700 individual checks were carried 
out on the samples including reviews of the safety 
information contained in the package leaflets.   
Authorised medicines accounted for 86% of the 
products examined and all of these were examined 
for signs of counterfeiting and tampering. No issues 
were identified in this regard. Borderline products 
accounted for the remaining 14%. In total, 35% of the 
products examined were parallel imported or parallel 
distributed products. Braille compliance checks were 
also carried out on 25% of the products. 
The following table outlines the type of examinations 
that were carried out:
Categories of products  
examined for packaging  
and labelling attributes
Number of 
samples 
examined
Authorised medicines   
(including samples for  
Braille compliance checks)
81
Authorised parallel imported  
and parallel distributed medicines
65
Borderline medicinal/non-medicinal 
products (associated with HPRA 
Classification Committee work)
23
Total 169
Market Compliance – Human 
and Veterinary Medicines
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Analytical Testing 
During the year in review, 337 medicinal and other 
product samples were sent for analytical testing. 
These included 250 samples sent to governmental 
laboratories in Ireland and 85 samples sent to 
governmental laboratories in other countries as part 
of European working-sharing arrangements. Two 
samples were sent to a non-governmental laboratory 
due to the nature of the testing required.  
Product categories selected for 
analytical testing in 2014
Number of 
samples 
analysed
Physico-chemical Analysis / 
Biological Analysis:
Nationally authorised medicines  
for human use
109
Enforcement-related products for 
human use
89
Non-biological Active / Intermediate 
pharmaceutical ingredients
32
Centrally authorised medicines  
for human use  
23
MRP/DCP authorised medicines  
for human use
15
Nationally authorised medicines  
for veterinary use
13
Borderline medicinal / non-medicinal 
products for human use
10
Other product categories 16
Microbiological Analysis:  
Nationally authorised medicines  
for human use
20
Nationally authorised medicines  
for veterinary use
5
Parallel imported and parallel 
distributed medicines for human use  
3
Borderline medicinal / non-medicinal 
products for human use 
2
Total 337
A breakdown of the types of samples tested is 
shown in the accompanying table. Approximately 
59% were authorised medicines, while 30% related 
to enforcement and borderline medicines / non-
medicines. The remaining 11% were actives and other 
substances.
Participation in EU Co-ordinated Market 
Surveillance Activities
The HPRA is an active participant in EU surveillance 
programmes that involve the sampling and analysis of 
medicines. This is achieved by its active participation 
in the Official Medicines Control Laboratories (OMCL) 
network, co-ordinated by the European Directorate for 
Quality of Medicines (EDQM) in Strasbourg.
The 2014 programme included: 
Centrally authorised medicines: 
• 24 sampled in Ireland for testing at OMCLs in 
other Member States and five tested at the HPRA’s 
OMCL (Public Analyst’s Laboratory, Galway). 
• 18 of the 29 products were sampled as part of an 
anti-counterfeiting collaboration.  
MRP/DCP: 
• 15 MRP / DCP medicines sampled in Ireland and 
analysed at other Member State OMCLs. 
• 3 MRP/DCP products analysed at HPRA’s OMCL 
as part of an MRP/DCP project run by the HPRA.
Other products: 
• A number were analysed at the HPRA’s request at 
OMCLs in other Member States. For example, 30 
products underwent microbiological analysis at 
the Finnish and Czech OMCLs. 
• The HPRA organised the analysis of 14 biological 
finished product samples and 12 biological 
active pharmaceutical ingredient / intermediate 
pharmaceutical ingredients that were obtained 
from manufacturing facilities in Ireland or from 
the Irish marketplace. Approximately half of these 
samples were tested by OMCLs in other countries 
for the HPRA.  
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Principal Findings
Analysis Findings
Laboratory 
analysis
While the majority of samples 
tested were compliant with 
their specifications, 22 out of 
specification results were obtained.  
There were also 11 deficiencies 
identified in the analytical methods 
and specification documents used 
by manufacturers of medicines.  
Packaging 
and labelling
In total, 22 non-compliances were 
identified across samples of a 
number of human and veterinary 
authorised medicines. Of these, 
eight related to parallel imported  
or parallel distributed products.  
Illegal 
Medicines
Nine samples across seven products 
were analysed and identified as 
illegal medicines.
Appropriate follow-up actions were taken in each 
case.
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Quality Defects and Recalls
The quality defects and recalls programme 
investigates, on the basis of risk to public and animal 
health, reports of suspected quality defects in both 
human and veterinary medicines and in their related 
active substances. The HPRA also co-ordinates any 
subsequent recall actions on the Irish market. Reports 
are received from both the Irish market and through a 
global network of regulators via a rapid alert system.
Number and Types of Quality Defects 
A total of 816 quality defects were reported to, or 
identified by, the HPRA during the past 12 months 
representing an increase of 5% on the figure for 2013. 
Medicines for human use accounted for 777 quality 
defect reports with 39 reports concerning veterinary 
medicines. 
The following table indicates a levelling off in the 
number of quality defect investigated by the HPRA 
over the last five years. The classification of these 
defects is shown below:
Year 2010 2011 2012 2013 2014
Minor Quality Defects 241 314 236 230 248
Major Quality Defects 332 364 303 300 199
Critical Quality Defects 173 231 189 235 365
Number of Quality Defect Reports Not Justified 5 8 13 9 4
Total Number Quality Defects 751 917 741 774 816
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Of the total number of reports received in 2014, 
falsified medicines was the most common category 
accounting for 24% of reports. While this represented 
a significant increase in this area, only six reports were 
determined to affect Ireland with the majority relating 
to supply of the implicated products by unauthorised 
wholesalers in Europe.  
Other common categories of defect were:
• Contamination issues - 16%.
• Stability issues - 11%.
• Non-compliance with marketing authorisation  
- 8%.
Critical quality defects, which are those defects 
defined as potentially life-threatening or a serious 
risk to health, accounted for 365 of the total reports 
received. This was an increase on the 235 such reports 
received in 2013. Overall, 45 of the 2014 reports were 
deemed to affect Ireland. These included 10 product 
contamination issues, 10 lack of sterility issues and 
six falsified medicine issues. However, in none of the 
cases was a falsified product identified on the Irish 
market. The remaining 19 critical reports related to 
a range of issues including product preparation/
administration, changes in benefit / risk and 
packaging components.
Sources of Quality Defects 
As in previous years, other competent authorities and 
pharmaceutical companies accounted for the majority 
of reports of quality defects received. 
Source of Reports Human Medicines
Veterinary 
Medicines
Other Competent 
Authorities (Regulators)
366 12
Companies 
(Manufacturers, 
distributors and/or 
authorisation holders)
329 23
Community Pharmacists 33
HPRA Staff Members 23 4
Hospital Pharmacists 18
Patients and/or Members 
of the Public
5
Other Health Care 
Professionals
3
Recalls of Human and Veterinary  
Medicinal Products 
In order to protect the health and safety of patients, it 
is deemed necessary in certain cases to withdraw, or 
recall, products from the Irish market. During the year 
in review, 102 medicine recalls occurred. Of these, 
96 related to human medicines and six to veterinary 
medicines. 
As regards the level of recall, 16% were to patient / 
user level, 37% to pharmacy / retail level and 47% to 
wholesale level. 
Exempt medicines accounted for 11% of recalls of 
human medicines while compounded products for 
human use accounted for 14%. Of the total number of 
recalls from the Irish market, 24% related to products 
manufactured at an Irish facility.
The most common causes of human medicine  
recalls were:
• Contamination issues (25)
• Stability issues (15)
• Non-compliance with GMP (8)
• Non-compliance with marketing authorisation (8)
• Lack of sterility assurance (7)
• Non-compliance with specifications (7)
• Unauthorised products on the Irish market (5)
In respect of veterinary medicines, three recalls related 
to printed packaging components, one concerned 
a stability issue and one was due to non-compliance 
with specifications. There was also one unauthorised 
veterinary product found on the Irish market.
102
MEDICINE RECALLS  
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Retail Sales Monitoring 
General Retail Sale Investigations
The sale of consumer health products by retail 
outlets such as grocery shops, health food shops 
and, in some instances pharmacies, is monitored 
by the HPRA using a proactive and reactive, risk 
based, retail monitoring programme. During 2014, 
46 cases, some of which involved multiple products, 
were investigated. Of these, 29 related to the sale 
of medicines that did not carry a valid registration 
number or authorisation number for the Irish market. 
The remaining 17 pertained to the sale of medicines 
that had been incorrectly classified as non-medicines 
by those placing them on the market. A total of 224 
products that did not carry a valid registration or 
authorisation for the Irish market were removed  
from sale.
Exempt Medicines Programme
In general, medicines placed on the Irish market must 
be authorised by the HPRA or, in the case of centrally 
authorised products, by the European Commission. 
However, European regulations do provide for an 
exemption to this rule. In this case, registered doctors 
and dentists are permitted to prescribe unauthorised 
medicines for individual patients under their direct 
responsibility in order to fulfil the special needs of 
those patients. Such products are defined in Irish law 
as ‘exempt medicinal products’.
Under the medicinal products regulations, wholesalers 
and manufacturers of medicines are obliged to notify 
certain information to the HPRA in relation to any 
exempt products that they source. This is done by 
submitting electronic notification to a HPRA database. 
This information facilitates, when required, the 
effective recall of any defective exempt medicine from 
the Irish market.
In 2014, 3,235,232 packs of exempt medicines were 
notified to the HPRA compared to 2,555,351 packs 
during the previous 12 months. We also answered 
in the region of 200 queries related to the exempt 
medicinal products programme. 
We continue to work with stakeholders in several areas 
to identify and develop solutions aimed at limiting the 
use of exempt medicines in Ireland.
Regulatory Compliance Inspections 
These risk based inspections are carried out at the 
premises of marketing authorisation holders. The 
inspection seeks to determine the level of compliance 
with the legal requirements for the marketing and 
advertising of medicines. Five inspections were carried 
out and a number of non-compliances were identified. 
These were followed up and we monitored the 
implementation of corrective actions at the companies 
concerned. This inspection activity is linked to our 
advertising compliance programme.
Human Medicines Advertising Compliance 
Programme
It is our role at the HPRA to monitor and review 
advertising and promotion activities by the industry 
for compliance with the requirements of the Medicinal 
Products (Control of Advertising) Regulations, 2007.
During 2014, 397 advertisements were reviewed for 
compliance. While the majority were found to be 
compliant, non-compliances were identified in respect 
of 106 advertisements. In one instance, a detail aid 
was recalled from sales representatives as it included 
an indication that was not specified in the SmPC.
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Total Advertisements Reviewed Non-Compliances Identified
Proactive Monitoring:  
Pre-planned Projects 13 237*
49 individual advertisements  
were non-compliant.
Proactive Monitoring:  
Includes Randomly  
Selected Projects
47 127* 49 individual advertisements  
were non-compliant.
MAH Inspections  
Performed 5 Multiple
One critical and seven major 
deficiencies identified across a number 
of areas. One major related directly to 
advertising activities.
Complaints Received 10 16*
Four complaints upheld as being valid.  
Six advertisements in total were  
non-compliant. One complaint was 
carried into 2015.
Queries Received 43 17* Two advertisements were  
non-compliant.
 
*Note: Some of these figures are approximate. 
They may include website advertisements, and each 
page of a website is counted as one advertisement, 
because multiple pages can have multiple 
advertisements.  
In all cases of non-compliance identified via the 
different elements of the programme, the HPRA 
supervised implementation of the necessary corrective 
and/or preventative actions by the marketing 
authorisation holder.   
We also developed an approach to the surveillance of 
advertisements in digital media. This involved periodic 
reviews of social media content. No breaches of the 
advertising regulations were identified. This work will 
continue.
The five aspects to the programme are shown in the table below:
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Vigilance 
The medical devices vigilance system, which was 
established under European medical device directives, 
aims to minimise risks to the safety of patients, users 
and others. Vigilance activities include the following:
• The submission of vigilance reports by 
manufacturers and users to the relevant 
competent authorities (the HPRA in Ireland); 
• The evaluation of reported incidents by the 
competent authorities; 
• The dissemination of information, which may be 
used to prevent recurrence of the incident, or to 
alleviate the consequences of such incidents, in 
cases when it is necessary to do so; 
• A device being updated, modified or taken off the 
market in cases when it is necessary to do so. 
In 2014, there was a particular HPRA focus on the 
review and further development of medical device 
safety communications.  
2014 Reports in Summary 
A total of 2,113 medical device vigilance reports were 
received and assessed representing a slight decrease 
on 2013. Manufacturers accounted for 52% of all 
vigilance reports received in 2014 while 39% were 
received from competent authorities. In total, 33% of 
the reports received were as a result of an incident on 
the Irish market.
Concerning the regulatory response to the reports 
received, 63% resulted in an action being taken in 
Europe. In Ireland, the HPRA published online 548 
manufacturer’s field safety notices directly affecting 
the local market which represents a slight increase 
when compared with 2013. These notices are 
intended to inform users of safety issues relating to 
medical devices. 
Safety information was also highlighted to the public 
through HPRA safety notices. There were 47 such 
notices sent to relevant interest groups and published 
on the HPRA website. During the year in review, 
the HPRA issued 104 national competent authority 
reports.
Medical Devices
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2014 Reports by Product Type
Single use devices, particularly in the areas of infusion, 
transfusion and dialysis, and orthopaedic implants 
accounted for a large proportion of vigilance reports 
received. Reports continue to be received relating to 
software issues associated with medical devices. 
 
In the area of in-vitro diagnostic (IVD) devices, the 
largest number of vigilance reports received related 
to clinical biochemistry. Field safety corrective actions 
relating to clinical biochemistry reagents and analysers 
continued to have a high impact on the number of 
IVD vigilance cases.
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Market Surveillance
Medical device surveillance activities are focused 
on protecting the health and safety of those who 
use medical devices by ensuring that all devices on 
the Irish market comply with the relevant European 
directives.
Surveillance Cases
In 2014, the HPRA commenced 319 market 
surveillance cases. A significant number of cases 
related to notified body certificate withdrawals.
Certificate Withdrawals
The HPRA was notified of 583 notified body certificate 
withdrawals in 2014. Those with implications for the 
Irish market and those resulting from reduction or 
designation of notified bodies were investigated.
Technical File Reviews
In 2014, the HPRA increased its focus on review of 
technical documentation both in the context of market 
surveillance activities and notified body oversight.  
A total of 28 technical file reviews were completed in 
2014. The proactive technical file reviews focused on 
IVD manufacturers in conjunction with audits, technical 
reviews of client files certified by the NSAI and other 
technical files requested as part of reactive market 
surveillance.
Designation and Monitoring  
of Irish Notified Bodies 
During 2014, the HPRA conducted two surveillance 
assessments of the National Standards Authority of 
Ireland (NSAI). One of these surveillance assessments 
was carried out in its US-based office while the other 
was carried out in its Dublin headquarters. In addition, 
two observed audits were conducted by HPRA of 
NSAI staff auditing medical device manufacturing 
sites.
The HPRA received 122 certification notifications from 
the NSAI, including certificate issuance, modification 
and withdrawal, which were then uploaded as 
required to the European EUDAMED database.
319
MARKET SURVEILLANCE CASES 
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Proactive Market Surveillance
Post market surveillance of cosmetic products includes 
a national sampling programme and involves close 
co-operation between the HPRA and the HSE. In this 
context, the HSE Environmental Health Service and 
the three Public Analysts’ Laboratories based in Cork, 
Dublin and Galway were involved in the preparation of 
the market surveillance schedule and the subsequent 
proactive sampling and analysis of cosmetic products 
on the Irish market.
There is no pre-market approval of cosmetic products 
on the European market and, therefore, the safety 
of cosmetic products is monitored through post-
market surveillance, including review of the product 
information file (PIF). The requirement to have a 
PIF in place prior to placing a cosmetic product on 
the market is mandatory and is given legal status 
by virtue of Article 11 of the Cosmetic Products 
Regulation (1223/2009). Six product information files 
were technically reviewed in this regard. Labelling 
reviews were also carried out as part of the proactive 
surveillance campaign.
Reactive Market Surveillance
Reactive surveillance includes investigation of quality 
related complaints (compliance cases) and reports of 
undesirable effects relating to the use of cosmetics 
(vigilance cases). During 2014, 116 compliance cases 
were initiated and these accounted for the vast 
majority of investigations. There were 21 vigilance 
cases investigated with one product being withdrawn 
from the Irish market.
Reactive surveillance of cosmetic products also 
includes investigation of in-coming RAPEX Alerts 
(EU safety alerts for cosmetic and other consumer 
products). The National Consumer Agency (now 
part of the Competition and Consumer Protection 
Commission) is the national contact point for Rapex 
in Ireland. In conjunction with the HSE, the HPRA 
investigated 101 alerts on the basis of risk and, where 
appropriate, market action was taken. One of the 
products was found on the Irish market. In respect of 
this, a reaction report was submitted to the European 
Commission outlining the market actions taken.
Cosmetics
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As part of our regulatory role, we are focused 
on ensuring industry compliance with relevant 
standards and legislation. Our inspections and audits 
programme includes:
• Regular inspections of manufacturers (human and 
veterinary) and wholesalers (human) of medicines 
to check for compliance with EU guidelines on 
Good Manufacturing Practice (GMP) and Good 
Distribution Practice (GDP), respectively. 
• Inspection of clinical trial sites for compliance 
with EU and International Conference on 
Harmonisation (ICH) guidelines on Good Clinical 
Practice (GCP). 
• Inspection for compliance by marketing 
authorisation holders with Good 
Pharmacovigilance Practice.
• Regular audits of the NSAI, the notified body for 
medical devices that is designated by the HPRA. 
• Proactive audit of manufacturers of Class I devices 
and ‘for cause’ audits as required, for example, as 
part of the follow-up to a defect.
• Inspection of blood, tissue and cells, and organ 
establishments for compliance with applicable 
EU guidelines on the quality and safety of blood, 
blood products, tissues and cells and human 
organs intended for transplantation. 
• Inspection, often in conjunction with the Garda 
National Drugs Unit, of manufacturers and 
wholesalers of medicines containing controlled 
drugs (CD) and of precursors (chemicals that can 
be used in the preparation of illicit drugs).
• Inspections of manufacturers and distributors of 
cosmetics on a risk basis. 
Overview of the 2014  
Inspection Programme
A total of, 260 inspections and audits were performed 
compared to 313 in 2013 and 315 in 2012. The 
average number of days required to close-out 
inspections and audits conducted was 115.
In the past year:
• 106 GMP inspections were carried out at 
manufacturing sites. These included 22 
inspections in non-EEA countries, six of which 
were carried out at the request of the EMA 
for centrally authorised products. Of the GMP 
inspections carried out, 13 were of active 
substance manufacturers.
• 76 GDP inspections of wholesalers were 
performed. There were also 17 inspections of 
sites that handled controlled drugs or scheduled 
substances (precursors) and one inspection of a 
registered distributor of active substances. 
• 12 GCP inspections were carried out at 
investigator sites in Ireland. 
• Five pharmacovigilance inspections were 
performed. This included two at the facilities 
of Irish based marketing authorisation holders 
and three which related to centrally authorised 
medicines and were conducted at the request  
of the EMA.
• 20 medical device audits were performed.  
These were comprised:
 - Two observed audits of NSAI auditors while   
 they carried out audits at the premises of   
 medical device manufacturers;
 - One joint assessment audit was carried   
 out by the HPRA in conjunction with the   
 competent authority of an EEA country of a   
 medical devices manufacturer in that country; 
Inspections and Audits 
Performance Results and Statistics 2010 2011 2012 2013 2014
No. of national inspections and audits performed 293 271 289 279 229
No. of foreign inspections and audits performed 30 29 26 34 31
% inspections and audits closed on time (≤ 90 
days)
62 66 61 63 59
Average time for close-out (days) 194 79 76 103 115
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 - Two audits of authorised representatives of   
 medical device manufacturers; 
 - 15 audits at medical device manufacturers’   
 facilities. Of these, two were at manufacturers  
 of custom made medical devices, 12   
 were at manufacturers of in-vitro diagnostics  
 and the remaining audit was of a general   
 medical devices manufacturer.
• Nine blood establishment inspections were 
completed. These included seven inspections 
of facilities maintained by the IBTS and one 
inspection of the NHO. A total of 11 tissue 
establishment inspections were carried out.
• Three inspections were carried out to assess 
applications for authorisation of establishments 
involved in organ transplantation.
 
Enforcement
 
Illegal activity involving the manufacture, supply and 
sale of medicines or medical devices can have adverse 
consequences for public health. It is the role of the 
HPRA to investigate potential breaches of human 
medicines, medical device and the majority of other 
legislation within its remit. Where necessary, we will 
take the appropriate corrective action, including the 
possibility of legal proceedings. 
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INSPECTIONS AND  
AUDITS PERFORMED
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Enforcement Cases and  
Medicines Detained
A total of 3,703 enforcement cases were initiated, 
compared with 3,932 for 2013. There were a total 
of 730,056 dosage units were detained, down from 
919,965 in the previous year.
Sedative products again accounted for over half (56%) 
of all detentions (51% in 2013). Erectile dysfunction 
products and weight loss products accounted for 13% 
(11% in 2013) and 7% (19% in 2013) of detentions, 
respectively.
A summary of the HPRA enforcement data is provided 
in the accompanying table below.
 
Inter-Agency Co-operation  
and Pangea VII
The HPRA continues to liaise and work closely 
with other enforcement agencies both nationally 
and internationally, in combating, detecting and 
preventing the unauthorised flow of medicines and 
medical devices. 
In Ireland, co-operation between the HPRA, the 
Revenue’s Customs Service and An Garda Síochána 
continued and included Operation Pangea VII. During 
this operation in May, the inter-agency approach 
resulted in the detention of 101,182 tablets and 
capsules, with an estimated value of €297,557. 
Pangea VII was a global initiative which involved 
200 agencies drawn from health product regulatory 
authorities, police and customs across 110 countries. 
The operation, which was co-ordinated by INTERPOL, 
targeted criminal networks behind the sale of falsified 
and illegal medicines via illicit websites. 
In November, the HPRA and An Garda Síochána   
co-hosted the INTERPOL international conference, 
Ten Years of Combating Pharmaceutical Crime: 
Review and Prospects.
 
District Court Prosecutions
The policy of the HPRA is to prosecute where it 
is considered necessary in order to protect public 
health and where a compliance based approach is 
not considered appropriate. Ten prosecutions were 
initiated that included offences in relation to:
• Procurement and importation of medicines 
without manufacturing authorisations;
• Supply of prescription only medicines without 
prescriptions;
• Wholesale of medicines without a wholesaler’s 
authorisation;
• Advertising of prescription only and unauthorised 
medicinal products.
The products in question contained active substances 
indicated for mood stabilisation, performance 
enhancement, erectile dysfunction and weight loss.
Nine prosecutions were initiated annually during the 
three year period from 2011 to 2013.
Expert Statements
The HPRA’s Director of Scientific Affairs provides 
scientific advice to support the work of the 
enforcement unit. This includes the preparation of 
expert statements in respect of various products which 
are the subject of enforcement action. During 2014, 
14 such expert statements were prepared including 
one report requested by the Director of Public 
Prosecutions (DPP).
Year 2010 2011 2012 2013 2014
Product detained (dosage units) 822,484 762,641 758,276 919,965 730,056
Cases Opened 3,936 4,549 3,911 3,932 3,703
Prosecutions 5 9 11 9 10
Product destroyed 1,400kg 4,519kg 1,065kg 4,194kg 3,440kg
Voluntary Formal Caution (VFC) 19 12 6 27 13
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LEGISLATIVE AND  
REGULATORY  
DEVELOPMENTS  
As the national regulatory authority for health 
products, the remit and role of our organisation 
continues to change and expand in line with 
national and European legislative changes and in 
response to the addition of further competencies. 
This section of the 2014 annual report outlines 
the most significant legislative and regulatory 
developments during the past year by product 
type, how these changes influenced the work of  
the HPRA and, where relevant, the associated 
impact on stakeholders.
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New Clinical Trials Regulation 
New clinical trials legislation (Regulation (EU) No 
536/2014) was adopted and published in May 2014. 
It will come into effect in Europe in mid 2016. The 
new Regulation will create an environment that is 
favourable for conducting clinical trials in Europe. It 
allows for a streamlined application procedure via 
a single entry point, the EU portal and database, 
for all clinical trials conducted in Europe. There will 
be a single authorisation procedure for all clinical 
trials, allowing a faster and thorough assessment 
of an application by all Member States concerned, 
to ensure one single assessment outcome and 
authorisation. The aim is to increase the number of 
clinical trials conducted in Europe and provide for 
improved transparency. 
The HPRA contributed significantly to the consultation 
proposals on the development of the new Regulation. 
Since its publication, the HPRA has been working to 
progress the development of systems and procedures 
to meet the new requirements.
Interchangeable Medicines
Following commencement of the Health (Pricing and 
Supply of Medical Goods) Act in June 2013, the HPRA 
was tasked with publishing a list of interchangeable 
medicines to facilitate generic substitution by 
pharmacists and to allow for the introduction of a 
reference pricing system by the HSE. The Minister 
for Health requested that the approach to the 
development of the list be based on the inclusion 
of priority substances, identified as those which 
would provide the greatest cost saving to both the 
state and patients. Initially, 40 priority substances 
were identified. This was increased by a further eight 
substances towards the end of 2014.
There was further progress in the development of the 
list during the past 12 months. By the end of 2014, 
the list included a total 44 substances corresponding 
to in excess of 2,500 individual medicines. The list 
incorporates groups of medicines with products in 
each group considered appropriate for interchanging.
The work carried out by the HPRA and the HSE in 
this area has made an important contribution to cost 
savings at national level. Figures from the Department 
of Health and HSE indicate that generic penetration 
of the first 15 substances published is now at 90% and 
savings to the state are estimated at €50 million for 
2014.
Legal Classification of Medicines
Reclassification of the method of sale and supply 
of medicines was a specific area of focus for the 
HPRA during 2014. In July, we published a group 
of 12 substances which are considered suitable for 
reclassification. These related to over 30 medicines 
used for treatment of a variety of conditions 
including migraine, gastro-intestinal disorders and 
dermatological complaints. Medicines containing 
these substances can, in certain circumstances, be 
reclassified to be made available over the counter 
in pharmacies and supplied without prescription. 
The industry was invited to make reclassification 
applications for these medicines. On foot of this 
proactive approach, a number of applications are 
pending and it is anticipated that the reclassifications 
will be completed during 2015. The HPRA is 
continuing its work in this area.
Human Medicines
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Reclassification of NRT to 
General Sale from Pharmacy 
Only Status 
Also in July 2014, the HPRA confirmed the 
authorisation of a nicotine replacement therapy 
(NRT) product to be sold in general retail and 
grocery outlets. NRT products were previously only 
available in pharmacies and the HPRA’s decision 
to switch Nicorette™ NRT from ‘pharmacy only 
status’ to ‘general sale status’, was the result of an 
application from the authorisation holder. The HPRA 
announcement followed a detailed assessment of 
the safety and efficacy of several NRT products which 
have been available in non-pharmacy outlets in other 
EU countries for some time. The availability of NRT on 
general sale allows these products to become more 
accessible for people wishing to seek assistance to 
reduce or quit smoking.
Responding to Medicines 
Shortages
During 2014, the HPRA continued to collaborate 
closely with the Department of Health and the HSE in 
relation to the management of shortages of medicines 
within the Irish market place. One of the mechanisms 
used by the HPRA to aid continuity of supply to the 
market place in the event of a shortage includes the 
granting of a temporary authorisation for a batch of 
a product known as a ‘batch specific request’. During 
the year the HPRA approved 129 such requests to 
prevent or alleviate shortages. 
New Manufacturing 
Technologies
The HPRA is committed to supporting the introduction 
of new technologies to improve efficiency and 
quality assurance in the manufacture of the products 
which it regulates. To this end, it has established 
a multidisciplinary in-house team to assist in the 
introduction of process analytical technologies (PAT) 
and quality by design in the manufacture of medicinal 
products. This group is chaired by the Director of 
Scientific Affairs.
Working towards Full 
Implementation of EU 
Pharmacovigilance Legislation
The HPRA continued its work with stakeholders 
including the EMA, other national regulators and 
industry to support the phased implementation of EU 
pharmacovigilance legislation. Over the past 2 years 
of operation, prioritisation has been given to public 
health and transparency activities thus ensuring:
• more systematic and proactive risk management 
planning;
• real-time signal management activities; 
• EU co-ordination of safety messages;
• more efficient assessment and decision-making 
processes; 
• increased transparency resulting in 
a strengthening of the link between 
pharmacovigilance assessments and regulatory 
action such as labelling changes to optimise the 
safe and effective use of medicines. 
The HPRA was also active in the Strengthening 
Collaborations for Operating Pharmacovigilance in 
Europe (SCOPE) Joint Action project which serves to 
share expertise and best practice and deliver tools 
and guidance on the operation of pharmacovigilance 
in Europe. The HPRA is particularly involved in 
the areas of medicines risk communications and 
lifecycle management. The latter is focused on risk 
management planning and benefit-risk evaluation 
through the product lifecycle.
During 2014, the HPRA continued to contribute 
to three EMA / Member State project teams (PT) 
concerned with:
• collection of key information on medicines (PT1);
• better analysis and understanding of data and 
information (PT2); 
• committees and communications with 
stakeholders (PT3). 
The HPRA’s Pharmacovigilance and Risk Management 
Lead contributed to the project oversight governance 
through membership of the Project Co-ordination 
Group and the European Risk Management Strategy 
Facilitation Group.  
58 HPRA ANNUAL REPORT 2014
Contributing to the European 
and Global Regulatory Network
 
Europe
Throughout 2014, the HPRA continued to actively 
participate in the European medicines regulatory 
systems. HPRA scientific and technical staff 
contributed to a broad range of committees and 
working parties, preparing papers as appropriate, at 
the EMA, the European Commission, the HMA, and at 
other fora.
In addition to our regular participation at a European 
level, highlights from the past year included the 
following: 
• As part of the HPRA’s active contribution to the 
work of the PRAC, the Irish delegate continued to 
fulfil the role of Vice-Chair of the committee.
• The Pharmacovigilance and Risk Management 
Lead acted as Regulatory Chair for the ICH 
Implementation Working Group for the E2C R2 
guideline on Periodic Benefit Risk Evaluation 
Reports which successfully completed its intended 
deliverables in 2014. The HPRA also continued 
its contribution to the development of Good 
Vigilance Practice Modules.
• The HPRA contributed to a number of EU 
and International initiatives, including global 
workshops on accelerated access to innovative 
medicines for patients in need, Medicines 
Adaptive Pathways, the Adaptive Licensing 
Thought Group and joint meetings of EMA and 
EUnetHTA.
• The HPRA was a contributor to a number of 
strategies to support stakeholder engagement 
through participation in routine stakeholder 
meetings and on specialist topics such as benefit-
risk communication and on the use of social media 
in pharmacovigilance. As part of these efforts, 
the Pharmacovigilance and Risk Management 
Lead contributed to a number of publications on 
topics such as transparency, periodic benefit-risk 
evaluation reports and the work of the PRAC.
• The HPRA participated in a number of 
cross committee initiatives including the 
implementation of the EMA’s geriatric strategy, 
advancing paediatric pharmacovigilance and 
in the development of regulatory strategies to 
mitigate the risk of medication errors.
• HPRA delegates attending three meetings of 
the European Pharmacopoeia (Ph. Eur.) and 
participated in a number of the working parties 
and groups which provide expert advice to the 
Ph. Eur. including Group 13B (herbal medicines) 
and Group 12 (pharmaceutical dosage forms). The 
HPRA’s Director of Scientific Affairs is Chair of both 
the Process Analytical Technology (PAT) Working 
Party and the Homoeopathic Manufacturing 
Methods (HMM) Working Party each of which met 
on a number of occasions during 2014.
• The HPRA delegate was elected Vice-Chair of  
the HMA Working Group of Enforcement  
Officers (WGEO).
• We continued our active participation in the 
sampling and analysis programme of the  
network of Official Control Laboratories (OMCL) 
(co-ordinated by the EDQM) and in a number of 
its working.
 
Pharmaceutical Inspection Co-operation 
Scheme (PIC/S)
The Inspection Manager continued as a member of 
the Executive Bureau of the PIC/S and as chair of its 
Sub-Committee on Compliance. A number of HPRA 
inspectors were actively involved in organising expert 
circle activities and in working groups.
 
International Coalition of Medicines 
Regulatory Authorities
The HPRA is a member and currently one of 
the Vice-Chairs of the International Coalition of 
Medicines Regulatory Authorities (ICMRA). ICMRA 
is a voluntary, executive level entity of medicines 
regulatory authorities worldwide providing strategic 
coordination, advocacy and leadership. It acts as a 
forum to support international cooperation among 
medicines regulatory authorities. 
During 2014, discussions continued on the 
development of ICMRA terms of reference, rules of 
procedure and future membership criteria. ICMRA 
also continues to dialogue with existing international 
regulatory groups. 
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World Health Organization
The HPRA’s Pharmacovigilance Manager continued 
to represent the World Health Organization (WHO) 
as a member of the Board of the Uppsala Monitoring 
Centre (UMC) and WHO Collaborating Centre for 
International Drug Monitoring during 2014.
The HPRA attended the annual meeting of national 
centres participating in the WHO international 
drug monitoring programme in October 2014 and 
continued to provide details of reports received 
nationally to the WHO for inclusion on its international 
database. 
The volume of adverse reaction reports from 
Ireland continued to fall within the top 20 countries 
participating in the programme (121 full member 
countries in 2014). As can be seen from the 
accompanying graph, Ireland ranked as the tenth 
highest reporter during 2014.
Advisory Committee for  
Human Medicines
The Advisory Committee for Human Medicines, 
which is appointed by the Minister for Health, 
assists and advises the HPRA Authority in relation 
to any matters pertaining to the safety, quality 
or efficacy of medicines for human use. The 
committee met twice during 2014 and, in addition 
to considering matters referred to it by the 
Authority, it also reviewed the authorisations for 
human medicines, manufacturers and wholesalers 
as approved by the HPRA’s Management 
Committee. 
There are also a number of sub-committees 
appointed by the Advisory Committee for Human 
Medicines: 
• The Clinical Trials Sub-Committee met 12 times 
during the year. The Committee considered the 
suitability of trials submitted for approval under 
the European Communities (Clinical Trials on 
Medicinal Products for Human Use) Regulations 
2004, (S.I. No. 190 of 2004).
• The Herbal Medicines Sub-Committee met once 
in 2014. The Committee considered a number of 
matters including the Traditional Herbal Medicinal 
Products Registration Scheme and updates from 
the Committee on Herbal Medicinal Products of 
the EMA.
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Veterinary Clinical Field Trials
The role of the HPRA expanded further when our 
organisation became the competent authority for 
the authorisation of clinical field trials on veterinary 
medicines on 17 July 2014. 
The HPRA understands a ‘clinical trial’ to mean a  
study which aims to examine, under field conditions, 
the safety or efficacy (or both) of a veterinary 
medicinal product under normal conditions of animal 
husbandry or as part of normal veterinary practice for 
the purpose of obtaining a marketing authorisation  
or a change thereof.
 
Under legislation, tests and trials on a veterinary 
medicine for the purpose of generating data to 
support a marketing authorisation, or for other 
purposes, shall not be conducted without prior licence 
from the HPRA. A clinical field trial licence application 
must be submitted and approved in order for work 
to commence on any clinical field trial. The HPRA is 
obliged to consult with the Department of Agriculture, 
Food and the Marine prior to granting a licence for a 
clinical field trial. 
Relevant application forms, guides and fee details 
were developed and published by the HPRA during 
the second half of the year and are available from  
our website.
Veterinary Medicines
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Contributing to the European 
Regulatory Network
The European regulatory network for veterinary 
medicines has gained increased importance in recent 
decades. This is due to the fact that decisions on 
individual medicines that are on the market in several 
Member States, as well as policies, guidelines and 
initiatives which affect the systems and standards 
under which products are evaluated, are harmonised 
at an EU level. Given that most medicines are 
supplied to multiple European markets, it is obvious 
that in order for us to maximise our influence, we 
must have an input to decisions taken at a European 
level. This we do through our involvement across the 
EU network which includes active participation at 
the EMA, where our Veterinary Assessment Manager 
is the Vice-Chair of the Committee for Medicinal 
Products for Veterinary Use (CVMP), and at the HMA. 
Key regulatory issues discussed during 2014 were:
• The revision of the legal framework for veterinary 
medicines;
• The European surveillance strategy on 
pharmacovigilance work-sharing;
• The implementation of the HMA Action Plan on 
antimicrobial resistance.
We also contributed to EU discussions regarding 
restrictions on the use of barium selenate in injectable 
veterinary medicines.
Contributing to National  
Health Initiatives
During 2014, the HPRA participated in a working 
group of the Food Safety Authority of Ireland (FSAI) 
tasked with preparing a report on the risk of antibiotic 
resistance transfer posed by food. 
We also provided support to the Department of 
Agriculture, Food and the Marine in relation to 
matters of mutual interest.
Advisory Committee for 
Veterinary Medicines 
The Advisory Committee for Veterinary Medicines 
is the HPRA’s independent expert committee that 
advises on matters relating to the authorisation of 
veterinary medicines in Ireland. It met twice during  
the course of 2014 and considered such matters as:
• The content and implications of the proposal 
for a new Regulation for veterinary medicines  
in the EU; 
• Regulatory developments affecting medicines 
in the European network;
• A report of suspected adverse reactions to 
veterinary medicines in Ireland for 2013;
• A report on the consumption of veterinary 
antibiotics in Ireland for 2013;
• Various applications that had been considered 
by the HPRA previously but were submitted for 
peer review by the committee.
 
JULY2014
 
HPRA BECOMES THE  
COMPETENT AUTHORITY 
FOR VETERINARY  
CLINICAL FIELD TRIALS
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Advanced 
Therapies  
An advanced therapy medicinal product (ATMP) is a 
biological medicinal product which is a gene therapy 
medicinal product, a somatic cell therapy medicinal 
product or a tissue engineered product. This definition 
is set out in Directive 2001/83/EC, as amended, to 
reflect new innovative therapeutic products. Given 
their innovative nature, applications for marketing 
authorisations for advanced therapy products proceed 
through the centralised procedure in accordance with 
Regulation 726/2004/EC.  
We continued to actively participate in the EMA’s 
Committee for Advanced Therapies (CAT). The HPRA’s 
internal group on biological products and ATMPs also 
continued to meet regularly as a forum for information 
exchange and for discussion of areas of regulatory 
interest as relevant to ATMPs, blood, tissue and 
biological products.
Controlled 
Substances 
Controlled Drugs
There were two main amendments to the controlled 
drug legislative framework. In the first instance, the 
combination of the Misuse of Drugs (Designation) 
(Amendment) Order 2014 (S.I. No. 324 of 2014) 
and the Misuse of Drugs (Amendments) Regulations 
2014 (S.I. No. 323 of 2014) facilitated the legal 
introduction into the Irish market of authorised 
medicinal products containing a liquid extract of 
cannabis. Any such products must have a specified 
composition and presentation in order to permit 
prescription, supply and possession for the treatment 
of patients. In addition, S.I. No. 323 of 2014 removed 
the handwriting requirements in relation to certain 
details on prescriptions for controlled drugs that had 
been specified in the Schedule to the Misuse of Drugs 
(Supervision of Prescription and Supply of Methadone) 
Regulations 1998.
The second major amendment was the Misuse of 
Drugs (Amendment) (No. 2) Regulations 2014 (S.I. 583 
of 2014). This added certain substances to Schedule 
1 of the Misuse of Drugs Regulations (1988), as 
amended, and increased the extent of the controls 
applicable to 4-Hydroxybutanoic acid by changing its 
listing from Schedule 3 to Schedule 2.
Precursor Chemicals
There were two additions to the EU Voluntary 
Monitoring List of non-scheduled substances. 
These substances were chlorephedrine and 
chlorpseudoephedrine. The activity of trade in these 
substances will be monitored over time with the 
future potential for these substances to be included 
within the scheduled substances (precursor chemicals) 
legislative framework.  
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Revision of European Medical 
Devices Legislation
During 2014, the negotiation of the European 
Commission’s proposed Regulations on medical 
devices and in-vitro diagnostics (IVDs) continued 
at the European Council’s Working Party on 
Pharmaceuticals and Medical Devices. 
The proposals are intended to develop and reinforce 
the European legislative framework for medical 
devices and IVD medical devices to ensure a high 
level of protection for patients and healthcare 
professionals. At the same time, the proposed 
changes are focused on ensuring that the regulatory 
system enables safe innovation and access for patients 
and healthcare professionals to new therapeutic 
and diagnostic alternatives. The two proposed 
Regulations represent a significant development and 
improvement in comparison to the existing system 
but, as the associated legal text is lengthy and 
complex, it necessitates detailed review, discussion 
and negotiation. 
The HPRA has provided significant support to the 
negotiation of the legislation at the Working Party 
and at various expert working groups. The HPRA 
anticipates, that these proposals, which are subject to 
the ordinary legislative process including examination 
by both the European Council and the European 
Parliament, will be finalised by the end of 2015. 
The HPRA will continue to provide support to the 
Department of Health for the purposes of the Working 
Party negotiations. This will include advising on the 
further development of the legal texts, assistance 
with relevant stakeholder consultation and provision 
of input to the Department as it finalises a national 
position on the proposals.
Ongoing Development 
and Strengthening of the 
existing European Regulatory 
Framework 
Along with other European competent authorities 
and the European Commission, the HPRA has been 
dedicated to strengthening and developing the 
existing regulatory framework for medical devices in 
advance of the revised legal framework being agreed 
and coming into place. 
Since 2012, the HPRA has been using the European 
Commission’s Joint Plan for Immediate Actions as a 
roadmap for this development. This valuable plan 
outlined key actions for Member States and the 
Commission in the areas of notified body oversight, 
market surveillance, coordination and communication 
within the regulatory network, and transparency.
During 2014, the European Commission published its 
report on the implementation of the joint plan across 
Europe and identified those areas of ongoing focus. 
The HPRA remains fully committed to supporting and 
using the joint plan as a basis for development.
Oversight and Performance of Notified 
Bodies for Medical Devices
One of the central components of these joint actions 
is the implementation of the 2013 legislation that 
provides for joint assessment of notified bodies for 
medical devices by the relevant national authority 
and expert European assessors. The HPRA, having 
contributed to the development and implementation 
of this assessment scheme, is now part of a small 
expert group which oversees and co-ordinates 
its continued implementation. During 2014, the 
HPRA directly participated as experts in three joint 
assessments of EU notified bodies. 
Medical Devices
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Market Surveillance and Vigilance
Another key element of the joint plan, which was 
further highlighted by the EU Commission in its 2014 
report, was the strengthening of market surveillance 
activities by national regulatory authorities across 
Europe.
During the past year, the HPRA was an active 
participant in Medical Devices Expert Group (MDEG) 
vigilance meetings and vigilance teleconferences. 
The HPRA is chair of three taskforces including the 
vigilance co-ordinating competent authority role 
and is an active participant in eight other taskforces 
relating to specific devices or manufacturers.  
In response to the joint plan, the HPRA has also 
reviewed its existing market surveillance activities 
and has placed increased emphasis on proactive 
surveillance activities throughout the lifecycle of a 
medical device. Communication, and in particular 
reporting of medical device safety issues from users, 
is a continued focus for the HPRA. We continue to 
encourage users at national level to submit reports 
and have revised our methods for safety reporting to 
ensure the information is clear and targeted to the 
correct user group.
Contributing to the European 
and Global Regulatory Network
 
International Medical Device Regulatory 
Forum
During 2014, the HPRA continued as a member of the 
European delegation on the Management Committee 
of the International Medical Device Regulators Forum 
(IMDRF). This forum aims to develop and promote 
harmonisation of the regulation of medical devices 
issues across the globe and, in particular, in the 
member regions including Australia, Brazil, Canada, 
China, the EU, Japan, the Russian Federation and the 
US. In addition to contributing to the Management 
Committee, the HPRA assumed the role of secretariat 
for the IMDRF National Competent Authority Report 
(NCAR) Exchange mechanism which allows for the 
exchange of reports and key safety information from 
each global region. The HPRA also participated in the 
IMDRF working groups on NCAR and on developing 
Regulated Product Submission (RPS) standards (which 
facilitate standard formats for technical documentation 
for submission to regulatory authorities).
Competent Authority for Medical Devices
During 2014, the HPRA continued to engage actively 
and develop its partnerships with other European 
competent authorities. A key milestone in this work 
was achieved during 2014 with the formation of the 
Competent Authority for Medical Devices (CAMD) 
Executive Group the objective of which is to build 
mechanisms and structures to enable cooperation 
between authorities and to identify key work items 
and priorities for focus at European level. The HPRA 
was elected to this Executive Group along with 
colleagues from Austria, Belgium, France, Germany, 
the Netherlands and the UK (Chair).
Bilateral Meetings
During 2014, the HPRA hosted bilateral meetings  
with the US Food and Drug Administration (FDA),  
the EU Commission’s Joint Research Centre (JRC), the 
UK’s Medicines and Healthcare products Regulatory 
Authority (MHRA), the Croatian Ministry of Health 
and the Saudi FDA.
Advisory Committee  
for Medical Devices 
The Advisory Committee for Medical Devices 
met three times in 2014. Regular updates were 
provided on key medical device issues, regulatory 
developments, the revision of the medical devices 
legislation and HPRA activities in regulating medical 
devices. 
The Committee also invited a number of external 
stakeholders, such as academic researchers, to make 
presentations to the Committee in respect of their 
activities.
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Blood, Tissues and Cells,  
and Organs
We worked with Organ Donation and Transplant 
Ireland (ODTI) and the transplant centres on 
development of a Framework for the Quality and 
Safety of Human Organs intended for transplantation. 
The final text was published by ODTI, which is part  
of the HSE.  
 
 
 
We participated in European Commission Competent 
Authority meetings in these three areas. The primary 
purpose of these is to build and harmonise the 
regulatory systems and to identify emerging issues.
We contributed to Council of Europe / EDQM work on 
Guidelines, including that of the drafting group for the 
Guide to the Quality and Safety of Tissues and Cells 
for Human Application.
The HPRA became the competent authority 
responsible for the implementation of Directive 
2010/63/EU on the protection of animals used for 
scientific purposes on 1 January 2013. This authority 
was transferred from the Department of Health which 
regulated this area until 31 December 2012.
During 2014, there continued to be significant 
engagement with stakeholders within the research 
sector in order to highlight the requirements of the 
legislation. As part of this process, we published 
a number of further guidance documents in 
respect of authorisation procedures and policies 
and there continued to be a specific focus on the 
implementation of the 3R principles (reduction, 
refinement and replacement of animal testing). The 
HPRA also published its first annual statistical report 
on the use of animals for scientific purposes in Ireland. 
The report, which examined data for 2013, is a 
requirement under Article 54(2) of the Directive. The 
Department of Health published all previous reports in 
this area prior to the HPRA becoming the competent 
authority. 
The HPRA continued to interact with the Department 
of Health in relation to the overall implementation 
of the legislation and its potential impact on animal 
research in this country. Engagement also continued 
in respect of the development of an associated fee 
model for the regulation of this area. We provided 
support to the National Committee for the Protection 
of Animals used for Scientific Purposes in relation 
to its role in nurturing a culture of care at the 
establishments concerned. 
In relation to the EU network on scientific animal 
protection, the HPRA was involved in key topics such 
as the creation of an EU statistical database on the 
use of animals and played an active role as part of the 
EU National Committees for the Protection of Animals 
used for Scientific Purposes. 
Scientific Animal Protection
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STAKEHOLDER  
ENGAGEMENT AND  
COMMUNICATIONS  
The HPRA is committed to delivering 
a comprehensive programme of 
communications activities so as to ensure 
that all our stakeholders have timely access 
to relevant safety, licensing and regulatory 
information. This commitment is one of our 
core strategic goals and will continue to be 
an area of focus and development over the 
coming years.
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A number of significant 
communications programmes and 
initiatives took place during 2014 with a 
key focus being the introduction of the 
Health Products Regulatory Authority 
name and brand.
The Irish Medicines Board 
becomes the Health Products 
Regulatory Authority
The Irish Medicines Board (IMB) changed its name to 
the Health Products Regulatory Authority (HPRA) on 1 
July 2014. 
Over the course of our 18 years as the IMB our 
regulatory remit expanded to include other health 
products as well as a number of health related 
functions. Consequently, the IMB name and brand 
identity did not accurately reflect the nature and 
character of the organisation and our identity has not 
evolved in step with our size and expanding new areas 
of responsibility. 
The HPRA name now clearly reflects the wider scope 
of our work, functions and responsibilities across 
the health products sector. At the same time, it is 
intended to build on the IMB’s established reputation 
as a professional, progressive and science driven 
public sector organisation.
The introduction of the HPRA name was provided for 
in the Health (Pricing and Supply of Medical Goods) 
Act 2013.
Our New Brand Identity
The HPRA’s brand identity was developed following 
careful consideration to help us communicate in a 
consistent and clear manner with all our stakeholders. 
The identity consists of a number of core elements 
that come together to create a strong, credible and 
unique brand for the HPRA. 
Our logo, consisting of the acronym HPRA and the 
‘molecule’ symbol, has been crafted to reflect the 
foundation on which our brand identity system is built. 
The letters HPRA use a strong, balanced and modern 
font which projects a sense of authority and clarity. 
The ‘molecule’ design reflects the evidence and 
science that support all our actions and decisions. 
The connected circular molecule also stands for 
the way we work collaboratively with stakeholders 
including healthcare professionals, the research 
community and our colleagues in other health and 
regulatory agencies in Ireland and abroad. It stands 
too for the wider community, the public and patients 
who are at the heart of what we do. 
The colour palette combines the strong graphite 
colour of the letters with a blend of blues and greens. 
Blue signifies health, trust and authority while green 
symbolises safety, natural and national. 
Finally, our corporate fonts have been chosen for their 
clarity and legibility.
To support the introduction of the new identity 
and logo, a HPRA brand guidelines document was 
published and shared with all staff. These guidelines 
provide clear direction on the application of the new 
brand across all platforms and publications and will 
help to ensure that all our materials display a coherent 
and recognisable design. The document includes 
guidance on the design of external publications, the 
use of the brand on digital platforms and the adoption 
of a new typeface and templates for internally 
produced documents, presentations and e-mail.   
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Preparing for the Introduction of our  
New Name and Brand
The introduction of a new name and brand is a major 
project for any organisation and demands significant 
planning and preparation. In addition to a wide-
ranging external communications plan to inform 
stakeholders, a comprehensive internal strategy is also 
required. 
The external communications plan consisted of a 
range of activities and projects that were planned to 
coincide primarily with the 1 July introduction date 
and included:
• The launch of a new corporate website –  
www.hpra.ie;
• A series of ‘all-stakeholder’ e-mails which were 
sent to close to 5,000 key contacts identified by 
employees from across the organisation;
• The publication of a new corporate brochure and 
video outlining the reasons behind the name 
change and introducing the new brand identity; 
• A stakeholder launch event on the morning of 1 
July which was held in the HPRA offices in Dublin 
2. Over 60 external attendees representing 
patient and healthcare professionals, the 
Department of Health and other government 
departments and agencies were present. Guest 
speakers included RTÉ journalist Mr Tommie 
Gorman and the then Chief Executive of the IDA, 
Mr Barry O’Leary;
• The placement of an information notice in a series 
of health and related industry publications. The 
first notices started to appear in early July with the 
initiative repeated in the autumn; 
• The redesign and publication of all HPRA external 
guides and application forms for industry and 
other interested parties;
• The redesign and publication of 12 HPRA leaflets 
primarily intended for patients and members of 
the public;
• The dissemination of a number of press releases 
to national, regional and specialist media.  
A number of related articles were also published 
across various publications; 
• The introduction a new external e-mail address 
across the organisation incorporating ‘@hpra.ie’;
• The redesign and print of all corporate stationery; 
• The installation of new external and reception 
signage in the HPRA offices.  
To prepare internally for the change of name and new 
corporate identity, a brand implementation group 
was convened with representatives from a range of 
different organisational functions including IT, HR, 
finance, corporate services, quality management, 
business processing and communications.
Together, this group identified close to 200 individual 
rebrand tasks that were required to ensure a 
smooth and efficient introduction of the new name 
and identity. The vast majority of these tasks were 
successfully completed in advance of or on the key  
1 July date with the remainder planned for completion 
on a phased basis thereafter. 
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The following is just a small sample of the rebrand 
tasks involved:
• The rebrand of all internal IT platforms and 
systems;
• The design and print of newly branded staff  
ID cards;
• The introduction of a new corporate font for all 
word processor documents, presentations and 
e-mails;
• The introduction of newly branded document 
templates such as for meeting minutes and 
agendas;
• The rebrand of all finance documents and the 
internal financial IT system;
• The redesign of all regulatory certificates issued 
by the HPRA.
Finally, an internal communications plan was also 
implemented to support the introduction of the 
HPRA name and brand. Given the extent of the 
rebrand project, which impacted all departments 
and sections across the organisation, it was essential 
that staff were kept up-to-date and informed of 
progress and planned activities. Among the internal 
communications activities completed were regular 
e-mails including a brand newsletter, presentations, 
competitions and a number of staff events. A 
commemorative notebook to mark the introduction 
of the new name was also distributed to all staff 
members on the morning of 1 July. 
Our New HPRA Website
Development of the new HPRA website began 
in 2013 and was completed to coincide with the 
introduction of the HPRA name and brand on 1 July. 
This project incorporated a total redesign of the 
organisation’s online offering including a review of 
the user experience and all content. In particular, the 
focus was on ensuring an improved navigation thus 
allowing for easier access to content of interest. In 
addition, a new and modern look and feel for the site 
featuring the HPRA’s new brand identity was required. 
Other enhancements include: 
• a more comprehensive and accurate search 
facility;
• the ability to search the medicines product 
information section directly from the homepage. 
This is an important enhancement as this feature is 
by far the most used by visitors to the site;
• an improved and more targeted alerting system 
for subscribers;
• the inclusion of new sub homepages for each 
product divided clearly into ‘safety and quality’ 
and ‘regulatory information’ sections;
• the inclusion of new sub homepages for key 
stakeholder groups: members of the public, 
industry and healthcare professionals;
• the inclusion of a ‘latest news’ section for each 
product area and stakeholder group;
• the inclusion of quick links on the homepage 
which are based on the most popular visitor 
topics.
As with all websites however, we are conscious of the 
need to continuously improve the user experience 
and we are committed to the further enhancement of 
www.hpra.ie, including the launch of a mobile friendly 
responsive version of the site during the first half of 
2015.
Visitor Statistics
During the six month period from July to December 
2014, almost 126,000 unique visitors accessed the 
new HPRA website. There were in excess of 250,000 
visits in total. Of those who accessed the site, 38% 
were new or first time users. Among the most popular 
sections of the website were the human and veterinary 
medicines listings and the interchangeable medicines 
listing. 
126,000
UNIQUE VISITORS  
ACCESSED THE  
NEW HPRA  
WEBSITE
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Stakeholder Engagement
Meetings with Stakeholders –  
Human Medicines
A number of meetings were held with industry 
representative groups including the Association of 
Pharmaceutical Manufacturers in Ireland (APMI), the 
Irish Pharmaceutical Healthcare Association (IPHA), the 
Irish Health Trade Association (IHTA), Pharmachemical 
Ireland and the Pharmaceutical Distributors 
Federation. These meetings provide a forum for 
discussion of items of mutual interest. Among the main 
topics of discussion were timelines and deliverables, 
interchangeable medicines, the regulation of biosimilar 
medicines, increasing the number of applications for 
herbal medicines registrations and issues relating to 
the distribution of medicines.
There was also one meeting of the Advertising 
Compliance Technical Group which includes 
representatives from the HPRA and pharmaceutical 
industry. Issues of mutual interest were discussed with 
a goal of promoting good practice and compliance in 
this area.
Regular meetings took place with the Pharmaceutical 
Society of Ireland and the Irish Pharmacy Union. 
Meetings with Stakeholders –  
Veterinary Medicines
During 2014, we met with the Department of 
Agriculture, Food and the Marine in relation to 
ongoing matters of mutual interest, including the new 
proposal for the regulation of veterinary medicines in 
the EU and the transfer of the competent authority 
function for the authorisation of veterinary clinical trials 
to the HPRA. Meetings were also held with a number 
of stakeholders from the veterinary medicines industry 
and from the general agricultural and veterinary 
sectors.
Meetings with Stakeholders –  
Scientific Animal Protection 
A number of meetings were held with the Department 
of Health in relation to the implementation of Directive 
2010/63/EU regarding the protection of animals used 
for scientific purposes. We also held a number of 
meetings with individual establishments and interested 
parties, including the Irish Laboratory Animal Science 
Association and the Irish University Association, in  
relation to the protection of animals used in research 
nationally. A large number of presentations on the 
implementation of the Directive were also delivered to 
the research community throughout Ireland. 
 
Meetings with Stakeholders –  
Medical Devices
Regular meetings with key industry stakeholder groups 
continued during 2014. These included meetings with 
the National Standards Authority of Ireland (NSAI), 
the Irish Medical Devices Association (IMDA) and the 
Irish Medical and Surgical Trade Association (IMSTA). 
These meetings provide the HPRA with an opportunity 
to update stakeholders on regulatory developments 
at national and European level. They also enable the 
HPRA to be kept up-to-date on issues affecting the 
medical devices industry. A key topic for discussion 
during 2014 was the European Commission’s joint plan 
for immediate actions and the ongoing revision of the 
medical devices legislation.
 
Meetings with Stakeholders –  
Blood, Tissues and Cells, and Organs
A number of meetings were held with key 
stakeholders. These included the Department of 
Health on all of these areas, National Haemovigilance 
Office of the IBTS (blood) and Organ Donation and 
Transplant Ireland (organs).
Meetings with Stakeholders – Cosmetics
Regular meetings took place with the HSE 
(Environmental Health Service and Public Analyst 
Laboratories) in relation to the monitoring, sampling 
and analysis of cosmetics and implementation of 
the EU regulation and national legislation. We also 
participated in the Market Surveillance Forum hosted 
by the Department of Jobs, Enterprise and Innovation. 
We met with the Irish Cosmetics and Detergents 
Association which represents the industry.
Presentations to Stakeholders
As in recent years, the HPRA invested significant 
time in delivering a programme of presentations 
and talks at a range of external stakeholder events 
such as meetings, seminars, conferences and training 
courses. In addition, a programme of presentations 
was delivered to undergraduate and post graduate 
students studying courses related to the role of  
the HPRA.
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Such presentations contribute to the HPRA goal 
of providing stakeholders such as healthcare 
professionals and regulatory professionals with 
access to relevant, up-to-date information. The 
presentations are delivered by HPRA staff from across 
the organisation and cover all products and functions 
under our remit. While some were general in nature 
and primarily focused on explaining the role of the 
HPRA, others were more specific and dealt with 
specialist areas and/or new regulatory developments. 
A full list of all presentations delivered during 2014 is 
provided in Appendix 2.
Events 
Ten Years of Combating Pharmaceutical 
Crime – Global Conference
In November 2014, the HPRA joined An Garda 
Síochána as co-hosts of Ten Years of Combating 
Pharmaceutical Crime: Review and Future Prospects, 
a global INTERPOL conference held in Dublin.
This major conference was attended by senior law 
enforcement officials from across the world as well as 
representatives from government, intergovernmental 
organisations and the pharmaceutical industry. The 
event reviewed experiences to date, lessons learned, 
opportunities and constraints of international action 
against pharmaceutical crime. It also focused on 
identifying and recommending ways forward for 
strengthening international collaboration.
The two-day (19 and 20 November) event attracted 
close to 200 participants from some 50 countries and 
17 international organisations. There was significant 
national and international media interest in the 
conference resulting in extensive coverage which 
included a number of interviews with the HPRA 
Director of Compliance. The opening address was 
delivered by Minister of State at the Department of 
Justice and Equality, Aodhán Ó Ríordáin, TD. 
Information Days and Seminars 
HPRA information days and seminars provide 
regulatory guidance and updates to a range of 
stakeholders. As well as presentations from HPRA 
staff and, where appropriate, external contributors, 
the events enable attendees to submit questions, 
seek clarifications and network with colleagues. The 
following events were held during 2014:
• In January, we hosted an information seminar on 
the regulation of clinical trials for investigators 
and academic sponsors. The purpose of this event 
was to further enable and support clinical research 
in Ireland. The seminar included discussion on a 
range of topics including safety reporting, clinical 
trial applications and good clinical practice (GCP) 
requirements.
• In May 2014, we hosted an information session for 
the Association of Pharmaceutical Manufacturers 
of Ireland (APMI). This session included overviews 
of the HPRA pharmacovigilance inspection 
programme, the monitoring of pharmacovigilance 
compliance and an interactive discussion with 
attendees.
• An information event for parallel product 
authorisation holders (PPAs) was held in June. 
The agenda focussed on promotion of regulatory 
compliance in this area and discussion topics 
included requirements for regulatory submissions, 
quality defect investigations and recall 
requirements.
• On 23 October, we hosted an information day 
for the medical devices industry. This event was 
attended by over 250 delegates and included 
participation from a number of regulatory 
and industry partners including the European 
Commission, the UK’s MHRA and the European 
Medical Device Association. The meeting was also 
addressed by Ms. Mairead McGuinness MEP. A 
range of topics were discussed with a particular 
focus on the development of the European 
regulatory systems for medical devices and the 
on-going revision of the legislation governing 
medical devices.
• A wholesale distribution information day was 
held on 11 November and was aimed primarily 
at distributors of medicines. Among the topics 
discussed on the day were good distribution 
practices (GDP), including the Commission 
guidelines on GDP, the protection of the supply 
chain and the impact of medicine recalls on 
distributors.
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• On 12 November, we hosted an information 
day focused on good manufacturing practices 
(GMP) which was attended by manufacturers 
of medicines and active substances. As well as 
general GMP updates, the topics for discussion 
also included quality defect and product recalls, 
the Directive on falsified medicines, sterile 
manufacturing and market compliance.
• A pharmacovigilance information day was held 
on 21 November 2014 and was attended by 
over 250 participants from industry as well as 
healthcare professionals and patient organisation 
representatives. The aim of the event was to 
provide updates on implementation of the revised 
legislative provisions and to discuss their impact 
for stakeholders. 
• Also in November, the HPRA hosted a Topra 
networking meeting. This was an evening event 
focussing on a number of topics of regulatory 
interest including the new clinical trial regulation 
and HPRA’s role in the regulation of medical 
devices.
• On 2 December, an information day was held 
for marketing and manufacturing authorisation 
holders of veterinary medicines as well as other 
stakeholders with an interest in this area. The 
event was focused primarily on the proposed 
new EU legislative framework while an overview 
of recent changes to national legislation on 
clinical field trials was also provided. As well 
as presentations from HPRA staff, there were 
also contributions from representatives of the 
Department of Agriculture, Food and the Marine, 
and from the animal health industry.
BT Young Scientist and Technology 
Exhibition 2014
In January 2014, thousands of students as well 
as teachers, parents and members of the general 
public from all over Ireland visited the HPRA’s 
exhibition stand at the BT Young Scientist and 
Technology Exhibition. This was the fifth year of HPRA 
participation at this high profile event which was held 
in Dublin’s RDS. 
 
Our stand focused on building awareness of the 
significant role the HPRA plays in protecting public 
and animal health. In particular, the important 
issue of medicines and medical devices safety was 
highlighted. As in previous years, the stand also 
focused on the many interesting science related 
career opportunities that are available in the health 
products industry.
 
Publications
 
Guidance Documents
HPRA guidance documents provide stakeholders, 
primarily from the industry sectors we regulate, with 
advice and direction in respect of legislation and 
regulatory requirements. New and updated guidance 
documents are published regularly on our website 
with alerts issued to website subscribers. 
A number of new guidance documents were 
published during 2014 with a significant number of 
existing documents also being updated. In addition,  
a consultation process was commenced in respect of  
a number of proposed new guides. 
Among the new documents published during the past 
year were:
• Guide to the Notification System for Exempt 
Medicinal Products;
• Guide for Manufacturers and Sponsors on Clinical 
Investigations carried out in Ireland;
• Guide to Refusals and Appeals under Scientific 
Animal Protection Legislation;
• Guide to Transfers of Project Authorisations under 
Scientific Animal Protection Legislation;
• Guide to Managing Changes to Registration for 
Active Substance Manufacturers, Importers and 
Distributors;
• Clinical Field Trial Licence Applications under 
Animal Remedies Legislation.
All of the HPRA guidance documents can be accessed 
via the Publications section of www.hpra.ie. 
Newsletters
The HPRA publishes three newsletters with a number 
of editions of each being published throughout the 
year. Each newsletter was redesigned during 2014 to 
reflect the new HPRA name and brand.
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Medicinal Products Newsletter
This newsletter provides regulatory updates for those 
working in the pharmaceutical and cosmetics sectors 
on Irish and European legislation, new / revised HPRA 
regulatory publications and stakeholder events such 
as information days. 
Three editions of the Medicinal Products Newsletters 
were published during 2014. Topics covered included:
• Regulation of clinical trials on veterinary medicines 
in Ireland;
• Publication of public assessment reports for 
veterinary medicines on the HPRA website;
• Proactive approach to reclassification (switching);
• New EU clinical trials Regulation;
• New tools for manufacturers to help prevent 
medicines shortages;
• Amendment to the Misuse of Drugs Regulations;
• Report on veterinary antimicrobial consumption in 
2012 and update on collection of the 2013 data; 
• Update on certificates of free sale for cosmetic 
products.
The newsletter is published on the HPRA website 
and issued to those who subscribe to the HPRA alerts 
system via our website. 
Drug Safety Newsletter
January 2014 marked the first fully electronic 
distribution of the HPRA Drug Safety Newsletter. 
Healthcare professionals are invited to register with 
the HPRA to receive alerts when new editions of 
the DSN are published while we also work closely 
with relevant healthcare professional organisations 
to facilitate distribution of the newsletter via their 
networks. The electronic version of the newsletter is 
in PDF format, thus allowing the reader to save the 
publication to their own systems and to print specific 
pages. The online version also contains hyperlinks to 
product information and other relevant documents on 
the HPRA and EMA websites.
Seven editions of the newsletter were published on 
our website and made available electronically to 
registered doctors, dentists, nurses and pharmacists 
during 2014. An overview of the topics covered is 
included in Appendix 3.
 
Medical Devices Newsletter 
This newsletter provides regulatory and safety updates 
for those working in the medical devices sector and 
professionals working in the health area who regularly 
use or purchase medical devices. It provides updates 
on Irish and European legislation, on safety issues as 
well as details of HPRA medical devices publications 
and stakeholder events. There were three editions of 
this newsletter published in 2014. The following are 
some of the main topics covered:
• Scientific Committee on Emerging and Newly 
Identified Health Risks (SCENIHR) – Opinion 
update;
• HPRA post market surveillance audit plan for 
2014;
• Voluntary joint assessments update;
• 3D printing: Potential in implants and surgery;
• IMDRF unique device identification (UDI ) 
implementation for medical devices and IVDs; 
• Bringing medical device software development 
standards into a single model;
• HPRA overview of software as a medical device; 
• Proposals for new regulation on medical devices 
and in vitro diagnostic medical devices.
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External Articles 
Human Medicines
There were 16 articles published in MIMS Ireland by 
the HPRA. A further two articles were published in 
the Irish Medicines Formulary. The full list of topics 
covered in these articles in included in Appendix 3.  
All articles were also published on the HPRA website.
 
Veterinary Medicines
Consistent with our objective to improve 
stakeholder knowledge on the use of veterinary 
medicines, we contributed several articles to the 
relevant publications. This included an article on 
pharmacovigilance in the December edition of the 
Veterinary Ireland Journal and four articles in the 
specialist It’s Your Field publication.
 
Medical Devices
An article providing an overview of the medical 
devices vigilance system and an outline of the HPRA 
role in managing reports of suspected adverse 
incidents was published in the spring edition of  
the BEAI Spectrum publication.
Safety Warning and Notices 
Throughout 2014, the HPRA published various 
warning statements and notices on safety issues 
or benefit-risk evaluations of human medicines. 
There were 36 Direct Healthcare Professional 
Communications concerning human medicines 
published on the HPRA website and issued to 
subscribers. The PRAC published monthly agendas, 
minutes, meeting highlights, notifications of safety 
reviews and signals throughout 2014 and these were 
also made available via the HPRA website. 
Separately, 47 medical devices safety notices were 
sent to the relevant stakeholder groups and published 
online. Following feedback via a communications 
survey, the design of these notices was updated so 
as to highlight key content and enhance the structure 
and layout. More than 500 manufacturers field safety 
notices concerning medical devices on the Irish 
market were also published on the HPRA website.  
In addition, we published three generic safety 
notices with advice in relation to MRI safety, potential 
microbial contamination when using heater cooler 
units and finally to raise awareness of some of the 
common problems that have been identified with the 
use of insulin infusion pumps.  
Self-Test Products Consumer  
Information Leaflet
In November, we published Self-Test Products, 
an information leaflet to assist those patients and 
members of the public who use self-tests for a medical 
purpose. This publication was developed in response 
to the increasing availability of self-test products for 
a variety of health conditions and the concerning 
trends and issues observed by the HPRA when 
following up on adverse incidents relating to their 
use. Such products can be used to diagnose a variety 
of conditions or to monitor a particular treatment, 
including pregnancy tests and test kits for measuring 
blood sugar. The HPRA leaflet includes advice for 
people who are thinking about buying a self-test 
and highlights the potential risks associated with 
self-testing. The leaflet can be downloaded from our 
website while printed versions can be ordered from 
lealfets@hpra.ie.
47
MEDICAL DEVICES SAFETY NOTICES 
WERE SENT TO THE RELEVANT 
STAKEHOLDER GROUPS AND  
PUBLISHED ONLINE
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Media Communications
Throughout 2014, we continued our media 
communications programme to proactively 
communicate important safety messages and to build 
awareness of the role of the HPRA. We prepared 34 
press releases and statements which in a number of 
instances resulted in national and regional media 
interviews with a HPRA spokesperson. During the 
second half of the year, there was a particular focus on 
highlighting the introduction of the new HPRA name 
and explaining the rationale for this change. 
Among the issues highlighted through HPRA press 
releases during the past year were:
• Nicotine replacement therapy (NRT) medicines 
approved for sale in retail outlets;
• Publication of list of active substances suitable for 
reclassification (switching);
• Largest ever Interpol operation targeting online 
counterfeit and illegal medicines (Operation 
Pangea VII);
• Advice on seasonal maintenance of automated 
external defibrillators (AED).  
The HPRA also published a number of press releases 
to highlight successful prosecutions related to the 
illegal supply of unauthorised medicines.
In addition, we responded to approximately 400 
queries from national, local and specialist media 
during the year. Drafting responses to such queries 
involves subject matter experts from across the 
organisation. 
Public Consultations
Public consultations enable the HPRA to identify the 
needs and expectations of stakeholders so that we 
may incorporate their views into the way our services 
are planned and delivered.
During 2014, the HPRA completed a public 
consultation in respect of regulatory fees proposed 
for 2015 and also commenced a consultation on a 
draft version of the Guide for Retail Sale of Herbal 
Medicinal Products.
The HPRA also makes submissions to third party 
consultations where the topic is related to or impacts 
our regulatory functions and the broader public health 
agenda. In 2014, we provided comments in respect 
of eight public consultations from the Department 
of Health, The Medical Council, the Pharmaceutical 
Society of Ireland and CORU.        
Freedom of Information
The HPRA is subject to the Freedom of Information 
Acts 1997 and 2003. The Acts assert the right of 
members of the public to obtain access to official 
information to the greatest extent possible consistent 
with public interest and the right to privacy of 
individuals. During 2014, we received 17 Freedom 
of Information requests none of which related to 
requests for personal information.
17
FREEDOM OF  
INFORMATION  
REQUESTS
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Parliamentary Affairs 
 
Oireachtas Joint Committee on  
Health and Children
In June 2014, the HPRA was invited to address the 
Oireachtas Joint Committee on Health and Children. 
The issue being considered by the Committee was the 
use and availability of adrenaline auto-injectors and 
the HPRA presented an update on the authorisation 
and safety monitoring of these products.
Parliamentary Questions 
The HPRA received and responded to 54 
parliamentary questions. There were also 109 
additional requests from the Department of Health, 
other government departments or members of the 
Oireachtas during the year. Of the total number of 
queries (163), the three largest categories related to 
human medicines (88), staff, finance and payroll (20) 
and corporate (16). The human medicines queries 
concerned topics such as adverse reactions, the 
availability or supply of products, market shortages, 
enforcement, clinical trials, orphan status, herbals, 
vaccines, licensing or importation.
Customer Services
Close to 3,000 queries were received and dealt 
with by the customer services team. These included 
queries from industry representatives, healthcare 
professionals and members of the public. Queries 
were received primarily via email and by phone. 
In addition to the queries managed by customer 
services staff, a range of stakeholder queries are 
addressed by specialist staff across the organisation. 
Many of these queries come from healthcare 
professionals requesting information about specific 
medicines. 
For example, 200 queries were received relating to 
the exempt medicines programme while there were 
418 pre-market and surveillance queries relating to 
medical devices.17
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ORGANISATIONAL  
MANAGEMENT AND  
DEVELOPMENT 
It is essential that the HPRA have the 
necessary corporate functions, systems and 
supports in place to deliver on our public 
health mission. We must be flexible and 
proactive as an organisation to respond to 
regulatory and other external developments, 
and to adopt necessary changes in how we 
deliver our services. We must also ensure that 
the highest levels of corporate governance 
are developed and maintained. 
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Human Resources and Change
The HPRA’s people management practices and 
policies are central to the achievement of our strategic 
goals. Throughout 2014, the human resources 
department continued to focus on the areas of staff 
retention and engagement whilst at the same time 
further advancing the public sector reform agenda. 
The organisational ‘motivation and development 
competency’, rolled out as part of the Performance 
Development Programme (PDP), provided the 
overarching framework for the development of 
many of our HR initiatives during the past year. The 
focus of this competency is to actively promote a 
continuous learning environment where individuals 
are encouraged to take on new responsibilities, 
challenges and to continually learn to support their 
own development.
Performance Development
PDP continues to be one of our core platforms to 
support high performance, superior service delivery 
and the development of our staff. In line with our 
ethos of continuous improvement and in response 
to employee feedback from 2013, the programme 
was enhanced during 2014. A variety of support tools 
were designed and published to a dedicated page 
on the HPRA intranet. The amendments were initially 
piloted across the organisation prior to a planned full 
implementation in 2015.
Learning and Development 
Our learning and development strategy continued 
to focus on staff development as one of our key 
motivation and retention tools. 
In support of this, a development planning process 
was launched. The implementation of the process was 
supported through;
• The design and publishing of a development 
planning guide, job aid and individual 
development plan form within the PDP;
• The design and delivery of a workshop to 
support managers in partnering with staff in the 
development process.
The HPRA’s accredited Leadership Development 
Programme (LDP) continues to be an effective 
development tool for our managers and a second 
group commenced the programme in 2014. The 
HPRA also continues to support all staff members 
in meeting various development needs through 
providing support for third level qualification and 
technical training. 
Externally there is a focus on expand our knowledge 
and we collaborate as part of the EU Network Training 
Centre (EU NTC). We actively participated in the 
creation of the EU NTC vision, strategy, guiding 
principles and assessment of the current state of 
training and development activities across the network 
of regulators.
Change Management
The remit of the HR department expanded in late 
2014 to incorporate the change management 
function. This requires HR to be responsible for the 
effective management of change projects that provide 
for the availability, effective use and engagement of 
human resources within the HPRA so as to contribute 
to the delivery of the HPRA’s strategic plan.  
Employee Engagement and Commitment
The HPRA continues to place a high degree of 
emphasis on activities that will support employee 
engagement and commitment. In 2014, we focused 
on delivering a series of initiatives designed to 
support employees in meeting the challenges facing 
them both inside and outside of the workplace. Some 
examples include:
• Financial planning support, delivered via a 
seminar, and the opportunity to avail of one-to-
one financial wellbeing sessions;
• The development of a range of staff health and 
wellness initiatives including the provision of flu 
vaccines and the establishment of a smoking 
cessation initiative. We also continue to provide 
all staff with access to the Employee Assistance 
Programme (EAP);
• An emotional wellbeing week that focused on 
areas such as meditation, mindfulness and a 
healthy lifestyle.
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In addition to the above, we continued with our 
lunchtime learning initiatives which are highly popular 
with staff. Topics ranged from growing your own 
vegetables through to parenting and work, and mind 
mapping for life.
Often an indicator of levels of commitment and 
organisational health, we continue to record absence 
rates well within national averages with an overall 
2.4% rate recorded for 2014.  
Resourcing
We continue to develop and manage our resources 
in line with public sector policy by focusing where 
possible on internal skills development and the 
reallocation of tasks and responsibilities in response 
to specific challenges. Recruitment of staff in specialist 
areas was completed in line with Department of 
Health approvals.
As planned, a significant focus of human resources 
activity during the first six months of 2014 was the 
implementation, testing and piloting of a new human 
resource IT system selected via a public procurement 
process in 2013. All members of the human resources 
team were heavily engaged in providing training and 
on-going support to users post go-live. The benefits 
of the system in terms of effectiveness and efficiency 
have already been realised with users reporting a 
reduction in time spent administrating routine tasks.  
Information Technology and 
Business Services 
The Information Technology and Business 
Services department is responsible for all 
aspects of organisational technology, data and 
telecommunications. The department also manages 
the business services unit that is responsible 
for delivering specialist business services to the 
organisation, including business analysis and 
project management for both internal and external 
stakeholders. A core function of the business services 
unit is the management of the organisational Project 
Management Office (PMO) that formally manages 
projects and provides HPRA management with the 
necessary information to support the planning process 
while ensuring that organisational initiatives are fully 
aligned with corporate strategy.
Technology is recognised as a key component in 
supporting regulatory activities at both national 
and European levels and during 2014 a number of 
significant projects and initiatives were progressed. 
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National Developments 
A tender process was undertaken for the design and 
implementation of HPRA’s new workflow technology 
solution which is to be known as EOLAS. This system 
will enable the consolidation and replacement of a 
number of legacy solutions and will provide a new 
workflow and data management platform for the 
organisation. The tendering and evaluation process 
was completed at the end of 2014 and the design 
and development of the system is scheduled to be 
carried out in 2015. A planned implementation date 
of 2016 will coincide with implementation of new EU 
standards for regulatory data management.
In July of 2014, to coincide with the launch of the 
HPRA name, we launched a new website that provides 
stakeholders with improved access to information 
and enhanced product search capabilities online. 
Additional updates to the site and the information it 
provides are planned for 2015. 
In keeping with the government strategy for shared 
service provision, the HPRA also provides hosting 
services to a number of organisations, and works 
closely with agencies such as the Office of the 
Revenue Commissioners. The HPRA is also actively 
engaged at national level through its involvement with 
the National Health Data Standards Committee and in 
liaison with other relevant agencies, such as the HSE, 
NSAI and HIQA. During 2014, the HPRA contributed 
to the development of a National Medicinal Product 
and the ePrescribing data set standards developed  
by HIQA. 
The IT and business services team was also active 
in the development of processes and technology 
interfaces to support the exchange of information 
between stakeholders in areas such as the medical 
products database for both human and veterinary 
products, interchangeable medicines for the generic 
substitution programme and data for clinical and 
pharmacy systems. 
European Initiatives
During the past year, the HPRA continued to play 
a significant role in the development of European 
telematics strategies, standards and technologies 
through its engagement with programmes at the 
EMA, the European Commission and the HMA 
forum. The HPRA is represented on the EU telematics 
management board, the network data board and the 
eSubmisson group and leads on a number of key 
initiatives relating to single submission portals and 
data standards. 
As part of a European consortium, the HPRA is 
participating within the European Commission’s 
Horizon 2020 research programme on the 
openMedicine project. We are leading a significant 
work package within this project which is called 
Identification of Branded Medicinal Products and 
this work will continue throughout 2015. The project 
addresses drug identification and substitution 
challenges to better enable cross-border healthcare 
delivery particularly the exchange of ePrescriptions 
and safe dispensation of prescribed medicinal 
products. The openMedicine global initiative 
advances the unique identification of medicinal 
products and thereby patient safety in cross-border 
settings.
250,000
CESP SUBMISSIONS  
COMPARED TO THE 
100,000 IN 2013 
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Common Electronic Submission Portal
A key activity for the IMB is the development and 
management of the Common Electronic Submission 
Portal (CESP) on behalf of the wider EU regulatory 
community. We provide technical support through the 
operation of a helpdesk facility and we work with all 
relevant stakeholders throughout the year to deliver 
an optimum solution. 
In 2014, the CESP participation and activity levels 
grew significantly handling over 250,000 submissions 
compared to the 100,000 in 2013 and the portal 
now supports over 2,000 pharmaceutical companies 
and 6,000 users. The number of regulatory agencies 
using the system has also increased to over 32 across 
Europe and the system is now available 24 hours a 
day over a 7 day period. 
In 2015, the system will be further developed to 
provide online tracking capabilities and reporting for 
stakeholders.  
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The Chief Executive’s Office is responsible for 
communication, strategy and planning, quality 
management and a number of information functions 
for external stakeholders. It also provides the 
secretariat for the benchmarking programme  
across EU medicines agencies. 
BEMA
The Benchmarking of European Medicines Agencies 
(BEMA) programme provides assurance to the heads 
of the EU medicines agency network with respect to 
the quality of the systems and practices in place in 
agencies for regulating medicines and is a resource 
for sharing of best practices. The HPRA’s chief 
executive is co-chair of the BEMA steering group. 
The HPRA provides the secretariat for the group 
and is responsible for visit logistics. During 2014, we 
continued to lead the steering group as assessment 
visits were finished in this benchmarking cycle and the 
group began to review the outcomes.
Quality Management
During 2014, the HPRA’s quality management system 
continued to be extended with the deployment of 
procedures for functions and legislative requirements 
introduced in recent years. These included new and 
amended processes under the falsified medicines 
Directive, 2011/62/EU, our functions for scientific 
animal protection according to the European Union 
(Protection of Animals Used for Scientific Purposes) 
Regulations 2012, additional legislative requirements 
for pharmacovigilance systems (Directive 2010/84/
EU) and the establishment and maintenance of lists of 
interchangeable medicines under the Health (Pricing 
and Supply of Medical Goods) Act 2013.
Chief Executive’s Office
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The HPRA’s corporate affairs department is 
responsible for the delivery of a number of key service 
areas to the organisation. These include building and 
accommodation management as well as the provision 
of reception, canteen, travel, library and event 
management services. The department also manages 
legal matters, international co-operation and Freedom 
of Information requests. In addition, it provides 
secretarial support to the Authority and Committees 
and ensures adherence to best practice in the area  
of corporate governance.
Event Management
The HPRA held nine events in 2014 all of which were 
organised and managed in-house. This approach 
ensures cost effective delivery of events while also 
allowing HPRA staff to deal directly with stakeholders. 
This has resulted in very positive feedback from 
attendees via event questionnaires. 
A number of these events were information days 
which typically provide regulatory guidance and 
updates to interested parties. The 2014 information 
days focused on a range of topics including:
• Medical Devices 
• GMP 
• GDP 
• Pharmacovigilance
• Clinical Trials 
• Veterinary Sciences 
• Regulatory Science.
Freedom of Information
During 2014, the HPRA received 17 Freedom of 
Information requests (as outlined on page 76). 
Authority and Committees
The Corporate Services section provides secretarial 
support to the Authority and Committees of the HPRA 
and ensures adherence to best practice in the area of 
corporate governance.
Corporate Affairs
Authority Member
Number of meetings 
held during the period the 
member was on the Authority
Number of meetings 
attended during the period the 
member was on the Authority
Mr. Michael D. Hayes (Chair) 6 6
Mr. Pat Brangan 4 3
Mr. Wilfred J. Higgins 4 2
Ms. Ann Horan 6 6
Prof. Mary Horgan 6 5
Dr. Elizabeth Keane 4 4
Mr. Noel O’Donoghue 6 3
Prof. Caitriona O’Driscoll 6 6
Dr. Diarmuid Quinlan 4 3
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• The Authority of the HPRA met six times in  
2014 and considered a number of strategic 
matters including corporate policy, planning  
and finance matters. The latter included monthly 
management accounts, annual budgets and 
the financial statements for 2013. The Authority 
also reviewed update reports from the Statutory 
Advisory Committees and the Audit Committee. 
In addition, it reviewed the licences for all 
medicinal healthcare products as approved by  
the Management Committee.
 The number of meetings attended by each 
Authority member during 2014 is as follows:
• The Audit Committee, a subcommittee to the 
Authority, met four times in 2014. Further details 
are provided in the HPRA’s Financial Statements 
for 2014;
• Also during the year in review, the Advisory 
Committee for Human Medicines met twice, the 
Advisory Committee for Veterinary Medicines met 
twice and the Advisory Committee for Medical 
Devices met twice;
• The Herbal Medicines Sub-Committee, a sub-
committee to the Advisory Committee for Human 
Medicines, met once in 2014. The Clinical Trials 
Sub-Committee is also a sub-committee to the 
Advisory Committee for Human Medicines and it 
met twelve times in the past year;
• The National Committee for the Protection of 
Animals Used for Scientific Purposes, a statutory 
committee to provide guidance to the regulator 
and those working in this area, met twice in 2014.
Finance 
It is the role of the finance section to manage and 
safeguard the finances of the HPRA. It must ensure 
that the HPRA fulfils its legislative requirements 
and applies best practice to the governance of its 
affairs. All procedures are carried out using standard 
operating procedures under the quality management 
system. 
The 2014 financial statements presented in this report 
were prepared by the finance section and submitted 
for audit to the Comptroller and Auditor General. All 
financial transactions during the period under review 
are reflected and reported upon in these statements 
as is our commitment to the highest standards of 
corporate governance.
Legal 
The legal section oversaw the implementation of 
new legislation and advised on other relevant issues. 
The section dealt with various legal queries from 
across the organisation and attended and presented 
at the European meeting of lawyers held under the 
European Presidency.
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Overview  
of Energy  
Usage in 2014
Since 1 January 2011, the HPRA, as a public 
sector body, has been required to report annually 
on its energy usage and actions taken to reduce 
consumption in accordance with S.I. 542 of 2009. 
These regulations transpose the Energy End Use 
Efficiency and Energy Services Directive (Directive 
2006/32/EC) into Irish law.
The HPRA uses electricity for lighting, air conditioning 
or heating as required and the provision of hot water. 
Natural gas is used for central heating.
In 2014, the HPRA consumed 953 MWh of energy 
consisting of:
• 775 MWh of electricity; 
• 178 MWh of fossil fuels;
• 0 MWh of renewable fuels
Actions Undertaken in 2014
In the past year, the HPRA continued to focus on 
energy performance by maintaining framework 
agreements for the supply of both electricity and 
natural gas. Both of these framework agreements 
were established by the Office of Government 
Procurement (formerly the National Procurement 
Service) for the supply of electricity and natural 
gas to the Irish public sector. The agreements 
are intended to maximise volume discounts and 
provide for reductions in administrative and 
transaction costs for suppliers and public sector 
purchasers. During 2014, cost savings in respect of 
electricity was 5.3% while cost savings in respect of 
gas was 5% (compared to the cost of going directly 
to the market).
Total Energy Savings
The HPRA building, Kevin O’Malley House, was 
extended upward by two floors during the course 
of 2012 and 2013. Therefore, 2014 was the first full 
year of occupancy of the two additional floors and 
this resulted in an increase of 14% in total energy 
usage for the building.
Since 2009, the HPRA has been highly focussed 
on reducing energy usage. This is evidenced by 
the 2013 Sustainable Energy Authority of Ireland 
(SEAI) report for the HPRA which confirmed that 
the organisation has improved its energy usage by 
23.3% since 2009.
Actions Planned for 2015
In 2015, the HPRA intends to maintain energy 
performance by continuing its participation in newly 
contracted framework agreements for the supply 
of both electricity and natural gas to the public 
sector. It is anticipated that both these framework 
agreements, which will again be accessed via the 
Office of Government Procurement, will deliver 
savings when compared to the costs of going 
directly to the market. It is important to note that 
the Office of Government Procurement contract 
rates are fixed until early 2017 for electricity  
and gas.
5.3%
COST SAVINGS  
IN RESPECT OF  
ELECTRICITY 
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Board Members and  
Other Information
 
 
 
Board : Mr. Michael Hayes  Chairman
  Mr. Pat Brangan  term expired 31/12/2013 re-appointed 22/05/2014
  Mr. Wilfrid Higgins term expired 31/12/2013 re-appointed 22/05/2014
  Ms. Ann Horan
  Prof. Mary Horgan *
  Dr. Elizabeth Keane ** term expired 31/12/2013 re-appointed 22/05/2014
  Mr. Noel O’Donoghue
  Prof. Caitriona O’Driscoll
  Dr. Diarmuid Quinlan ***
  The Board was appointed by the Minister for Health on 18/01/2011.
  *     Prof. Mary Horgan was appointed on 08/11/2011.
  **   Dr. Elizabeth Keane was appointed on 24/10/2012.
  *** Dr. Diarmuid Quinlan was appointed on 22/05/2014.
Bankers: Allied Irish Bank
  1-3 Lower Baggot Street
  Dublin 2
  Bank of Ireland Corporate
  2 Burlington Plaza
  Burlington Road
  Dublin 4
Solicitors: Eugene F. Collins
  Temple Chambers
  3 Burlington Road
  Dublin 4
Head Office: Kevin O’Malley House
  Earlsfort Centre
  Earlsfort Terrace
  Dublin 2
Auditors: Comptroller and Auditor General
  Dublin Castle
  Dublin 2
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Corporate Governance
The Health Products Regulatory Authority (the HPRA) was established under the terms of the Irish Medicines Board 
Act, 1995 (as amended), and is governed by a Board which was appointed by the Minister for Health. The Board of 
the HPRA (the Board) consists of a chairman and eight unremunerated non executive members. On 1 July 2014 the 
organisation changed its name from the Irish Medicines Board, as provided for in Section 36 of the Health (Pricing 
and Supply of Medical Goods) Act 2013 and SI (205/2014) Health (Pricing and Supply of Medical Goods) Act 2013 
(Commencement) order 2014. 
The HPRA is committed to the highest standards of Corporate Governance and has implemented the Department of 
Finance “Code of Practice for the Governance of State Bodies”. This Code of Practice, which was issued to the HPRA 
in January 2002, incorporates many of the principles under which the HPRA operates, taking account of the size and 
legal nature of the organisation. 
An updated Code of Practice was published by the Minister for Finance in June 2009, to take account of 
administrative and legislative developments in the corporate governance framework since 2001. The HPRA has 
carried out a detailed review of this updated Code, to ensure that its provisions are still reflected in the principles 
under which the HPRA operates.
The HPRA has in place an extensive Code of Conduct and conflicts of interest policy for all staff, committees and 
Board members. The HPRA applies the highest standards of disclosure and transparency in respect of interests  
held by staff, committees and Board members.
Audit Committee
The HPRA has an audit committee comprising three Board members, which met on 4 occasions during 2014.  
This committee is responsible for reviewing internal control matters, together with any other issues raised by 
the external auditors, the Board or management. The external auditor is invited annually to meet with the audit 
committee to brief them on the outcome of the external audit and the audit committee also meets annually with the 
internal auditor. During 2014 the internal auditor carried out internal audits and reported to the audit committee on 
the areas of salaries/payroll and bank/finance. The audit committee has also been involved with the review of the 
quality systems as described below.
Quality Systems
During 2014, the finance section of the HPRA continued the process of implementing and reviewing standard 
operating procedures (SOPs) under the quality management system. This process involved a critical review and 
analysis of internal controls and processes throughout the section with particular emphasis on risk management.  
This system now underpins the internal control environment and feeds into the internal audit process and ultimately 
into the audit committee.
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Remuneration Policy - Board Members and Executive Directors
Remuneration and travel expenses paid to Board members are disclosed in note 17 to the financial statements.  
The Chairman receives remuneration as directed by the Minister for Health in accordance with the Irish Medicines 
Board Act, 1995. Other Board members receive travel expenses in accordance with circulars issued by the 
Department of Health. The Chief Executive is remunerated in accordance with guidelines issued from Government 
and other Executive Directors are paid in accordance with Department of Health pay scales. 
Remuneration Committee
The HPRA has established a remuneration committee as a sub-committee of the Board to review the remuneration 
of the Chief Executive, in accordance with guidelines issued by the Department of Finance and the Department of 
Health. The Chief Executive’s remuneration is disclosed in note 18 to the Financial Statements.
Internal Control
The Board is responsible for the HPRA’s systems of internal control. Such systems can only provide reasonable and 
not absolute assurance against material misstatement or loss. The systems of internal controls in use in the HPRA  
are described more fully in the Chairman’s report on page 93.
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Statement on Internal  
Financial Control
  
1. I, as Chairman, acknowledge that the Board is responsible for the body’s system of internal financial control.
2. The HPRA system of internal financial control can provide only reasonable and not absolute assurance against 
material error, misstatement or loss.
3. The Board confirms that there is an ongoing process for identifying, evaluating and managing the significant 
risks faced by the HPRA. The HPRA maintains a risk register which is reviewed and updated by management, 
considered by the audit committee and presented to the Board.  
Management are responsible for the identification and evaluation of significant risks applicable to their areas 
of business together with the design and operation of suitable internal controls. These risks are assessed 
on a continuing basis and may be associated with a variety of internal or external sources including control 
breakdowns, disruption in information systems, natural catastrophe and regulatory requirements. These risks  
are recorded in the risk register. 
 
Management reports fortnightly on operational issues and risks and how they are managed to the Management 
Committee. The Management Committee’s role in this regard is to review on behalf of the Board the key risks 
inherent in the affairs of the HPRA and the system of actions necessary to manage such risks and to present their 
findings on significant matters via the Chief Executive to the Board. 
 
The Chief Executive reports to the Board on behalf of the executive management on significant changes in 
the work of the HPRA and on the external environment, which affects significant risks. The Director of Finance, 
Corporate and International provides the Board with monthly financial information, which includes key 
performance indicators. Where areas for improvement in the system are identified, the Board considers the 
recommendations made by the Management Committee. 
 
An appropriate control framework is in place with clearly defined matters which are reserved for Board approval 
only or, as delegated by the Board, for appropriate Management Committee approval. The Board has delegated 
the day-to-day management of the HPRA and established appropriate limits for expenditure authorisation to the 
Management Committee. The Chief Executive is responsible for implementation of internal controls, including 
internal financial control. 
 
The system of internal financial control is monitored in general by the processes outlined above. In addition,  
the Audit Committee of the Board reviews specific areas of internal control. The HPRA has outsourced the 
internal audit function to an independent professional firm. During 2014 two reviews were conducted.  
The Audit Committee considers reports from internal audit and recommendations from the Comptroller  
and Auditor General arising as a result of the external audit. 
4. The Board have carried out a review of the effectiveness of internal financial control, in order to demonstrate 
compliance with the Code of Practice. This review was carried out at its meeting on 20 May 2015.
 
 
Mr. Michael Hayes 
Chairman to the Board
Date: 16 June 2015
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Statement of Board  
Members’ Responsibilities
 
The Board is required by the Irish Medicines Board Act, 1995 to prepare financial statements for each financial  
year which give a true and fair view of the state of affairs of the HPRA and of its surplus or deficit for that period.
In preparing those statements the Board is required to:
• select suitable accounting policies and apply them consistently
• make judgements and estimates that are reasonable and prudent
• disclose and explain any material departures from applicable accounting standards, and
• prepare the financial statements on a going concern basis unless it is inappropriate to presume that the  
HPRA will continue in existence.
The Board is responsible for keeping proper accounting records which disclose with reasonable accuracy at any 
time the financial position of the HPRA and which enable it to ensure that the financial statements comply with the 
Irish Medicines Board Act and with accounting standards generally accepted in Ireland. It is also responsible for 
safeguarding the assets of the HPRA and hence for taking reasonable steps for the prevention and detection of  
fraud and other irregularities. 
 
 
 
 
On behalf of the Board 
 
Chairman Board Member
Mr. Michael Hayes Ms. Ann Horan 
16 June 2015
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Comptroller and  
Auditor General Report  
for Presentation to the  
Houses of The Oireachtas
 
 
I have audited the financial statements of the Health Products Regulatory Authority for the year ended 31 
December 2014 under the Irish Medicines Board Act, 1995. The financial statements, which have been prepared 
under the accounting policies set out therein, comprise the accounting policies, the statement of income and 
expenditure, the balance sheet, the cash flow statement and the related notes. The financial statements have 
been prepared in the form prescribed under Section 18 of the Act, and in accordance with generally accepted 
accounting practice in Ireland as modified by the directions of the Minister for Health in relation to accounting 
for superannuation costs.
 
Responsibilities of the Board of the Authority
The Board of the Authority is responsible for the preparation of the financial statements, for ensuring that they 
give a true and fair view of the state of the Authority’s affairs and of its income and expenditure, and for ensuring 
the regularity of transactions.
 
Responsibilities of the Comptroller and Auditor General 
My responsibility is to audit the financial statements and report on them in accordance with applicable law.
My audit is conducted by reference to the special considerations which attach to State bodies in relation to their 
management and operation.
My audit is carried out in accordance with the International Standards on Auditing (UK and Ireland) and in 
compliance with the Auditing Practices Board’s Ethical Standards for Auditors.
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Scope of audit of the financial statements
An audit involves obtaining evidence about the amounts and disclosures in the financial statements, sufficient to give 
reasonable assurance that the financial statements are free from material misstatement, whether caused by fraud or 
error. This includes an assessment of
• whether the accounting policies are appropriate to the Authority’s circumstances, and have been consistently 
applied and adequately disclosed.
• the reasonableness of significant accounting estimates made in the preparation of the financial statements, and
• the overall presentation of the financial statements.
I also seek to obtain evidence about the regularity of financial transactions in the course of audit.
In addition, I read the Authority annual report to identify material inconsistencies with the audited financial 
statements. If I become aware of any apparent material misstatements or inconsistencies, I consider the implications 
for my report.
Opinion on the financial statements
In compliance with the directions of the Minister for Health, the Authority accounts for the costs of superannuation 
entitlements only as they become payable. This basis of accounting does not comply with Financial Reporting 
Standard 17 which requires such costs to be recognised in the year the entitlements are earned. 
In my opinion, except for the accounting treatment of the Authority’s superannuation costs and liabilities, the 
financial statements have been properly prepared in accordance with generally accepted accounting practice in 
Ireland and give a true and fair view of the state of the Authority’s affairs at 31 December 2014 and of its income and 
expenditure for 2014.
In my opinion, proper books of account have been kept by the Authority. The financial statements are in agreement 
with the books of account.
HPRA ANNUAL REPORT 2014 97
Matters on which I report by exception
I report by exception if
• I have not received all the information and explanations I required for my audit, or
• my audit noted any material instance where money has not been applied for the purposes intended or where the 
transactions did not conform to the authorities governing them, or
• the information given in the Authority’s annual report is not consistent with the related financial statements, or
• the statement on internal financial control does not reflect the Authority’s compliance with the Code of Practice 
for the Governance of State Bodies, or
• I find there are other material matters relating to the manner in which public business has been conducted. 
 
 
I have nothing to report in regard to those matters upon which reporting is by exception.
 
Patricia Sheehan 
For and on behalf of the
Comptroller and Auditor General 
25 June 2015
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Accounting Policies
Historical Cost Convention
The financial statements are prepared in accordance with generally accepted accounting practice under the historical 
cost convention and comply with the financial reporting standards issued by the Financial Reporting Council, with the 
exception of superannuation - see note below. 
Income Recognition
Income is recognised in the financial statements on the following basis:
• In the case of applications for marketing authorisations (new applications, variations to existing authorisations, or 
transfers) and clinical trial applications, income is recognised in the financial statements when a valid application 
form is received.  
• In the case of wholesale and manufacturing licences and maintenance of marketing authorisations, fees are 
payable annually and a full year’s income is accrued in each financial year.
Expenditure Recognition
Expenditure is recognised in the financial statements on an accruals basis as it is incurred.
Reporting Currency and Currency Translation
The financial statements are prepared in euros.
Transactions in currencies other than euro are recorded at the rates ruling at the date of the transactions or at a 
contracted date. Monetary assets and liabilities are translated into euro at the balance sheet date or at a contracted 
date. Exchange differences are dealt with in the income and expenditure account.  
Tangible Assets
Tangible Assets excluding Premises
Tangible assets excluding premises are stated at cost less accumulated depreciation. Depreciation is calculated in 
order to write off the cost of tangible assets to their estimated residual values over their estimated useful lives by 
equal annual instalments.
The estimated useful lives of tangible assets by reference to which depreciation has been calculated are as follows:
Fixtures and Fittings :   5 years 
Computer Equipment :   3 years 
Improvements to Premises : 10 years
Premises
The HPRA purchased its premises at Kevin O’Malley House, Earlsfort Centre, Earlsfort Terrace, Dublin 2 
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on 22 December 2004. The value capitalised was equal to the purchase price plus those costs directly attributable  
to bringing the asset into use.
No depreciation has been calculated on the value of premises, as the remaining useful economic life is estimated  
to be greater than 50 years.
Taxation
The HPRA is exempt from liability to Corporation Tax under Section 227 of the Taxes Consolidation Act, 1997.
Debtors
Known bad debts are written off and specific provision is made for any amount the collection of which is considered 
doubtful. 
Superannuation
The superannuation scheme operated by the HPRA is in accordance with the Local Government (Superannuation 
Revision) (Consolidation) Scheme, 1986. It is an unfunded statutory scheme and benefits are met from current income 
as they arise.
The charge to salaries and wages is stated gross of superannuation deductions of €748,987 (2013 - €800,739). 
The surplus for the year on page 100 is then shown both before and after superannuation deductions less lump 
sum amounts paid in the year. The income and expenditure reserve on the balance sheet is split between retained 
reserves and superannuation reserves in note 11. The balance on the superannuation reserve represents the 
cumulative superannuation deductions made since 1996.
By direction of the Minister for Health, the provisions of FRS 17 are not being complied with.  
Provisions
A provision is recognised when the HPRA has a present obligation as a result of a past event, it is probable that this 
will be settled at a cost to the HPRA and a reliable estimate can be made of the amount of the obligation.
Library
No value has been placed on the books, audio-visual resources and electronic databases in the library. Expenditure 
on these items is written off in the year in which it is incurred.
Leases
All leases are treated as operating leases and the rentals thereunder are charged to the Income and Expenditure  
account on a straight line basis over the lease period. 
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 Note  2014  2013
  € €
Fee Income  2  20,938,909  20,225,400
Other Income  3  4,700,860  4,430,585
   
  25,639,769  24,655,985 
Salaries and Wages  4  17,501,062  17,765,250
Other Operating Costs  5  4,738,449  4,823,934
Depreciation  1  1,310,329  1,150,820
   
  23,549,840  23,740,004
 
Surplus for the year before write
back of Superannuation contributions   2,089,929  915,981
 
Staff Superannuation Contributions   443,890  749,418
 
 
Surplus for the year   2,533,819  1,665,399
 
Balance brought forward   24,539,298  22,873,899
 
Balance carried forward   27,073,117  24,539,298
 
 
 
All income and the surplus for the year arises from continuing activities.
 
 
 
 
 
 
 
 
Chairman Board Member
Mr. Michael Hayes Ms. Ann Horan 
16 June 2015
The accounting policies on pages 98 to 99 and the notes on pages 103 to109 form part of the financial statements.
 
STATEMENT OF INCOME AND EXPENDITURE
for the year ended 31 December 2014
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 Note  2014  2013
  € €
Tangible Assets  1  25,574,039 25,890,663
 
Current Assets
Debtors and Prepayments  6  727,029  644,387
Stock of Stationery   2,259  2,407
Cash at Bank and in Hand  12  205,531  160,832
Short Term Deposits   15,649,391  12,940,623 
  16,584,210  13,748,249
Creditors - Amounts falling
due within one year
Creditors and Accruals  7  7,151,792  6,372,942
Mortgage  13  793,332  793,332
   
  7,945,124  7,166,274
 
Net Current Assets   8,639,086  6,581,975
 
Long Term Liabilities
Mortgage  13  7,140,008  7,933,340
 
 
TOTAL NET ASSETS   27,073,117  24,539,298
 
 
Financed by
Income and Expenditure Reserve  11  27,073,117  24,539,298
   
  27,073,117  24,539,298
 
 
 
 
Chairman Board Member
Mr. Michael Hayes Ms. Ann Horan 
16 June 2015
The accounting policies on pages 98 to 99 and the notes on pages 103 to109 form part of the financial statements.
 
BALANCE SHEET
for the year ended 31 December 2014
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 Note  2014  2013
  € €
Reconciliation of surplus to net cash
inflow from operating activities
 
Surplus for Year   2,533,819  1,665,399
Depreciation Charge   1,310,329  1,150,820
(Increase)/Decrease in Debtors   (6,127)  228,197
Decrease in Stocks   148  296
Increase/(Decrease) in Creditors - amounts
falling due within one year   777,470  (1,035,225)
Deposit Interest   (131,249)  (183,195)
Bank Interest and Charges   355,712  393,502
Loss/(Gain) on Disposal of Fixed Assets   61  (1,290)
Net Cash Inflow
from Operating Activities   4,840,163  2,218,504
Cash Flow Statement
Net Cash Inflow from Operating Activities   4,840,163  2,218,504
Return on Investments and
Servicing of Finance  8  (299,599)  (133,976)
Capital Expenditure  8  (993,765)  (3,877,741)
Management of Liquid Resources  8  (2,708,768)  2,560,202
Financing  8  (793,332)  (793,332)
Increase/(Decrease) in Cash   44,699  (26,343)
Reconciliation of net cash flow
to movement in net debt
Increase/(Decrease) In Cash   44,699  (26,343)
Increase/(Decrease) In Short Term Deposits   2,708,768  (2,560,202)
Decrease In Long Term Finance   793,332  793,332
 
Change In Net Funds/(Debt)   3,546,799  (1,793,213)
Net Funds at start of year   4,374,783  6,167,996
 
Net Funds at end of year  9  7,921,582  4,374,783
The accounting policies on pages 98 to 99 and the notes on pages 103 to109 form part of the financial statements.
 
 
CASH FLOW STATEMENT 
For the year ended 31 December 2014
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NOTES TO THE FINANCIAL STATEMENTS 
For the year ended 31 December 2014
1. Tangible Assets Fixtures and Computer  Leasehold Improvements Premises Total 
  Fittings Equipment Improvements To Premises   
  € € € € € €
  Cost
  Balance as at   1,134,883  9,849,076  502,445  4,314,888  23,156,037  38,957,329
  1 January 2014  
  Additions for the year  16,683  977,452  -  -  -  994,135
  Disposals for the year  (3,595)  (147,286)  -  -  - (150,881)
  As at 31 December 2014  1,147,971  10,679,242  502,445  4,314,888  23,156,037  39,800,583
  Depreciation
  Balance as at 1 January 2014  969,013  9,097,438  450,948  2,549,267  -  13,066,666
  Charge for the year  57,004  771,591  50,245  431,489  -  1,310,329
  Disposals for the year  (3,595)  (146,856)  -  -  -  (150,451)
  As at 31 December 2014  1,022,422  9,722,173  501,193  2,980,756  -  14,226,544
  Net Book value at  
 31 December 2014  125,549  957,069  1,252  1,334,132  23,156,037  25,574,039
  Net Book value at 
  1 January 2014  165,870  751,638  51,497  1,765,621  23,156,037  25,890,663
2. Income
     2014     2013
     €     €
 Fee Income
 Clinical Trials  123,844  152,714
 Human Medicine - National Fees  6,588,544  6,597,201
 Human Medicine - European Fees  6,860,718  5,809,092
 Veterinary Medicine - National Fees  1,357,676  1,226,329
 Veterinary Medicine - European Fees  1,338,780  1,682,126
 Compliance Department  4,294,355  4,406,871
 Medical Devices  374,992  351,067
   
  20,938,909  20,225,400
 Other Income (Note 3)  4,700,860  4,430,585
  
 Total Income  25,639,769  24,655,985
 
  
 Certain fees, totalling €16,815,145 are required by law to be disposed of in accordance
 with the directions of the Minister for Public Expenditure and Reform. 
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NOTES TO THE FINANCIAL STATEMENTS 
For the year ended 31 December 2014
3. Other Income
     2014     2013
     €     €
  
 Dept Of Health Funding (Vote 38 Subhead E1)  3,916,000  3 ,937,000
 Conference Fee Income  184,075  6 ,100
 Deposit Interest  131,249  183,195
 (Loss)/Gain on Disposal of Fixed Assets  (61)  1 ,290
 IT Income  469,597  303,000
   
  4,700,860  4,430,585
4. Salaries and Wages  
 
 Salaries and Wages  15,663,696  15,948,022
 Pensions  382,144  359,984
 Social Welfare Costs  1,455,222  1,457,244
   
  17,501,062  17,765,250
 
  
 The average number of staff employed during the year was 291 (2013 - 292).
 Payroll numbers at 31 December 2014 can be analysed across the following departments : -
 
 Chief Executive  11  10
 Compliance  62  62
 Finance, Corporate & International  19  19
 Human Products Authorisation & Registration  106  103
 Human Products Monitoring  44  46
 Human Resources & Change  8  9
 IT & Business Services  13  14
 Scientific Affairs  2  2
 Veterinary Sciences  22  25
 Staff  287  290
 Pensioners  30  25
   
  317  315
 
Pension related deductions for Public Servants of €942,745 were deducted  
from staff during the year and paid over to the Department of Health. 
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NOTES TO THE FINANCIAL STATEMENTS 
For the year ended 31 December 2014
5. Operating Costs
     2014     2013
     €     €
  
 Accommodation Costs  1,048,954  1,281,687
 Travel, Representation and Training  730,412  920,613
 Bank Charges and Interest  363,697  398,152
 Legal & Professional Fees  106,604  124,286
 Stationery, Publications and Postage  418,624  409,221
 Other Operating Costs  2,070,158  1,689,975
   
  4,738,449  4,823,934
  
  
 Operating costs of €4,738,449 includes an amount of €7,894 related to staff hospitality.
 
6.  Debtors (all due within one year) 
 
 Trade Debtors  303,875  336,335
 Prepayments  238,854  186,716
 Other Debtors  184,300  121,336
   
  727,029  644,387
 
7.  Creditors (amounts falling due within one year) 
 
 Trade Creditors  287,858  268,817
 Accruals  6,321,754  5,563,837
 Revenue Commissioners  542,180  540,288
   
  7,151,792  6,372,942
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NOTES TO THE FINANCIAL STATEMENTS 
For the year ended 31 December 2014
8. Gross Cash Flows     2014     2013
      €     € 
  
 Returns on Investment and Servicing of Finance:
 Deposit Interest  54,732  259,169
 Bank Interest and Charges  (354,331)  (393,145)
   
  (299,599)  (133,976)
 Capital Expenditure
 Payments to acquire Tangible Fixed Assets  (994,135)  (3,879,031)
 Receipts from sales of Tangible Fixed Assets  370  1,290
  
  (993,765)  (3,877,741)
 Management of Liquid Resources
 (Increase)/Decrease in Short Term Deposits  (2,708,768)  2,560,202
   
  (2,708,768)  2,560,202
 Financing
 (Decrease) in Long Term Finance  (793,332)  (793,332)
   
  (793,332)  (793,332)
9. Analysis of Changes in Net Funds/(Debt)    As At   As At
  01/01/2014  Cashflow  31/12/2014 
  
  
 Cash at Bank and in Hand  160,832  44,699  205,531
 Short Term Deposits  12,940,623  2,708,768  15,649,391
 Debt Due Within One Year  (793,332)  0  (793,332)
 Debt Due After One Year  (7,933,340)  793,332  (7,140,008)
 
  4,374,783  3,546,799  7,921,582
 
10. Administration Expenses  2014  2013 
  
  
 Surplus for the year was calculated having charged : -
 
 Auditor’s Remuneration  17,300  17,390
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11. Movement on Income and Expenditure Reserves    
 
  As At   As At
  01/01/2014  Movement  31/12/2014 
  €  € € 
  
 Retained Reserves  17,315,836  2,089,929 19,405,765
 Staff Superannuation Contributions  7,223,462  443,890  7,667,352
   
  24,539,298  2,533,819 27,073,117
 
12. Cash and Bank Balances      2014     2013
     
 Current Account Balances    204,441  160,302
 Cash on Hand    1,090  530
   
  205,531  160,832
 
13. Long Term Liabilities      
       
  Mortgage
  On 22 December 2004 the HPRA purchased its premises at Kevin O’Malley House, Earlsfort Centre,
  Earlsfort Terrace, Dublin 2. The purchase was financed by way of a mortgage, secured on the premises,
  of €20,400,000 over 20 years from Bank of Ireland Corporate Lending.
  
  The HPRA is committed to making the following capital repayments on its mortgage : 
       
 
  - within one year    793,332  793,332
  - between one and five years    3,173,328  3,173,328
  - after five years    3,966,680  4,760,012
   
     7,933,340  8,726,672
14. Interest Rate Exposure       
 
 The HPRA have taken all necessary steps to minimise its interest rate exposure by fixing 2/3s
 of the borrowings for the mortgage duration. The balance of the borrowings are fully offset
 by cash reserves. For 2015 it is estimated that the net borrowings for which an interest rate
 exposure may arise is €0.
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15. Financial Commitments    
    2014     2013
      €     € 
 Operating Leases
 Amounts payable during the next twelve
 months in respect of leases which expire
 - within one year (in respect of Ormonde House)  -  -
 - within one year (in respect of Longphort House)  -  -
 - after five years ( in respect of Alexandra House )  285,984  285,984
   
  285,984  285,984
  
 Included in Accommodation Costs (Note 5) is expenditure of €285,984 under operating leases.
  
 On 28 January 2005 the HPRA signed a leasehold interest in respect of the 5th floor, Alexandra House,
 Earlsfort Centre, Dublin 2. At 31 December 2014 this lease had 7 years and four months remaining.
16. Capital Commitments    
     
 Contracted For ( Contract Signed )    -  440,000
 Not Contracted For  2,510,000  2,600,000
   
  2,510,000  3,040,000
17. Board Remuneration
  
 Chairman’s Salary  20,520  20,520
 Board Members’ Travel Expenses  5,247  6,710
   
  25,767  27,230
18. Staff Remuneration
    
 Chief Executive’s Total Remuneration
 Basic Salary  145,985  151,186
   
  145,985  151,186
  
  
 The Chief Executive’s pension entitlements do not extend beyond the standard entitlements 
 in the model public sector defined benefit superannuation scheme.
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19.  Related Party Transactions
  
 There have been no transactions with related parties which require disclosure under Financial Reporting Standard 8.
20.  Prompt Payment Of Accounts
  
 The Health Products Regulatory Authority (HPRA) confirms that it is complying with EU law in relation  
 to prompt payments of account.
21.  Exchange Rates
  
 The exchange rates used in preparing these financial statements were as follows : -
  
 2014 €1 = STG £0.7825
 2013 €1 = STG £0.8348
22.  Provisions
  
 The HPRA has been notified of a number of legal proceedings or potential proceedings.  
 The information usually required by FRS 12 Provisions, contingent liabilities and contingent  
 assets is not disclosed as the HPRA believes that to do so would be prejudicial to the outcome. 
23.  Going Concern
  
 The HPRA has a reasonable expectation, at the time of appoving the financial statements, that the HPRA 
 has adequate resources to continue its operations. For this reason, the HPRA continues to adopt the 
 going concern basis in preparing the financial statements. 
24.  Approval of Financial Statements
  
 The financial statements were approved by the board of the HPRA on 20 May 2015.

APPENDICES
112 HPRA ANNUAL REPORT 2014
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Committee Members
Management Committee
Mr. Pat O’Mahony   
Chief Executive
Dr. Gabriel Beechinor  
Director of Veterinary Sciences
Dr. Joan Gilvarry  
Director of Human Products Monitoring
Mr. Kevin Horan  
Director of Information Technology  
and Business Services (appointed July 2014)
Ms. Frances Lynch  
Director of Human Resources (resigned October 2014)
Mr. John Lynch  
Director of Compliance
Ms. Suzanne McDonald  
Director of Information Technology and Change 
Management (resigned July 2014)
Dr. Mike Morris  
Director of Scientific Affairs
Dr. Lorraine Nolan   
Director of Human Products Authorisation  
and Registration
Ms. Lynsey Perdisatt   
Director Human Resources and Change  
(appointed October 2014)
Ms. Rita Purcell  
Director of Finance and Corporate Affairs
Board
Mr. Michael D Hayes – Chairman
Mr. Pat Brangan (reappointed May 2014)
Mr. Wilfrid J. Higgins (reappointed May 2014)
Ms. Ann Horan
Prof. Mary Horgan
Dr. Elizabeth Keane (reappointed May 2014)
Mr. Noel O’Donoghue
Prof. Caitriona O’Driscoll
Dr. Diarmuid Quinlan (appointed May 2014)
Audit Committee
Ms. Ann Horan - Chairman
Mr. Pat Brangan
Dr. Elizabeth Keane
Advisory Committee for Human Medicines
Prof. Mary Horgan – Chairman
Dr. Paul Browne
Dr. Kevin Connolly
Dr. Desmond Corrigan
Prof. Tom Fahey
Prof. David Kerins
Ms. Marita Kinsella
Prof. Patrick Murray
Dr. Brian O’Connell
Mr. Ronan Quirke
Dr. Patrick A. Sullivan
Prof. Peter Weedle
Advisory Committee for  
Veterinary Medicines
Mr. Pat Brangan – Chairman
Dr. Ruaidhri Breathnach
Ms. Eugenie Canavan
Mr. Michael F. Clancy
Dr. Martin Danaher
Dr. Rodhri Evans (resigned July 2014)
Dr. Helena Kelly
Mr. Des Leadon
Dr. Nola Leonard
Mr. Ciaran Mellet
Mr. John Moriarty
Mr. John Underhill
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Advisory Committee for Medical Devices
Mr. Wilfrid J. Higgins – Chairman
Dr. Gillian Carlos McDowell
Dr. Geoffrey Chadwick
Mr. Darragh Hynes
Dr. Jonathan Lyne
Prof. Fergal O’Brien
Prof. Richard Reilly
Ms. Mary Sharp
Ms. Maebh Smith
Mr. Sean Paul Teeling
Prof. Wil van der Putten
Dr. Vivion Crowley
Clinical Trial Sub-Committee of Advisory 
Committee for Human Medicines
Dr. Patrick A. Sullivan – Chairman
Dr. Liam Bannan
Dr. Geraldine Boylan
Dr. Paul Browne
Dr. Peter Crean
Dr. Catherine Kelly 
Dr. Thomas Peirce
Dr. Bryan Whelan
Dr. Lee Helman (CT Expert)
Dr. Filip Janku (CT Expert)
Advisory Sub-Committee  
for Herbal Medicines
Dr. Des Corrigan – Chairman
Dr. James Barlow
Dr. Kevin Connolly
Mrs. Ingrid Hook
Ms. Claudine Hughes
Ms. Anna-Maria Keaveney
Dr. Celine Leonard
Dr. Donal O’Mathuna
Dr. Camillus Power
Dr. Helen Sheridan
Ms. Anne Varley
Dr. Emma Wallace
Experts Sub-Committee of the Advisory 
Committee for Human Medicines
Prof. Mary Horgan – Chairman
Dr. Colin Buckley
Dr. Owen Carey (resigned January 2014)
Dr. Linda Coate
Dr. Kevin Connolly
Dr. James Colville
Dr. Noreen Dowd
Dr. Stephen Eustace
Dr. Stephen Flint
Dr. Tim Fulcher
Dr. Joseph Galvin
Dr. Patrick Gavin
Dr. Paul Gallagher
Dr. Kevin Kelleher
Dr. Catherine Kelly
Dr. Mary Keogan
Prof. David Kerins
Dr. Lorraine Kyne (resigned May 2014)
Dr. Mark Ledwidge
Prof. Aidan McCormick
Dr. Frank Murray
Dr. Yvonne O’Meara
Dr. Cormac Owens (appointed May 2014)
Mr. Ashley Poynton
Dr. Brion Sweeney
Dr. Jogin Thakore
Dr. Gerry Wilson (appointed May 2014)
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Presentations 2014
Third Level Presentations
Institution Course Presentation Title
Letterkenny IT Veterinary Nursing Regulation of Veterinary Medicines 
PIER / UCC Pharmacy Vigilance Assessment and Career Paths
RCSI Industrial Pharmaceutical Science Clinical Trials: Investigational Medicinal Product Dossier  
 and Overview of the CT Directive
RCSI Nurse/Midwife Prescribing Pharmacovigilance 
RCSI Nurse/Midwife Prescribing Role of the HPRA
RCSI Pharmacy Advanced Therapy Medicinal Products
RCSI Pharmacy Regulation of New and Generic Medicines
RCSI Pharmacy Regulatory Affairs and Authorities
RCSI Pharmacy The Regulation of Biotechnology
Sligo IT Medical Biotechnology and  HPRA Inspections / Pharmacovigilance 
 Pharmaceutical Science  
St. Johns, Cork Veterinary Nursing Regulation of Veterinary Medicines 
TCD Bioprocess Engineering Biopharmaceuticals – Introduction to EU Regulation
TCD Pharmaceutical Manufacturing Role of the Pharmacopoeia in the Regulation of Medicines
TCD Pharmaceutical Medicine Clinical Trials for Biologics and Advanced Therapies  
  (2 presentations)
TCD Pharmaceutical Medicine Communication of Drug Safety Data
TCD Pharmaceutical Medicine Implementation of the EU Pharmacovigilance Legislation 
TCD Pharmaceutical Medicine Medicines Regulation: International Quality Standards and  
  Pharmacopoeias
TCD Pharmaceutical Medicine Pharmacovigilance Risk Assessment Committee (PRAC)
TCD Pharmaceutical Medicine Quality Issues relating to Clinical Trials for Biologicals  
  and ATMPs
TCD Pharmaceutical Medicine Regulation of Traditional Herbal Products (2 presentations)
TCD Pharmacy Overview of Pharmacovigilance Role and Career Paths
UCC Pharmacy Notification of Adverse Events
UCD Biopharmaceutical Engineering Biopharmaceuticals – Introduction to EU Regulation 
UCD Nurse/Midwife Prescribing Pharmacovigilance (2 presentations)
UCD Nurse/Midwife Prescribing Role of the HPRA (2 presentations)
UCD Veterinary Medicine Regulation of Veterinary Medicines 
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Regulatory and Training Presentations 
Event/Organiser Presentation Title
Association of Irish Racecourse New EU proposed Legislation on Regulation and Use  
Veterinary Surgeons of Veterinary Medicines
Association of Occupational  The Role and Functions of the HPRA / Management  
Therapists of Ireland of Suspected Medical Device Adverse Incidents
CMG Conference  Medication Errors – The Regulatory Role
DIA EuroMeeting  Periodic Benefit Risk Evaluation Reporting
Drug Safety Research Unit EU Conference Measuring the Effectiveness of Risk Minimisation
EDQM  Committee of the Supply Classification of Medicines
EMA Pharmacovigilance Stakeholder Information Day Update on Post Authorisation Safety Studies
Enterprise Ireland / Health Research Board About the HPRA 
(NCRF Panel Briefing) 
Informa Conference Module 3: Drug device Combinations
Informa Conference Commission Regulation 712/2012 – An Update
Informa Conference Examining Opportunities for Harmonisation under   
  Commission Regulation 712/2012
Irish Cosmetics and Detergents Association Cosmetic Products Regulation
Irish External Quality Assessment Scheme Overview of the Medical Device Vigilance System
Irish Medical Devices Association Selling Medical Devices in Ireland
Joint CP - Ph. Eur. Seminar Specific Monographs in European Pharmacopoeia  
  (Ph. Eur.) 
Joint CP - Ph. Eur. Seminar Quality Control and Product Registration in the EU
Management Forum: Pharmaceutical  A Regulatory Perspective 
Packaging, Labelling and Artwork 
Laboratory Animal Science and Training (LAST) Directive 2010/63/EU (2 presentations)
Medicines Adaptive Pathways Workshop An Agency Perspective
MedTec Ireland  Overview of the Medical Devices Vigilance System
NMBI Medicines Management Workshop The Role and Functions of the HPRA / Reporting of   
  Suspected Adverse Reactions
PDA Conference   GDP Guidance
PDA Conference  BEMA – Benchmarking for Pharmaceutical Regulators
PDA Seminar  The Supply Chain – A GDP Regulatory Perspective
PharmaChemical Ireland CMC Regulatory Affairs Training Common Deficiencies in CMC Part of Application
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Regulatory and Training Presentations continued
Event/Organiser Presentation Title 
PharmaChemical Ireland CMC  Module 3: Drug Product 
Regulatory Affairs Training 
PharmaChemical Ireland CMC Common Issues with Variations 
Regulatory Affairs Training 
PIC/S Expert Circle Meeting on GDP Computerised Systems Validation
Q1 Medical Devices Conference Post Market Trends
Seminar on Strategies and Product View of Regulatory Authority on Quality Aspects for  
Development of Veterinary Medicines Pharmaceuticals
Stem Cells and Tissue Engineering Conference The Regulatory Environment of ATMPS
Teagasc  Implementation of Directive 2010/63/EU 
Topra Annual Meeting Pharmacovigilance – A view from PRAC and a National  
  Competent Authority
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Human Medicines Safety: 
Publications and Articles
Drug Safety Newsletters 
Edition Topics Covered
February  -  Combined Hormonal Contraceptives: Update on risk of VTE 
59th Edition 
April -  Strontium ranelate: New restricted indication and monitoring recommendations due to  
60th Edition  concerns regarding cardiovascular safety 
 -  Hydroxyethylstarch (HES) Infusion Solutions: EU review confirms products should   
  not to be used in patients with sepsis or burn injuries or in critically ill patients 
 -  Cetuximab: Update on revised recommendations for use and risk of  
  infusion-related reactions 
 -  IMB Pharmacovigilance Information day
May  -  Domperidone-containing medicines: Risk of cardiac adverse reactions and  
61st Edition  restrictions for use 
 -  Recommendations to restrict the combined use of medicines affecting the 
   renin-angiotensin (RAS) system 
 - Ferumoxytol: Reminder regarding the risk of serious hypersensitivity reactions
June -  Ivabradine: Reminder of conditions for use to avoid potentially dangerous bradycardia 
62nd Edition -  HIQA: New Guidance for HCPs aimed at reducing medication errors 
 -  IMB Name Change
September - Transdermal fentanyl: Reminder about the potential for life-threatening harm from   
63rd Edition  accidental exposure  
 -  Denosumab: Updated information to minimise the risk of osteonecrosis of the jaw   
  and hypocalcaemia 
 -  Ferumoxytol: New important advice to mitigate the risk of serious  
  hypersensitivity reactions 
 -  Beta Interferons: Risk of thrombotic microangiopathy and nephrotic syndrome 
 -  Adverse Reaction Reporting during 2013
November  -  Oral Anticoagulants: Update on National Monitoring Experience 
64th Edition -  Chlorhexidine cutaneous solutions: Chemical injury including burns when used in skin  
  disinfection in premature infants 
 - Reminder regarding arrangements for DSN distribution 
 - Adverse Reaction Reporting-Reminder
December  - Valproate-containing medicines: Recommendation to further restrict use in  
65th Edition   women andgirls 
 -  Ivabradine: New contraindication and recommendations to minimise the risk  
  of cardiovascular adverse events 
 -  Agomelatine: Reminder of the importance of hepatic monitoring to reduce the risk  
  of serious hepatic adverse reactions 
 -  Testosterone: EU review does not confirm increased risk of cardiovascular events 
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HPRA Articles in External Publications
Month Publication Topic
January MIMS Agomelatine: New contraindication and a reminder of the   
  importance of liver function monitoring
February MIMS Combined Hormonal Contraceptives: Update on risk of venous  
  thromboembolism
February IMF Domperidone-containing medicines: Risk of cardiac adverse   
  reactions and restrictions for use
March MIMS Trazodone: Reminder of the risk of postural hypotension and   
  somnolence in the elderly
March MIMS Supplement Ondansetron: Updated information on posology to mitigate   
 (Cardiology)  dose-dependent risk of QT interval prolongation 
April MIMS Strontium Ranelate: New restricted indication and monitoring  
  recommendations due to concerns regarding cardiovascular safety
May MIMS Metoclopramide-containing medicines: Update on outcome of  
  review and revised recommendations for use
May MIMS Supplement Cetuximab: Update on revised recommendations for use and risk  
 (Oncology) of infusion related reactions 
June MIMS Medicines subject to additional monitoring requirements: Update
July MIMS Domperidone-containing medicines: Risk of cardiac adverse   
  reactions and restrictions for use
August MIMS Recommendation to restrict the combined use of medicines   
  affecting the renin-angiotensin (RAS) system
August IMF Recommendation to restrict the combined use of medicines   
  affecting the renin-angiotensin (RAS) system
September MIMS New important advice to mitigate the risk of serious hypersensitivity  
  reactions with Ferumoxytol
October MIMS Denosumab: Updated information to minimise the risk of   
  osteonecrosis of the jaw and hypocalcaemia
November MIMS Transdermal Fentanyl: Reminder about the potential for   
  life-threatening harm from accidental exposure
November MIMS Supplement Adverse Reaction Reporting during 2013  
 (Diabetes)
December MIMS Agomelatine: Reminder of the importance of liver function   
  monitoring to reduce the risk of serious hepatic adverse reactions
December MIMS Compendium Oral Anticoagulants: Update on National Monitoring Experience 
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European and National  
Committee /  
Working Group Participation
Third Level Presentations
Committee/Working Group Organisation Meetings in 2014
Compliance and Enforcement Working Party (COEN) Competent Authorities  3 
 Working Group
In-Vitro Diagnostic Technical Working Group Competent Authorities  2 
 Working Group
Committee of Experts Combating Risks of Counterfeit Medicines Council of Europe 2
European Pharmacopoeia Commission  Council of Europe 3
Pompidou Group – Drug Precursors Council of Europe 1
P-SC-COS (Committee of Experts on Cosmetics) Council of Europe 2
Medication Safety Forum Department of Health 2
Market Surveillance Forum Department of Jobs  4  
 Enterprise and Innovation 
Official Medicines Control Laboratories network EDQM 6
Tissues and Cells Guide / ART Drafting Group EDQM 1
Committee for Advanced Therapies EMA 11
Committee for Medicinal Products for Human Use (CHMP) EMA 11
Committee for Medicinal Products for Veterinary Use (CVMP) EMA 11
Committee for Orphan Medicinal Products (COMP) EMA 11
Committee on Herbal Medicinal Products (HMPC) EMA 6
Efficacy Working Party EMA 3
ESVAC EMA 1
GCP Inspectors Working Group  EMA 4
GMDP Inspectors Working Group EMA 4
Immunological Working Party EMA 3
Paediatric Committee (PDCO) EMA 12
Pharmacovigilance Inspectors Working Group - Human EMA 4
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Committee/Working Group Organisation Meetings in 2014
Pharmacovigilance Inspectors Working Group - Veterinary EMA 4
Pharmacovigilance Risk Assessment Committee  EMA 13
Quality Working Party EMA 4
Safety Working Party EMA 4 
Scientific Advice Working Party EMA 11
Heads of Medicines Agencies meetings – Human EU Presidency 4
Heads of Medicines Agencies meetings – Veterinary EU Presidency 4
Notified Body Operations Group EU Working Group 2
Competent Authorities for Blood European Commission 2
Competent Authorities for Organs for human transplantation European Commission 2
Competent Authorities for Tissues and Cells European Commission 2
Cosmetic Borderline Working Group European Commission 2
Cosmetic Standing Committee and Working Group European Commission 3
Drug Precursors Working Group European Commission 2
European Commission Sub-working Group on Cosmetovigilance European Commission 2
European Surveillance Strategy European Commission 2
MDEG Working Group on Vigilance European Commission 2
Medical Device Expert Group European Commission 3
National Contact Points for Directive 2010/63/EU European Commission 2
PEMSAC (Platform of European Market Surveillance  European Commission 2 
Authorities for Cosmetics) Market Surveillance 
PEMSAC (Platform of European Market Surveillance  European Commission 2 
Authorities for Cosmetics) Analytical Methods 
SCOPE Launch and Work Package Meetings European Commission 3
Working Group of the Implementation of the Single  European Commission 2 
European Code (SEC) for Tissues and Cells 
Working Group on Import of Human Tissues and Cells European Commission 2
Medicines Reconciliation Advisory Group  HIQA 3
Co-ordination Group for Mutual-recognition and  
Decentralised Procedures (Human) CMD(h) HMA 10
Co-ordination Group for Mutual-recognition and  
Decentralised Procedures (Veterinary) CMD(v) HMA 10
EU PSUR Work-Sharing Working Party HMA 11
HMA ICT Working Groups HMA 
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Committee/Working Group Organisation Meetings in 2014
Homeopathic Medicinal Products Working Group (HMPWG) HMA 2
Working Group of Communications Professionals HMA 2
Working Group of Enforcement Officers HMA 2
Working Group of Quality Managers HMA 2
HPRA – UK Department for Business Innovation & Skills Ireland/UK Working Group 5
HSE/National Organ Donation and Transplant Office (ODTI) HSE / ODTI / HPRA 5
Cosmetic Standards Advisory Group NSAI 2
Permanent Forum on International Pharmaceutical Crime (PFIPC)  PFIPC 1
PIC/S GDP Working Group PIC/S 5
National Immunisation Advisory Committee RCPI 6
Anti-doping Committee of the Sports Council Sports Council 3
Board of the WHO/UMC Collaborating Centre WHO 3
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APPENDIX 5 
Glossary
AED Automated External Defibrillator 
APMI Association of Pharmaceutical Manufacturers in Ireland 
ASR Annual Safety Report 
ATMP Advanced Therapy Medicinal Product
BEMA Benchmarking of European Medicines Agencies
CAMD Competent Authority for Medical Devices 
CAT Committee for Advanced Therapies 
CD Controlled Drugs 
CESP Common European Submission Portal
CHMP Committee for Medicinal Products for Human Use 
CMC Central Management Committee 
CMD(h) Co-ordination Group for Mutual Recognition and Decentralised Procedures - Human
CMD(v) Co-ordination Group for Mutual Recognition and Decentralised Procedures - Veterinary 
CMS Concerned Member State
COMP  Committee for Orphan Medicinal Products 
CTFG  Clinical Trials Facilitation Group 
CVMP  Committee for Medicinal Products for Veterinary Use 
DCP  Decentralised Procedure 
DPP  Director of Public Prosecutions
EDQM European Directorate for Quality of Medicines 
EEA European Economic Area 
EMA European Medicines Agency 
EUDAMED European Database on Medical Devices
GCP Good Clinical Practice 
GDP Good Distribution Practice 
GMP Good Manufacturing Practice
GVP Good Vigilance Practice 
HIQA Health Information and Quality Authority 
HMA Heads of Medicines Agencies
HMPC Committee on Herbal Medicinal Products 
HPSC Health Protection Surveillance Centre 
HSE Health Service Executive
HTA Health Technology Assessment
IAHS Irish Association of Health Stores 
IBTS Irish Blood Transfusion Service 
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ICH International Conference of Harmonisation 
ICMRA International Coalition of Medicines Regulatory Authorities
IMDA Irish Medical Devices Association 
IMDRF International Medical Device Regulators Forum
IMF Irish Medicines Formulary
IMSTA  Irish Medical and Surgical Trade Association
IPHA Irish Pharmaceutical Healthcare Association
IVD In-Vitro Diagnostics 
MAH Marketing Authorisation Holder 
MEDDEV Medical Devices Guidance Document from the European Commission
MIMS Monthly Index of Medical Specialities 
MRP Mutual Recognition Procedure 
NBOG  Notified Body Operations Group 
NCA National Consumer Agency 
NHO National Haemovigilance Office
NSAI National Standards Authority of Ireland 
OMCL Official Medicines Control Laboratories 
OTC  Over-the-Counter 
PASS  Post Authorisation Safety Studies 
PCI Pharmachemical Ireland 
PDCO  Paediatric Committee 
PDP Performance Development Programme
PIC/S Pharmaceutical Inspection Co-operation Scheme 
PIF  Product Information File 
PRAC Pharmacovigilance Risk Assessment Committee
PSUR Periodic Safety Update Report
PSUSA EU Single Assessment Procedures
RMP Risk Management Plan 
RMS  Reference Member State 
SmPC Summary of Product Characteristics
THMP Traditional Herbal Medicinal Product
UMC Uppsala Monitoring Centre 
VHP Voluntary Harmonisation Procedures 
VMD Veterinary Medicines Directorate 
WHO World Health Organization 
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